

CITATION REPORT

List of articles citing

The hallmarks of cancer

DOI: 10.1016/s0092-8674(00)81683-9
Cell, 2000, 100, 57-70.

Source: <https://exaly.com/paper-pdf/32091714/citation-report.pdf>

Version: 2024-04-10

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2233	Cancer Drug Target Identification by SAGE, LongSAGE, and Digital Karyotyping. 2005 , 19-30		
2232	Intrinsic optical biomarkers associated with the invasive potential of tumor cells in engineered tissue models. 2010 , 1, 1387		
2231	Intrinsic optical biomarkers associated with the invasive potential of tumor cells in engineered tissue models. 2010 , 1, 1387		
2230	The difficulties in cancer treatment. 2012 , 6, ed16		66
2229	supplementaryMovie.mp4.		
2228	World health and global health challenges. 54-112		
2227	Technologies for early detection and prevention of cancer. 248-304		
2226	Iron Oxide Nanoparticle-Induced Neoplastic-Like Cell Transformation in Vitro Is Reduced with a Protective Amorphous Silica Coating.		
2225	Something going on in Milan: a review of the 4th International PhD Student Cancer Conference. 2010 , 4, 198		
2224	Polyisoprenylated methylated protein methyl esterase as a putative drug target for androgen-insensitive prostate cancer. 2014 , 8, 459		5
2223	Validity of Chemical Balance Studies in Eviscerated Animals, as Index of Carbohydrate Utilization. 1940 , 44, 257-261		3
2222	The identification of micronucleated chromosomes: a possible assay for aneuploidy. 1988 , 3, 415-8		143
2221	Keratin subunit expression in human cultured melanocytes and mouse neural crest cells without formation of filamentous structures. 1999 , 4, 110-5		9
2220	Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. 2000 , 105, 1045-7		579
2219	Fibrosis and angiogenesis. 2000 , 9, 413-8		65
2218	Genetics of brain tumors. 2000 , 12, 543-8		16
2217	Serine/threonine-specific protein phosphatases and cancer. 2000 , 4, 581-608		3

2216	Regulation of apoptosis in prostatic disease. 2000 , 9, 25-8	15
2215	Aneuploidy, the somatic mutation that makes cancer a species of its own. 2000 , 47, 81-107	163
2214	International conference on basic and clinical aspects of cell-cycle control. 2000 , 185, 481-5	0
2213	Somatic mutation theory of carcinogenesis: why it should be dropped and replaced. 2000 , 29, 205-11	114
2212	Breast Cancer in the Third Millennium. 2000 , 6, 280-287	16
2211	Oncogenes and angiogenesis: signaling three-dimensional tumor growth. 2000 , 5, 24-33	159
2210	Cell cycle checkpoints and their inactivation in human cancer. 2000 , 33, 261-74	294
2209	The most unkindest cut of all: on the multiple roles of mammalian caspases. 2000 , 14, 1514-25	86
2208	Hepatocellular carcinoma in WHV/N-myc2 transgenic mice: oncogenic mutations of beta-catenin and synergistic effect of p53 null alleles. 2000 , 19, 2678-86	42
2207	Transcriptional control of SPARC by v-Jun and other members of the AP1 family of transcription factors. 2000 , 19, 5020-9	30
2206	Dual functions of E2F-1 in a transgenic mouse model of liver carcinogenesis. 2000 , 19, 5054-62	127
2205	From oncogene to drug: development of small molecule tyrosine kinase inhibitors as anti-tumor and anti-angiogenic agents. 2000 , 19, 6574-83	101
2204	Benefits of bad telomeres. 2000 , 406, 573-4	34
2203	Angiogenesis in cancer and other diseases. 2000 , 407, 249-57	6972
2202	Cancer: looking outside the genome. 2000 , 1, 76-9	159
2201	Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. 2000 , 2, 737-44	2191
2200	Defying death after DNA damage. 2000 , 407, 777-83	549
2199	The age of cancer. 2000 , 408, 248-54	745

2198	RNA aptamers as pathway-specific MAP kinase inhibitors. 2000 , 7, 833-43	61
2197	The influence of the microenvironment on the malignant phenotype. 2000 , 6, 324-9	323
2196	The thin red line: angiogenesis in normal and malignant hematopoiesis. 2000 , 28, 993-1000	71
2195	The biology and analysis of single disseminated tumour cells. 2000 , 10, 489-93	26
2194	The Rel/NF-kappa B family: friend and foe. 2000 , 25, 434-40	321
2193	New molecular mediators in tumor angiogenesis. 2000 , 4, 262-269	33
2192	Cancer of the oral cavity. 2000 , 37, 633-731	9
2191	TGFbeta1 stimulates the secretion of matrix metalloproteinase 2 (MMP2) and the invasive behavior in human ovarian cancer cells, which is suppressed by MMP inhibitor BB3103. 2000 , 18, 493-9	44
2190	The interferon regulatory factors and oncogenesis. 2000 , 10, 73-81	67
2189	Genetics of hepatocellular carcinoma. 2000 , 10, 185-200	258
2188	Tumor growth-promoting properties of macrophage migration inhibitory factor (MIF). 2000 , 10, 359-66	128
2187	Telomerase and human tumorigenesis. 2000 , 10, 399-406	119
2186	HIF-1: using two hands to flip the angiogenic switch. 2000 , 19, 59-65	176
2185	Endogenous regulators of angiogenesis--emphasis on proteins with thrombospondin--type I motifs. 2000 , 19, 159-65	38
2184	The retinoblastoma gene family: its role in cancer onset and progression. 2000 , 4, 765-783	7
2183	Analysis of erythrocyte glycophorin-A variants by flow cytometry in lung disease patients detects the effect of tobacco smoke. 2000 , 21, 35-40	5
2182	Intratumor heterogeneity of k-ras and p53 mutations among human colorectal adenomas containing early cancer. 2000 , 21, 49-57	20
2181	The Effect of a 20-Minute Exposure of Colloidal Silver on the Membrane of Human Peripheral Blood Lymphocytes and Raji Cells. 2000 , 6, 890-891	

2180	Changes in Tumorigenesis- and Angiogenesis-related Gene Transcript Abundance Profiles in Ovarian Cancer Detected by Tailored High Density cDNA Arrays. 2000 , 6, 750-765	92
2179	Role of transforming growth factor-beta signaling in cancer. 2000 , 92, 1388-402	417
2178	Epidermal growth factor-induced nuclear factor kappa B activation: A major pathway of cell-cycle progression in estrogen-receptor negative breast cancer cells. 2000 , 97, 8542-7	291
2177	Smad4/DPC4-mediated tumor suppression through suppression of angiogenesis. 2000 , 97, 9624-9	221
2176	Cancer gene therapy: developments to 2000. 2000 , 9, 2799-813	6
2175	Exploring the relationship between neutral and selective mutations in cancer. 2000 , 6, 325-45	31
2174	Phenotypically different cells with heterogeneous nuclear ribonucleoprotein A2/B1 overexpression show similar genetic alterations. 2000 , 23, 636-45	34
2173	Selective depletion of heat shock protein 70 (Hsp70) activates a tumor-specific death program that is independent of caspases and bypasses Bcl-2. 2000 , 97, 7871-6	347
2172	Macromolecular intelligence in microorganisms. 2000 , 381, 965-72	21
2171	Neuropilin-1 expression by tumor cells promotes tumor angiogenesis and progression. 2000 , 14, 2532-9	255
2170	Neoplastic transformation and tumorigenesis associated with sam68 protein deficiency in cultured murine fibroblasts. 2000 , 275, 40195-201	45
2169	A soluble form of B cell maturation antigen, a receptor for the tumor necrosis factor family member APRIL, inhibits tumor cell growth. 2000 , 192, 1677-84	204
2168	A chimpanzee genome project is a biomedical imperative. 2000 , 10, 1065-70	84
2167	The Fas-induced apoptosis analyzed by high throughput proteome analysis. 2000 , 275, 39018-26	132
2166	Hypothesis: chemical carcinogenesis mediated by a transiently active carcinogen receptor. 2000 , 91, 102-4	2
2165	Response to Klaunig J.E. et al.'s "Epigenetic mechanisms of chemical carcinogenesis". 2000 , 19, 569-70; discussion 571-2	1
2164	Rho GTPases: signaling, migration, and invasion. 2000 , 261, 1-12	492
2163	Mechanism-based target identification and drug discovery in cancer research. 2000 , 287, 1969-73	381

2162	Mutations and copy number increase of HRAS in Spitz nevi with distinctive histopathological features. 2000 , 157, 967-72		369
2161	Deregulation of the Rb and p53 pathways in uveal melanoma. 2000 , 157, 1795-801		100
2160	Interactions between tumour cells and stromal cells and proteolytic modification of the extracellular matrix by metalloproteinases in cancer. 2000 , 36, 1258-68		119
2159	Overexpression and regulation of expression of scatter factor/hepatocyte growth factor in prostatic carcinoma. 2000 , 56, 1071-4		30
2158	Distinct initiation and maintenance mechanisms cooperate to induce G1 cell cycle arrest in response to DNA damage. <i>Cell</i> , 2000 , 102, 55-66	56.2	323
2157	Cellular senescence: mitotic clock or culture shock?. <i>Cell</i> , 2000 , 102, 407-10	56.2	655
2156	MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis. <i>Cell</i> , 2000 , 103, 481-90	56.2	1126
2155	Regulation of [Ca(2+)](i) homeostasis in MRP1 overexpressing cells. 2000 , 474, 107-10		8
2154	Gene expression profiling: monitoring transcription and translation products using DNA microarrays and proteomics. 2000 , 480, 2-16		229
2153	Differential gene expression in mesothelioma. 2000 , 480, 95-100		53
2152	BAP37 and Prohibitin are specifically recognized by an SV40 T antigen antibody. 2000 , 4, 219-23		3
2151	Cell cycle. Piecing together the p53 puzzle. 2000 , 287, 1765-6		98
2150	An alternate splicing variant of the human telomerase catalytic subunit inhibits telomerase activity. 2000 , 2, 433-40		153
2149	Metastases: the glycan connection. 2000 , 2, 321-3		69
2148	Reprimo, a new candidate mediator of the p53-mediated cell cycle arrest at the G2 phase. 2000 , 275, 22627-30		136
2147	Regulation of cutaneous malignancy by gammadelta T cells. 2001 , 294, 605-9		779
2146	Clinical practice in the new era. A fusion of molecular biology and classical medicine is transforming the way we look at and treat diseases. 2001 , 2, 80-2		10
2145	Cisplatin: from DNA damage to cancer chemotherapy. 2001 , 67, 93-130		428

2144	Tamoxifen resistance in breast cancer: elucidating mechanisms. 2001 , 61, 1721-33	72
2143	Lack of replicative senescence in cultured rat oligodendrocyte precursor cells. 2001 , 291, 868-71	210
2142	Nicotine inhibits UV-induced activation of the apoptotic pathway. 2001 , 125, 61-5	30
2141	PTEN deficiency: a role in mammary carcinogenesis. 2001 , 3, 356-60	34
2140	Five-lipoxygenase inhibitors can mediate apoptosis in human breast cancer cell lines through complex eicosanoid interactions. 2001 , 15, 2007-9	164
2139	Gene expression profiling. Methods and clinical applications in oncology. 2001 , 15, 911-30, ix	17
2138	Downregulation of Akt1 inhibits anchorage-independent cell growth and induces apoptosis in cancer cells. 2001 , 3, 278-86	33
2137	Gene therapy for prostate cancer: current status and future prospects. 2001 , 166, 1220-33	50
2136	Cloning, characterization, and expression of human LIG1. 2001 , 284, 1155-61	111
2135	c-jun cooperates with SV40 T-antigen to sustain MMP-2 expression in immortalized cells. 2001 , 284, 1134-9	11
2134	Mouse models for sporadic cancer. 2001 , 264, 100-10	28
2133	Evading apoptosis by calcitriol-differentiated human leukemic HL-60 cells is not mediated by changes in CD95 receptor system but by increased sensitivity of these cells to insulin. 2001 , 270, 119-27	10
2132	New insights into the role of nuclear factor-kappaB in cell growth regulation. 2001 , 159, 387-97	392
2131	Aberrant expression of fetal RNA-binding protein p62 in liver cancer and liver cirrhosis. 2001 , 159, 945-53	83
2130	Thymic epithelial tumors can develop along two different pathogenetic pathways. 2001 , 159, 1853-60	48
2129	Thrombospondin-1 gene expression affects survival and tumor spectrum of p53-deficient mice. 2001 , 159, 1949-56	100
2128	Tissue inhibitor of metalloproteinase-1 alters the tumorigenicity of Burkitt's lymphoma via divergent effects on tumor growth and angiogenesis. 2001 , 158, 1207-15	102
2127	Comparative genome-scale analysis of gene expression profiles in T cell lymphoma cells during malignant progression using a complementary DNA microarray. 2001 , 158, 1231-7	59

2126	Production of bioengineered cancer tissue constructs in vitro: epithelium-mesenchyme heterotypic interactions. 2001 , 37, 434-9	5
2125	Global analysis of differential gene expression after transformation with the v-H-ras oncogene in a murine tumor model. 2001 , 20, 2854-8	29
2124	Cancer and diabetes: two pathological conditions in which adrenomedullin may be involved. 2001 , 22, 1719-29	10
2123	Three mutations in v-Rel render it resistant to cleavage by cell-death protease caspase-3. 2001 , 1526, 25-36	19
2122	Degradation of cellular and viral Fos proteins. 2001 , 83, 357-62	11
2121	Cyclin D1 in breast premalignancy and early breast cancer: implications for prevention and treatment. 2001 , 162, 3-17	30
2120	Role of serine/threonine protein phosphatase 2A in cancer. 2001 , 170, 1-13	155
2119	Telomerase: biology and phase I trials. 2001 , 2, 95-102	40
2118	Tumour metastasis: is tissue an issue?. 2001 , 2, 109-12	34
2117	Cancer chemoprevention by dietary constituents: a tale of failure and promise. 2001 , 2, 371-9	87
2116	Three down and counting: the transformation of human mammary cells from normal to malignant in three steps. 2001 , 7, 142-3	4
2115	No longer a molecular black box--new clues to apoptosis and drug resistance in melanoma. 2001 , 7, 191-4	38
2114	Tumor environment: a potent driving force in colorectal cancer?. 2001 , 7, 535-7	40
2113	Gène et cancer: aspects fondamentaux et cliniques. 2001 , 5, 36s-41s	
2112	Ski/Sno and TGF-beta signaling. 2001 , 12, 1-8	181
2111	Human immunodeficiency virus type-1 and chemokines: beyond competition for common cellular receptors. 2001 , 12, 219-43	63
2110	Tuberous sclerosis gene products in proliferation control. 2001 , 488, 233-9	40
2109	From exposure to effect: a comparison of modeling approaches to chemical carcinogenesis. 2001 , 489, 17-45	18

2108	Molecular markers of tumor initiation and progression. 2001 , 11, 60-3		5
2107	The mechanisms of neoplastic transformation. 2001 , 37 Suppl 8, S114-7		33
2106	Molecular mechanisms of prostate cancer. 2001 , 37 Suppl 7, S119-25		18
2105	The effects of aromatase overexpression on mammary growth and gene expression in the aromatase x transforming growth factor alpha double transgenic mice. 2001 , 78, 419-26		6
2104	Urologic oncology: extraordinary opportunities for discovery: New initiatives in radiation oncology. 2001 , 6, 185-188		
2103	The C. elegans E2F- and DP-related proteins are required for embryonic asymmetry and negatively regulate Ras/MAPK signaling. 2001 , 7, 451-60		84
2102	The Peutz-Jegher gene product LKB1 is a mediator of p53-dependent cell death. 2001 , 7, 1307-19		253
2101	Pathways governing G1/S transition and their response to DNA damage. 2001 , 490, 117-22		336
2100	Activation of the extracellular signal-regulated protein kinase (ERK) cascade by membrane-type-1 matrix metalloproteinase (MT1-MMP). 2001 , 507, 231-6		92
2099	Cancer of the oral cavity. 2001 , 47, 266-361		4
2098	Farnesyl protein transferase inhibitors as targeted therapies for hematologic malignancies. 2001 , 38, 16-23		37
2097	Chronic myeloid leukemia with increased granulocyte progenitors in mice lacking junB expression in the myeloid lineage. <i>Cell</i> , 2001 , 104, 21-32	56.2	197
2096	Defective interplay of activators and repressors with TFIH in xeroderma pigmentosum. <i>Cell</i> , 2001 , 104, 353-63	56.2	106
2095	After the genome: DNA and human disease. <i>Cell</i> , 2001 , 104, 465-7	56.2	7
2094	NF1 tumor suppressor gene function: narrowing the GAP. <i>Cell</i> , 2001 , 104, 593-604	56.2	493
2093	Hyperproliferation and defects in epithelial polarity upon conditional ablation of alpha-catenin in skin. <i>Cell</i> , 2001 , 104, 605-17	56.2	361
2092	Epithelial mesenchymal interactions in cancer and development. <i>Cell</i> , 2001 , 105, 425-31	56.2	172
2091	Matrilysin [MMP-7] expression selects for cells with reduced sensitivity to apoptosis. 2001 , 3, 459-68		125

2090	Innovative cancer drug targets: genomics, transcriptomics and clinomics. 2001 , 2, 911-5	7
2089	Animal models of hepadnavirus-associated hepatocellular carcinoma. 2001 , 5, 43-68	30
2088	Endothelial cell surface F1-F0 ATP synthase is active in ATP synthesis and is inhibited by angiostatin. 2001 , 98, 6656-61	270
2087	Src inhibitors: genomics to therapeutics. 2001 , 10, 1327-44	40
2086	Wild-type adenovirus decreases tumor xenograft growth, but despite viral persistence complete tumor responses are rarely achieved--deletion of the viral E1b-19-kD gene increases the viral oncolytic effect. 2001 , 12, 1323-32	70
2085	Androgen receptor signaling in androgen-refractory prostate cancer. 2001 , 93, 1687-97	445
2084	E2Fs regulate the expression of genes involved in differentiation, development, proliferation, and apoptosis. 2001 , 15, 267-85	580
2083	ATR inhibition selectively sensitizes G1 checkpoint-deficient cells to lethal premature chromatin condensation. 2001 , 98, 9092-7	265
2082	Platelets in other thrombotic conditions. 2001 , 308-322	
2081	Growth Factors and Their Clinical Applications. 2001 , 8, 372	1
2080	Genomic approaches to skin cancer diagnosis. 2001 , 137, 1507-11	12
2079	Thérapies antisens dirigées contre le récepteur de IGF-I. 2001 , 17, 1343-1348	
2078	Telomerase activity in touch-imprint cell preparations from fresh prostate needle biopsy specimens. 2001 , 40, 666-72	11
2077	STAT3-mediated constitutive expression of SOCS-3 in cutaneous T-cell lymphoma. 2001 , 97, 1056-62	110
2076	El Premio Nobel en Fisiología o Medicina, año 2001: avanza el conocimiento del cáncer. 2001 , 21, 303	
2075	Diet, nutrition and cancer prevention: where are we going from here?. 2001 , 131, 3121S-6S	30
2074	The Metastatic Odyssey: Integrin Connection. 2001 , 10, 313-328	24
2073	Relationship of the K-ras/c-mos Expression Patterns With Angiogenesis in Non-Small Cell Lung Carcinomas. 2001 , 7, 590-597	11

2072	The Small GTPase Rac Suppresses Apoptosis Caused by Serum Deprivation in Fibroblasts. 2001 , 7, 293-300	30
2071	Critical Steps in Hematogenous Metastasis. 2001 , 10, 243-255	149
2070	The Receptor Tyrosine Kinases. 2001 , 10, 271-288	34
2069	Aging, immunity, and cancer. 2001 , 8, 288-90	
2068	Cancer--emerging breakthrough drugs. 2001 , 30, 626-8, 630, 632	2
2067	Human Papillomavirus in the Oral Cavity. 2001 , 6, 1-12	10
2066	Alpha(v)beta3 and alpha(v)beta5 integrin expression in glioma periphery. 2001 , 49, 380-9; discussion 390	253
2065	DNA methylation: an alternative pathway to cancer. 2001 , 234, 10-20	191
2064	Return of de-differentiation: why cancer is a developmental disease. 2001 , 13, 58-62	13
2063	Different mechanisms in the tumorigenesis of proximal and distal colon cancers. 2001 , 13, 63-9	153
2062	Cancer genetics fundamentals. 2001 , 24, 446-61; quiz 462	6
2061	Analysis of allelic imbalance in patients with colorectal cancer according to stage and presence of synchronous liver metastases. 2001 , 234, 795-802; discussion 802-3	16
2060	Selenium in cancer prevention: clinical issues and implications. 2001 , 19, 540-53	36
2059	The role of CXC chemokines in the regulation of tumor angiogenesis. 2001 , 19, 732-8	25
2058	Identifying intercellular signaling genes expressed in malignant plasma cells by using complementary DNA arrays. 2001 , 98, 771-80	139
2057	Resting and activated endothelial cells are increased in the peripheral blood of cancer patients. 2001 , 97, 3658-61	369
2056	Epithelial membrane protein 2, a 4-transmembrane protein that suppresses B-cell lymphoma tumorigenicity. 2001 , 97, 3890-5	44
2055	Regulatory role of tetraspanin CD9 in tumor-endothelial cell interaction during transendothelial invasion of melanoma cells. 2001 , 98, 3717-26	91

2054	Human herpesvirus-8 and Kaposi's sarcoma: relationship with the multistep concept of tumorigenesis. 2001 , 81, 125-59	59
2053	Chapter 14. Cell cycle kinases and checkpoint regulation in cancer. 2001 , 36, 139-148	8
2052	UV radiation, mutations and oncogenic pathways in skin cancer. 2001 , 287-302	1
2051	α5β1 and α5β3 Integrin Expression in Glioma Periphery. 2001 , 49, 380-390	177
2050	Differentiation genes: are they primary targets for human carcinogenesis?. 2001 , 226, 805-13	13
2049	Oncogenes. 2001 ,	1
2048	G2 DNA damage checkpoint inhibition and antimitotic activity of 13-hydroxy-15-oxoapatlin. 2001 , 276, 48231-6	22
2047	Predictive molecular markers in non-small cell lung cancer. 2001 , 13, 101-9	27
2046	Grading in soft tissue tumors: principles and problems. 2001 , 30, 543-59	55
2045	International Conference on Translational Research and Preclinical Strategies in Radio-Oncology (ICTR)--conference summary. 2001 , 49, 301-9	6
2044	Mast cells express functional CD30 ligand and are the predominant CD30L-positive cells in Hodgkin's disease. 2001 , 114, 616-23	98
2043	De-novo humoral immune responses to cancer-associated autoantigens during transition from chronic liver disease to hepatocellular carcinoma. 2001 , 125, 3-9	57
2042	CCK-B/gastrin receptors in human colorectal cancer. 2001 , 31, 812-20	60
2041	Ways of escape: are all tumours angiogenic?. 2001 , 39, 551-3	9
2040	Pathology of lymphoma progression. 2001 , 38, 285-306	43
2039	UV-induced DNA damage, repair, mutations and oncogenic pathways in skin cancer. 2001 , 63, 19-27	382
2038	Molecular classification of breast cancer patients by gene expression profiling. 2001 , 195, 312-20	69
2037	Commentary: Is the concept of tumor promotion a useful paradigm?. 2001 , 30, 131-137	75

2036	Deregulated expression of DP1 induces epidermal proliferation and enhances skin carcinogenesis. 2001 , 31, 90-100	20
2035	Breast cancer in the third millennium. 2001 , 77, 225-32	4
2034	Improved prediction of metastasis in tongue carcinomas, combining vascular and nuclear tumor parameters. 2001 , 92, 1881-7	5
2033	The role of FGF and VEGF in angioblast induction and migration during vascular development. 2001 , 220, 1-17	192
2032	Emerging roles for telomerase in neuronal development and apoptosis. 2001 , 63, 1-9	58
2031	Expression of Fas ligand is an early event in colorectal carcinogenesis. 2001 , 76, 63-8; discussion 69	17
2030	Regulation of the eukaryotic cell cycle: molecular antagonism, hysteresis, and irreversible transitions. 2001 , 210, 249-63	279
2029	Progression of heterogeneous breast tumors. 2001 , 210, 107-19	7
2028	Multiple primary cancers of the colon, breast and skin (melanoma) as models for polygenic cancers. 2001 , 92, 883-7	42
2027	Cadherins in neural crest cell development and transformation. 2001 , 189, 121-32	106
2026	Sp1 and kr��pel-like factor family of transcription factors in cell growth regulation and cancer. 2001 , 188, 143-60	823
2025	Cancer: the evolved consequence of a destabilized genome. 2001 , 23, 1037-46	53
2024	Analysis of c-Ha-ras gene mutations in skin tumors induced in carcinogenesis-susceptible and carcinogenesis-resistant mice by different two-stage protocols or tumor promoter alone. 2001 , 30, 111-8	13
2023	Laminin-5-mediated gene expression in human prostate carcinoma cells. 2001 , 30, 119-29	18
2022	Vascular endothelial growth factor signaling pathway as an emerging target in hematologic malignancies. 2001 , 6 Suppl 5, 24-31	66
2021	Autoantibodies as reporters identifying aberrant cellular mechanisms in tumorigenesis. 2001 , 108, 1411-5	153
2020	Phosphoproteomics. 2001 , 70, 327-31	20
2019	Cell cycle aberrations in the pathogenesis of squamous cell carcinoma of the uterine cervix. 2001 , 82, 238-46	31

2018	Expression of cell cycle proteins in ovarian carcinoma cells in serous effusions-biological and prognostic implications. 2001 , 83, 249-56	29
2017	Gene expression profile in endometrioid endometrial carcinoma. 2001 , 83, 175-6	3
2016	Tumors are unique organs defined by abnormal signaling and context. 2001 , 11, 87-95	135
2015	Proteases in invasion: matrix metalloproteinases. 2001 , 11, 143-52	327
2014	Modeling chromosomal instability and epithelial carcinogenesis in the telomerase-deficient mouse. 2001 , 11, 227-39	56
2013	Recent advances in arsenic carcinogenesis: modes of action, animal model systems, and methylated arsenic metabolites. 2001 , 172, 249-61	634
2012	Activated Notch1 signaling cooperates with papillomavirus oncogenes in transformation and generates resistance to apoptosis on matrix withdrawal through PKB/Akt. 2001 , 286, 23-30	128
2011	Carcinogenic metals and NF- κ B activation. 2001 , 222, 159-171	53
2010	It takes a tissue to make a tumor: epigenetics, cancer and the microenvironment. 2001 , 6, 213-21	90
2009	Integrin laminin receptors and breast carcinoma progression. 2001 , 6, 299-309	57
2008	The challenge of pathway and environment-mediated drug resistance. 2001 , 20, 117-22	19
2007	Molecular and cellular biology of pre-malignancy in the gastrointestinal tract. 2001 , 15, 175-89	8
2006	Human kallikrein gene 5 (KLK5) expression is an indicator of poor prognosis in ovarian cancer. 2001 , 84, 643-50	103
2005	Brakes and gas pedals. Meeting: Spetses 2000, molecular mechanisms of development and disease. 2001 , 2, 563-7	
2004	Thrombospondin-2 plays a protective role in multistep carcinogenesis: a novel host anti-tumor defense mechanism. 2001 , 20, 2631-40	115
2003	Urokinase plasminogen activator is localized in stromal cells in ductal breast cancer. 2001 , 81, 1485-501	64
2002	Tumor-specific gene expression in hepatic metastases by a replication-activated adenovirus vector. 2001 , 7, 240-3	54
2001	Mutational and functional analyses reveal that ST7 is a highly conserved tumor-suppressor gene on human chromosome 7q31. 2001 , 27, 392-8	76

2000	Defective DNA polymerase-delta proofreading causes cancer susceptibility in mice. 2001 , 7, 638-9	137
1999	Still more debate over VEGF. 2001 , 7, 639-41	22
1998	TGF-beta signaling in tumor suppression and cancer progression. 2001 , 29, 117-29	1931
1997	An apoptosis signaling pathway induced by the death domain of FADD selectively kills normal but not cancerous prostate epithelial cells. 2001 , 8, 696-705	31
1996	Cellular and viral Fos proteins are degraded by different proteolytic systems. 2001 , 20, 942-50	10
1995	Gene expression and amplification in breast carcinoma cells with intrinsic and acquired doxorubicin resistance. 2001 , 20, 1300-6	96
1994	Distinct roles of Jun : Fos and Jun : ATF dimers in oncogenesis. 2001 , 20, 2453-64	346
1993	Reverse phase protein microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion front. 2001 , 20, 1981-9	844
1992	DNA methylation, methyltransferases, and cancer. 2001 , 20, 3139-55	599
1991	Bcl-2 expression in F-MuLV-induced erythroleukemias: a role for the anti-apoptotic action of Bcl-2 during tumor progression. 2001 , 20, 2291-300	9
1990	Function and regulation of AP-1 subunits in skin physiology and pathology. 2001 , 20, 2413-23	343
1989	AP-1 in mouse development and tumorigenesis. 2001 , 20, 2401-12	585
1988	Identification of a novel gene, CDCP1, overexpressed in human colorectal cancer. 2001 , 20, 4402-8	100
1987	Identification of human cancer-related genes by naturally occurring Hepatitis B Virus DNA tagging. 2001 , 20, 6233-40	90
1986	Mouse model for lung tumorigenesis through Cre/lox controlled sporadic activation of the K-Ras oncogene. 2001 , 20, 6551-8	168
1985	Id proteins at the cross-road of development and cancer. 2001 , 20, 8326-33	220
1984	Cancer. Improved mouse models. 2001 , 410, 1043-4	28
1983	New life. 2001 , 410, 1044-1044	

1982	Cancer genetics. 2001 , 411, 336-41	439
1981	Proliferation, cell cycle and apoptosis in cancer. 2001 , 411, 342-8	2495
1980	The Hedgehog and Wnt signalling pathways in cancer. 2001 , 411, 349-54	1173
1979	Oncogenic kinase signalling. 2001 , 411, 355-65	3016
1978	The microenvironment of the tumour-host interface. 2001 , 411, 375-9	1949
1977	Apaf-1 is a transcriptional target for E2F and p53. 2001 , 3, 552-8	503
1976	The ins and outs of signalling. 2001 , 411, 759-62	165
1975	Rescuing the function of mutant p53. 2001 , 1, 68-76	466
1974	Network dynamics and cell physiology. 2001 , 2, 908-16	407
1973	Cell senescence and cancer. 2001 , 1, 203-13	211
1972	Emerging roles for telomerase in regulating cell differentiation and survival: a neuroscientist's perspective. 2001 , 122, 659-71	50
1971	Mutant and genetically modified mice as models for studying the relationship between aging and carcinogenesis. 2001 , 122, 1221-55	31
1970	Ever since Knudson. 2001 , 17, 569-73	90
1969	Gene expression microarray analysis in cancer biology, pharmacology, and drug development: progress and potential. 2001 , 62, 1311-36	167
1968	Genetic epidemiology of multistage carcinogenesis. 2001 , 473, 11-21	33
1967	Effects of arsenite on p53, p21 and cyclin D expression in normal human fibroblasts -- a possible mechanism for arsenite's comutagenicity. 2001 , 478, 159-68	94
1966	The role of bile acids in carcinogenesis. 2001 , 480-481, 359-69	117
1965	From the chromosome to DNA: Restriction fragment length polymorphism analysis and its clinical application. 2001 , 59, 660-7	10

1964	The many faces of metalloproteases: cell growth, invasion, angiogenesis and metastasis. 2001 , 11, S37-43	406
1963	Apoptosis and cancer chemotherapy. 2001 , 11, S22-6	109
1962	A Trends Guide to Cancer Biology. 2001 , 11, S1	0
1961	Programmed cell death: alive and well in the new millennium. 2001 , 11, 526-34	540
1960	A trends guide to cancer biology. 2001 , 11, S1	
1959	Apoptosis and cancer chemotherapy. 2001 , 11, S22-S26	92
1958	The many faces of metalloproteases: cell growth, invasion, angiogenesis and metastasis. 2001 , 11, S37-S43	356
1957	Invited Commentary to: "The Traumatic Orbital Lesion [Methods and Quality Control]" 2001 , 33, 96-96	
1956	Eingeladener Kommentar zu: Der prognostische Wert der p53-Immunhistochemie beim Gallenblasenkarzinom 2001 , 33, 96-98	
1955	Multi-modal combination gene therapy for malignant glioma using replication-defective HSV vectors. 2001 , 6, 347-356	10
1954	Novel expression of cyclin-dependent kinase inhibitors in human B-cell precursors. 2001 , 29, 490-8	12
1953	Centrosome abnormalities, genomic instability and carcinogenic progression. 2001 , 1471, M81-8	49
1952	Regulation of the p53 pathway by Ras, the plot thickens. 2001 , 1471, M63-71	15
1951	Apoptosis regulators and their role in tumorigenesis. 2001 , 1551, F1-37	73
1950	Epigenetics: unforeseen regulators in cancer. 2001 , 1552, 15-26	3
1949	Highlights from: 2nd International Lung Cancer Congress Kauai, Hawaii, July 18-21, 2001. 2001 , 3, 93-6	
1948	Overexpression of Hp95 induces G1 phase arrest in confluent HeLa cells. 2001 , 67, 139-53	39
1947	Immunodetection of nmt55/p54nrb isoforms in human breast cancer. 2001 , 1, 15	30

1946	Growth-stimulating pathways in lung cancer: implications for targets of therapy. 2001 , 2, 299-306; discussion 307	3
1945	Unraveling resistance to trastuzumab (Herceptin): insulin-like growth factor-I receptor, a new suspect. 2001 , 93, 1830-2	78
1944	Angiogenic potential of prostate carcinoma cells overexpressing bcl-2. 2001 , 93, 208-13	85
1943	Oncogenic ras activates the ARF-p53 pathway to suppress epithelial cell transformation. 2001 , 98, 5025-30	183
1942	Suppression of Ras-mediated tumorigenicity and metastasis through inhibition of the Met receptor tyrosine kinase. 2001 , 98, 10722-7	88
1941	AKT plays a central role in tumorigenesis. 2001 , 98, 10983-5	756
1940	The woodchuck model of hepatitis B virus infection. 2001 , 42, 89-102	67
1939	Mechanisms of Toxicity, Carcinogenesis, Cancer Prevention, and Cancer Therapy: July 15-18, 2001, The Gant Conference Center, Aspen, Colorado. 2001 , 29, 677-717	
1938	Ribonucleoprotein infrastructure regulating the flow of genetic information between the genome and the proteome. 2001 , 98, 7018-24	201
1937	Hematologic malignancies: an opportunity for targeted drug therapy. 2001 , 6 Suppl 5, 1-3	1
1936	A low-molecular-weight fraction of human seminal plasma activates adenylyl cyclase and induces caspase 3-independent apoptosis in prostatic epithelial cells by decreasing mitochondrial potential and Bcl-2/Bax ratio. 2001 , 15, 673-83	19
1935	Angiogenesis in chronic myeloproliferative diseases. 2001 , 106, 177-83	53
1934	New drug targets for genomic cancer therapy: successes, limitations, opportunities and future challenges. 2001 , 1, 33-47	42
1933	Tissue inhibitor of metalloproteinases-2 (TIMP-2) suppresses TKR-growth factor signaling independent of metalloproteinase inhibition. 2001 , 276, 3203-14	97
1932	Molecular cloning and characterization of endosialin, a C-type lectin-like cell surface receptor of tumor endothelium. 2001 , 276, 7408-14	110
1931	Regulation of G protein-initiated signal transduction in yeast: paradigms and principles. 2001 , 70, 703-54	362
1930	Horizontal transfer of oncogenes by uptake of apoptotic bodies. 2001 , 98, 6407-11	369
1929	Forward: Aging and cancer: Are telomeres and telomerase the connection?. 2001 , 8, 1-13	

1928	Dual growth arrest pathways in astrocytes and astrocytic tumors in response to Raf-1 activation. 2001 , 276, 18871-7	43
1927	Thrombospondin-1 suppresses spontaneous tumor growth and inhibits activation of matrix metalloproteinase-9 and mobilization of vascular endothelial growth factor. 2001 , 98, 12485-90	393
1926	Conditional immortalization of freshly isolated human mammary fibroblasts and endothelial cells. 2001 , 98, 646-51	202
1925	Molecular characterization of the mouse Tem1/endosialin gene regulated by cell density in vitro and expressed in normal tissues in vivo. 2001 , 276, 38795-807	50
1924	Molecular classification of multiple tumor types. 2001 , 17 Suppl 1, S316-22	160
1923	The nation-wide Swedish family-cancer database--updated structure and familial rates. 2001 , 40, 772-7	220
1922	Defective repression of c-myc in breast cancer cells: A loss at the core of the transforming growth factor beta growth arrest program. 2001 , 98, 992-9	276
1921	Telomerase in brain development and neurodegenerative disorders. 2001 , 167-183	
1920	Inflammatory cells and cancer: think different!. 2001 , 193, F23-6	312
1919	Transcriptional control at regulatory checkpoints by histone deacetylases: molecular connections between cancer and chromatin. 2001 , 10, 693-8	239
1918	Myc potentiates apoptosis by stimulating Bax activity at the mitochondria. 2001 , 21, 4725-36	119
1917	Inhibition of the motility and growth of B16F10 mouse melanoma cells by dominant negative mutants of Dok-1. 2001 , 21, 5437-46	26
1916	Multiple controlling mechanisms of FGF1 gene expression through multiple tissue-specific promoters. 2001 , 70, 155-74	33
1915	Apoptosis and its relevance in cancer therapy. 2001 , 24, 433-40	13
1914	Activation of the Met receptor by cell attachment induces and sustains hepatocellular carcinomas in transgenic mice. 2001 , 153, 1023-34	251
1913	Targeted therapies for killing tumor cells. 2001 , 98, 10028-30	16
1912	JAC, a direct target of oncogenic transcription factor Jun, is involved in cell transformation and tumorigenesis. 2001 , 98, 13601-6	22
1911	Variable beta-catenin expression in colorectal cancers indicates tumor progression driven by the tumor environment. 2001 , 98, 10356-61	871

1910	Tumor suppressors on 3p: a neoclassic quartet. 2001 , 98, 14763-5	31
1909	The breast cancer beta 4 integrin and endothelial human CLCA2 mediate lung metastasis. 2001 , 276, 25438-46	109
1908	Architectural transcription factor HMGI(Y) promotes tumor progression and mesenchymal transition of human epithelial cells. 2001 , 21, 575-94	211
1907	Repair of double-strand breaks by homologous recombination in mismatch repair-defective mammalian cells. 2001 , 21, 2671-82	148
1906	Perspectives on brain tumor formation involving macrophages, glia, and neural stem cells. 2001 , 44, 263-82	46
1905	Targeted inhibition of telomerase in human cancer: will it be a double-edged sword?. 2001 , 24, 22-6	1
1904	Human neural stem and progenitor cells: in vitro and in vivo properties, and potential for gene therapy and cell replacement in the CNS. 2001 , 1, 279-99	78
1903	Operational reversibility is a key aspect of carcinogenesis. 2001 , 64, 147-8	10
1902	Molecular, metabolic, and genetic control: An introduction. 2001 , 11, 81-83	10
1901	Induction and apoptotic regression of lung adenocarcinomas by regulation of a K-Ras transgene in the presence and absence of tumor suppressor genes. 2001 , 15, 3249-62	476
1900	Drugs targeted against protein kinases. 2001 , 6, 303-15	25
1899	Clinical application of antiangiogenic therapy: microvessel density, what it does and doesn't tell us. 2002 , 94, 883-93	584
1898	Angiogenesis and pulmonary hypertension: a unique process in a unique disease. 2002 , 4, 833-43	39
1897	Multistage carcinogenesis and the incidence of colorectal cancer. 2002 , 99, 15095-100	267
1896	Is cisplatin still the best platinum compound in non-small-cell lung cancer?. 2002 , 13, 1515-7	16
1895	T antigens of simian virus 40: molecular chaperones for viral replication and tumorigenesis. 2002 , 66, 179-202	182
1894	E7 abolishes raf-induced arrest via mislocalization of p21(Cip1). 2002 , 22, 7041-52	49
1893	Requirement of ATM in UVA-induced signaling and apoptosis. 2002 , 277, 3124-31	68

1892	Symptomatic and asymptomatic benign prostatic hyperplasia: molecular differentiation by using microarrays. 2002 , 99, 7598-603	105
1891	Short RNA duplexes produced by hydrolysis with Escherichia coli RNase III mediate effective RNA interference in mammalian cells. 2002 , 99, 9942-7	262
1890	AI and SAR approaches for predicting chemical carcinogenicity: survey and status report. 2002 , 13, 1-19	60
1889	The Arf tumor suppressor gene promotes hyaloid vascular regression during mouse eye development. 2002 , 99, 3848-53	102
1888	A tumor-specific kinase activity regulates the viral death protein Apoptin. 2002 , 277, 50820-7	87
1887	High incidence of epithelial cancers in mice deficient for DNA polymerase delta proofreading. 2002 , 99, 15560-5	140
1886	Hepatocyte growth factor inhibits anoikis in head and neck squamous cell carcinoma cells by activation of ERK and Akt signaling independent of NFkappa B. 2002 , 277, 25203-8	107
1885	Ras and TGF[beta] cooperatively regulate epithelial cell plasticity and metastasis: dissection of Ras signaling pathways. 2002 , 156, 299-313	621
1884	Mechanism of action for N-substituted benzamide-induced apoptosis. 2002 , 86, 971-8	18
1883	Tumor suppressor PTEN is mutated in canine osteosarcoma cell lines and tumors. 2002 , 39, 372-8	76
1882	Altered DNA methylation: a secondary mechanism involved in carcinogenesis. 2002 , 42, 501-25	100
1881	Induction of apoptosis by stomach cancer-associated protein-tyrosine phosphatase-1. 2002 , 277, 34359-66	28
1880	Cell cycle regulators: role in etiology, prognosis and treatment in cancer. 2002 , 13 Suppl 4, 39	8
1879	The Restriction Point of the Cell Cycle. 2002 , 1, 102-109	197
1878	Quantitation of molecular endpoints for the dose-response component of cancer risk assessment. 2002 , 30, 112-6	23
1877	Hyperthermia exhibits anti-vascular activity in the s.c. BT4An rat glioma: lack of interaction with the angiogenesis inhibitor batimastat. 2002 , 18, 141-52	16
1876	Functional cloning, sorting, and expression profiling of nucleic acid-binding proteins. 2002 , 12, 1175-84	6
1875	A fragment of the HMGN2 protein homes to the nuclei of tumor cells and tumor endothelial cells in vivo. 2002 , 99, 7444-9	234

1874	Differential proteome analysis of replicative senescence in rat embryo fibroblasts. 2002 , 1, 280-92	39
1873	Occurrence of H-ras codon 61 CAA to AAA mutation during mouse liver tumor progression. 2002 , 23, 943-8	15
1872	Heterotopic implantation alters the regulation of apoptosis and the cell cycle and generates a new metastatic site in a human pancreatic tumor xenograft model. 2002 , 16, 975-82	18
1871	Infrequent somatic deletion of the 5' region of the COL1A2 gene in oesophageal squamous cell cancer patients. 2002 , 40, 941-5	7
1870	Regulation of HEF1 expression and phosphorylation by TGF-beta 1 and cell adhesion. 2002 , 277, 39599-608	59
1869	Hepatocyte growth factor inhibits anoikis by induction of activator protein 1-dependent cyclooxygenase-2. Implication in head and neck squamous cell carcinoma progression. 2002 , 277, 50137-42	51
1868	Transduction of wild-type merlin into human schwannoma cells decreases schwannoma cell growth and induces apoptosis. 2002 , 11, 69-76	52
1867	Clinicopathologic correlations of genomic gains and losses in follicular lymphoma. 2002 , 20, 4523-30	68
1866	HMG-CoA reductase inhibitors and the malignant cell: the statin family of drugs as triggers of tumor-specific apoptosis. 2002 , 16, 508-19	444
1865	Activation of BAD by therapeutic inhibition of epidermal growth factor receptor and transactivation by insulin-like growth factor receptor. 2002 , 277, 27643-50	156
1864	Cyclotherapy: protection of normal cells and unshielding of cancer cells. 2002 , 1, 375-82	76
1863	Four Birds with One Stone: RAPA as Potential Anticancer. 2002 , 1, 358-360	8
1862	From the war on cancer to translational oncology. 2002 , 1, 711-4	1
1861	p53: a key player in the telomere dynamics. 2002 , 1, 518-9	0
1860	Basic Cell Cycle and Cancer Research: Is Harmony Possible?. 2002 , 1, 2-2	3
1859	Effect of reproductive hormones on ovarian epithelial tumors: II. Effect on angiogenic activity. 2002 , 1, 307-12	3
1858	Duplication of the genome in normal and cancer cell cycles. 2002 , 1, 8-13	10
1857	The FLIP side of cancer cell death. 2002 , 1, 407-8	6

1856	Phytochemicals as Cell Cycle Modulators A Less Toxic Approach in Halting Human Cancers. 2002 , 1, 155-160	117
1855	Role of MRIT/cFLIP in protection against chemotherapy-induced apoptosis. 2002 , 1, 652-60	25
1854	Hsp-90-associated oncoproteins: multiple targets of geldanamycin and its analogs. 2002 , 16, 455-62	199
1853	The emergence of resistance to targeted cancer therapeutics. 2002 , 3, 603-23	21
1852	Pancreatic Cancer. 2002 ,	1
1851	Multiparameter analyses of cell cycle regulatory proteins in human breast cancer: a key to definition of separate pathways in tumorigenesis. 2002 , 84, 35-56	15
1850	Myeloid differentiation (MyD)/growth arrest DNA damage (GADD) genes in tumor suppression, immunity and inflammation. 2002 , 16, 527-41	74
1849	Dissecting the molecular mechanism of chronic myelogenous leukemia using murine models. 2002 , 43, 1549-61	6
1848	The role of adjuvant therapy for pancreatic cancer. 2002 , 11, 87-107	7
1847	Therapies directed at vascular endothelial growth factor. 2002 , 11, 1715-36	80
1846	Continuous intravascular secretion of endostatin in mice from transduced hematopoietic stem cells. 2002 , 5, 345-51	50
1845	Application of phage display technology to cancer research. 2002 , 3, 29-43	14
1844	Silymarin inhibits growth and causes regression of established skin tumors in SENCAR mice via modulation of mitogen-activated protein kinases and induction of apoptosis. 2002 , 23, 499-510	117
1843	The effects of adrenomedullin overexpression in breast tumor cells. 2002 , 94, 1226-37	91
1842	The impact of genomic and proteomic technologies on the development of new cancer drugs. 2002 , 13 Suppl 4, 115-24	15
1841	Enterococcus faecalis produces extracellular superoxide and hydrogen peroxide that damages colonic epithelial cell DNA. 2002 , 23, 529-36	297
1840	Differential inactivation of caspase-8 in lung cancers. 2002 , 1, 65-9	122
1839	Molecular aspects of the mammalian cell cycle and cancer. 2002 , 7, 73-81	90

1838	Radiation oncology--linking technology and biology in the treatment of cancer. 2002 , 41, 6-13	17
1837	Cancer epigenomics. 2002 , 11, 2479-88	92
1836	Cdk4 disruption renders primary mouse cells resistant to oncogenic transformation, leading to Arf/p53-independent senescence. 2002 , 16, 2923-34	110
1835	Interrelationships among angiogenesis, proliferation, and apoptosis in the tumor microenvironment during N-methyl-N-nitrosourea androgen-induced prostate carcinogenesis in rats. 2002 , 23, 1701-11	28
1834	Determinants of 4-aminobiphenyl-DNA adducts in bladder cancer biopsies. 2002 , 23, 861-6	43
1833	Why the epidermal growth factor receptor? The rationale for cancer therapy. 2002 , 7 Suppl 4, 2-8	346
1832	Toward better early-phase brain tumor clinical trials: a reappraisal of current methods and proposals for future strategies. 2002 , 4, 268-77	38
1831	Neurofibromas in NF1: Schwann cell origin and role of tumor environment. 2002 , 296, 920-2	482
1830	mtCLIC/CLIC4, an organellar chloride channel protein, is increased by DNA damage and participates in the apoptotic response to p53. 2002 , 22, 3610-20	144
1829	MECHANISM-BASED HIGH-THROUGHPUT SCREENING FOR NOVEL ANTICANCER DRUG DISCOVERY. 2002 , 249-267	5
1828	Vascular growth factors and lymphangiogenesis. 2002 , 82, 673-700	322
1827	Cell cycle arrest and repression of cyclin D1 transcription by INI1/hSNF5. 2002 , 22, 5975-88	206
1826	Antiangiogenesis therapeutic strategies in prostate cancer. 2002 , 317-330	
1825	The RASputin effect. 2002 , 16, 2033-8	24
1824	Adenomatous polyposis coli (APC) protein expression in primary and metastatic serous ovarian carcinoma. 2002 , 10, 175-80	27
1823	Regulation of insulin-like growth factor type I (IGF-I) receptor kinase activity by protein tyrosine phosphatase 1B (PTP-1B) and enhanced IGF-I-mediated suppression of apoptosis and motility in PTP-1B-deficient fibroblasts. 2002 , 22, 1998-2010	105
1822	Interactions between Ras1, dMyc, and dPI3K signaling in the developing Drosophila wing. 2002 , 16, 2286-99	135
1821	Integrin (alpha 6 beta 4) regulation of eIF-4E activity and VEGF translation: a survival mechanism for carcinoma cells. 2002 , 158, 165-74	169

1820	Is TIG1 a new tumor suppressor in prostate cancer?. 2002 , 94, 469-70	9
1819	c-Myc augments the apoptotic activity of cytosolic death receptor signaling proteins by engaging the mitochondrial apoptotic pathway. 2002 , 277, 43224-32	61
1818	Preferential misincorporation of purine nucleotides by human DNA polymerase eta opposite benzo[a]pyrene 7,8-diol 9,10-epoxide deoxyguanosine adducts. 2002 , 277, 11765-71	75
1817	The role of Raf kinases in malignant transformation. 2002 , 4, 1-18	55
1816	The molecular perspective: VEGF and angiogenesis. 2002 , 7, 569-70	20
1815	Plasma from cancer patients featuring a characteristic protein composition mediates protection against apoptosis. 2002 , 1, 387-93	34
1814	Prostate Cancer: New Horizons in Research and Treatment. 2002 ,	
1813	Multilevel dysregulation of STAT3 activation in anaplastic lymphoma kinase-positive T/null-cell lymphoma. 2002 , 168, 466-74	223
1812	Signaling networks that link cell proliferation and cell fate. 2002 , 277, 11617-20	249
1811	Skilled use of DNA polymorphisms as a tool for polygenic cancers. 2002 , 23, 379-80	14
1810	Mechanisms and Biological Markers of Carcinogenesis. 2002 , 7-19	
1809	Role and regulation of activator protein-1 in toxicant-induced responses of the lung. 2002 , 283, L1161-78	118
1808	Functional analysis of the antimitogenic activity of tumor suppressors. 2003 , 218, 3-15	3
1807	Janus face of vascular endothelial growth factor: the obligatory survival factor for lung vascular endothelium controls precapillary artery remodeling in severe pulmonary hypertension. 2002 , 30, S251-6	79
1806	Expression of cell cycle-related gene products in Langerhans cell histiocytosis. 2002 , 24, 727-32	60
1805	Epigenetics in colorectal cancer. 2002 , 18, 68-73	25
1804	Molecular pathogenesis of pituitary disorders. 2002 , 9, 61-78	5
1803	The molecular biology of lung cancer. 2002 , 8, 265-9	8

1802	Etiology of osteosarcoma. 2002 , 40-52	167
1801	NF-kappaB activation and inhibition: a review. 2002 , 18, 99-106	192
1800	Pulses and carcinogenesis: potential for the prevention of colon, breast and other cancers. 2002 , 88 Suppl 3, S273-9	101
1799	7 The role of MUC18 in prostate carcinoma. 2002 , 347-358	3
1798	Retinoblastoma tumor suppressor and genome stability. 2002 , 85, 13-50	41
1797	A novel form of the RelA nuclear factor kappaB subunit is induced by and forms a complex with the proto-oncogene c-Myc. 2002 , 366, 459-69	24
1796	Cytomorphologic, immunohistochemical, and cytogenetic profiles of follicular lymphoma: 2 types of follicular lymphoma grade 3. 2002 , 99, 3806-12	227
1795	The death-promoting activity of p53 can be inhibited by distinct signaling pathways. 2002 , 100, 3990-4000	17
1794	Myeloid cell factor-1 is a critical survival factor for multiple myeloma. 2002 , 99, 1885-93	318
1793	Cross signaling, cell specificity, and physiology. 2002 , 283, C2-28	59
1792	Cell and molecular biology of the multifunctional peptide, adrenomedullin. 2002 , 221, 1-92	110
1791	Oncogenes and growth factors. 2002 , 6, 51-84	
1790	Differential Display of Gene Expression in Human Carcinomas. 2002 , 75-83	
1789	Genetic advances will influence the practice of medicine: examples from cancer research and care of cancer patients. 2002 , 4, 15S-20S	6
1788	PIN1 is an E2F target gene essential for Neu/Ras-induced transformation of mammary epithelial cells. 2002 , 22, 5281-95	219
1787	Angiogenesis in chondrosarcoma. 2002 , 13, 449-453	3
1786	The estrogen-occupied estrogen receptor functions as a negative regulator to inhibit cell proliferation induced by insulin/IGF-1: a cell context-specific antimitogenic action of estradiol on rat lactotrophs in culture. 2002 , 143, 2750-8	36
1785	Genetic changes in neoplasms arising in congenital melanocytic nevi: differences between nodular proliferations and melanomas. 2002 , 161, 1163-9	188

1784	Proliferation, but not apoptosis, is associated with distinct beta-catenin expression patterns in non-small-cell lung carcinomas: relationship with adenomatous polyposis coli and G(1)-to S-phase cell-cycle regulators. 2002 , 161, 1619-34	40
1783	Generation of a syngeneic mouse model to study the effects of vascular endothelial growth factor in ovarian carcinoma. 2002 , 161, 2295-309	111
1782	Quantitative assessment of promoter hypermethylation during breast cancer development. 2002 , 160, 605-12	191
1781	Temperature-dependent localization of TLS-CHOP to splicing factor compartments. 2002 , 278, 125-32	17
1780	Regulation of epithelial cell migration and tumor formation by beta-catenin signaling. 2002 , 280, 119-33	146
1779	Sphingosine kinase type 1 promotes estrogen-dependent tumorigenesis of breast cancer MCF-7 cells. 2002 , 281, 115-27	191
1778	Role of cyclooxygenase-2 in breast cancer. 2002 , 108, 173-9	89
1777	Global and gene-specific methylation patterns in cancer: aspects of tumor biology and clinical potential. 2002 , 75, 1-16	48
1776	Reaction-diffusion model for the growth of avascular tumor. 2002 , 65, 021907	151
1775	Overexpression of the mouse Fas gene in human Hep3B hepatoma cells overcomes their resistance to Fas-mediated apoptosis. 2002 , 36, 385-94	16
1774	HSP90 as a new therapeutic target for cancer therapy: the story unfolds. 2002 , 2, 3-24	437
1773	Colorectal adenoma to carcinoma progression follows multiple pathways of chromosomal instability. 2002 , 123, 1109-19	243
1772	Resistance to trastuzumab: a necessary evil or a temporary challenge?. 2002 , 3, 247-57; discussion 258-9	54
1771	Irinotecan in non-small-cell lung cancer: status of ongoing trials. 2002 , 4 Suppl 1, S15-20	3
1770	Natural and pharmacological regulation of telomerase. 2002 , 30, 839-65	284
1769	Molecular Mechanisms of Cancer Invasion. 2002 , 221-233	2
1768	Cancer. Addiction to oncogenes--the Achilles heal of cancer. 2002 , 297, 63-4	1429
1767	Maspin is a tumour suppressor that inhibits breast cancer tumour metastasis in vivo. 2002 , 4, 137-40	23

1766	Rules for making human tumor cells. 2002 , 347, 1593-603	750
1765	Rho GTPases in transformation and metastasis. 2002 , 84, 57-80	217
1764	Combination of endostatin and a protein kinase Calpha DNA enzyme improves the survival of rats with malignant glioma. 2002 , 4, 474-9	14
1763	Cytotoxic cyplasin of the sea hare, <i>Aplysia punctata</i> , cDNA cloning, and expression of bioactive recombinants in insect cells. 2002 , 4, 49-59	12
1762	. 2002 , 4, 42-49	5
1761	Induction of apoptosis in cancer: new therapeutic opportunities. 2002 , 34, 451-69	40
1760	Order and disorder: the role of extracellular matrix in epithelial cancer. 2002 , 20, 139-53	83
1759	Anti-cancer drugs of today and tomorrow: are we close to making the turn from treating to curing cancer?. 2002 , 8, 1723-34	15
1758	Mechanism of human telomerase inhibition by BIBR1532, a synthetic, non-nucleosidic drug candidate. 2002 , 277, 15566-72	201
1757	Apoptosis: a link between cancer genetics and chemotherapy. <i>Cell</i> , 2002 , 108, 153-64	56.2 1883
1756	Suppression of Myc-induced apoptosis in beta cells exposes multiple oncogenic properties of Myc and triggers carcinogenic progression. <i>Cell</i> , 2002 , 109, 321-34	56.2 537
1755	Taking the study of cancer cell survival to a new dimension. <i>Cell</i> , 2002 , 111, 923-5	56.2 253
1754	Hallmarks of cancer progression in Barrett's oesophagus. 2002 , 360, 1587-9	125
1753	Radiotherapy in soft-tissue sarcoma. 2002 , 360, 1989	1
1752	Clonal heterogeneity in differentiation potential of immortalized human mesenchymal stem cells. 2002 , 295, 354-61	210
1751	Molecular mechanisms of anti-angiogenic effect of curcumin. 2002 , 297, 934-42	210
1750	Differential regulation of transcription and induction of programmed cell death by human p53-family members p63 and p73. 2002 , 525, 93-9	49
1749	Risk factors for metastasis in retinoblastoma. 2002 , 47, 1-16	152

1748	Determination of the epigenetic effects of ochratoxin in a human kidney and a rat liver epithelial cell line. 2002 , 40, 273-82	45
1747	Anticancer activity of Hemsleya amabilis extract. 2002 , 71, 2161-70	68
1746	Looking to the Future: Advances in the Management of Hormone-Refractory Prostate Cancer. 2002 , 1, 44-53	7
1745	The E-cadherin cell-cell adhesion complex and lung cancer invasion, metastasis, and prognosis. 2002 , 36, 115-24	189
1744	Growth index is independent of microvessel density in non-small-cell lung carcinomas. 2002 , 33, 812-8	16
1743	Signaling and proapoptotic functions of transformed cell-derived reactive oxygen species. 2002 , 66, 41-56	37
1742	Direct interaction of c-Myc with Smad2 and Smad3 to inhibit TGF-beta-mediated induction of the CDK inhibitor p15(Ink4B). 2002 , 9, 133-43	181
1741	Mechanisms of caspase activation and inhibition during apoptosis. 2002 , 9, 459-70	1334
1740	B cell growth is controlled by phosphatidylinositol 3-kinase-dependent induction of Rel/NF-kappaB regulated c-myc transcription. 2002 , 10, 1283-94	118
1739	Melanoma-stroma interactions: structural and functional aspects. 2002 , 3, 35-43	190
1738	Cancer causation: the Darwinian downside of past success?. 2002 , 3, 244-51	73
1737	Cigarette smoking and lung cancer: chemical mechanisms and approaches to prevention. 2002 , 3, 461-9	361
1736	The price of anticancer intervention. Treatment-induced malignancy. 2002 , 3, 575-6	3
1735	Antisense therapy for cancer--the time of truth. 2002 , 3, 672-83	149
1734	Changes and challenges--the world post-Gleevec (Glivec). 2002 , 2, 357-60	1
1733	The origin of CD95-gene mutations in B-cell lymphoma. 2002 , 23, 75-80	69
1732	Unraveling the complexities of the Raf/MAP kinase pathway for pharmacological intervention. 2002 , 8, S27-31	77
1731	Translating basic cancer research into new cancer therapeutics. 2002 , 8, S1-9	59

1730	The fabric of cancer cell biology-Weaving together the strands. 2002 , 1, 3-10	44
1729	A matter of life and death. 2002 , 1, 19-30	887
1728	Cancer genomics. 2002 , 1, 37-47	51
1727	VEGF-A has a critical, nonredundant role in angiogenic switching and pancreatic beta cell carcinogenesis. 2002 , 1, 193-202	336
1726	Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. 2002 , 1, 133-43	1541
1725	Selectively replicating adenoviruses targeting deregulated E2F activity are potent, systemic antitumor agents. 2002 , 1, 325-37	166
1724	(Re-)Engineering tumor cell-selective replicating adenoviruses: a step in the right direction toward systemic therapy for metastatic disease. 2002 , 1, 307-9	14
1723	Senescence: a companion in chemotherapy?. 2002 , 1, 309-11	12
1722	Mutational specificity of mice defective in the MTH1 and/or the MSH2 genes. 2002 , 1, 881-93	68
1721	Cell metabolism in the regulation of programmed cell death. 2002 , 13, 75-8	187
1720	Cancer and aging: a model for the cancer promoting effects of the aging stroma. 2002 , 34, 1401-14	244
1719	Senescence and epigenetic dysregulation in cancer. 2002 , 34, 1475-90	47
1718	Acentromeric micronuclei are increased in peripheral blood lymphocytes of untreated cancer patients. 2002 , 520, 189-98	31
1717	The role of p53 and pRB in apoptosis and cancer. 2002 , 12, 60-6	169
1716	Apoptosis and tumourigenesis. 2002 , 12, 67-72	86
1715	Editorial comment on 'Frequent 3p allele loss and epigenetic inactivation of the RASSF1A tumour suppressor gene from region 3p21.3 in head and neck squamous cell carcinoma' by Hogg and colleagues. 2002 , 38, 1561-3	2
1714	Pharmacology of imatinib (STI571). 2002 , 38 Suppl 5, S28-36	180
1713	Intragenomic conflict and cancer. 2002 , 59, 170-9	21

1712	Linking cyclins to transcriptional control. 2002 , 299, 35-55	357
1711	In vitro models for the identification and characterization of tumor-promoting and protective factors for colon carcinogenesis. 2002 , 40, 1099-104	13
1710	TP53: a key gene in human cancer. 2002 , 84, 83-93	133
1709	Molecular pathogenesis of granulosa cell tumours. 2002 , 191, 89-96	34
1708	Molecular and immunohistochemical analysis of signaling adaptor protein Crk in human cancers. 2002 , 180, 55-61	54
1707	Effect of Bcl-2 expression on hepatic preneoplasia in mice. 2002 , 177, 189-95	5
1706	The myc oncogene: MarvelouslyY Complex. 2002 , 84, 81-154	347
1705	The genetic pathogenesis of colorectal cancer. 2002 , 16, 775-810	48
1704	Transcriptional analyses of Barrett's metaplasia and normal upper GI mucosae. 2002 , 4, 121-8	35
1703	Angiogenesis as a target for cancer therapy. 2002 , 16, 1125-71	20
1702	Clinical trial designs for targeted agents. 2002 , 16, 1287-305	12
1701	Some tools for molecular imaging. 2002 , 9, 629-31	17
1700	A G-quadruplex-interactive potent small-molecule inhibitor of telomerase exhibiting in vitro and in vivo antitumor activity. 2002 , 61, 1154-62	246
1699	Modélisation, analyse et simulation des réseaux génétiques. 2002 , 18, 492-502	1
1698	Angiogenesis in Health and Disease: Insights into Basic Mechanisms and Therapeutic Opportunities. 2002 , 66, 962-975	55
1697	Signaling from toxic metals to NF-kappaB and beyond: not just a matter of reactive oxygen species. 2002 , 110 Suppl 5, 807-11	41
1696	Molecular mechanisms in signal transduction: new targets for the therapy of gynecologic malignancies. 2002 , 25, 240-7	3
1695	Energy imbalance and prostate cancer. 2002 , 132, 3471S-3481S	44

1694	Homeostasis of extracellular matrix by TGF-beta and lefty. 2002 , 7, d1231-46	28
1693	Cancer risk assessment, indicators, and guidelines for polycyclic aromatic hydrocarbons in the ambient air. 2002 , 110 Suppl 3, 451-88	828
1692	ErbB receptor tyrosine kinase inhibitors as therapeutic agents. 2002 , 7, d1926	9
1691	DNA microarrays in clinical oncology. 2002 , 20, 1932-41	283
1690	Expression microarray analysis of brain tumors: what have we learned so far. 2002 , 7, c74-82	
1689	Expression of anaplastic lymphoma kinase in non-Hodgkin's lymphomas and other malignant neoplasms. Biological, diagnostic, and clinical implications. 2002 , 118 Suppl, S81-92	4
1688	PI3K Blockade by Ad-PTEN Inhibits Invasion and Induces Apoptosis in Radial Growth Phase and Metastatic Melanoma Cells. 2002 , 8, 451-461	70
1687	Matrix metalloproteinases and matrix metalloproteinase inhibitors in lung cancer. 2002 , 29, 78-86	67
1686	Between Scylla and Charybdis: p53 links tumor suppression and aging. 2002 , 123, 567-73	28
1685	Gene expression profiling in RAS oncogene-transformed cell lines and in solid tumors using subtractive suppression hybridization and cDNA arrays. 2002 , 42, 63-82	17
1684	If at first you don't succeed em leaderfructose utilization by Escherichia coli. 2002 , 42, 349-60	3
1683	Protein kinases as targets for anticancer agents: from inhibitors to useful drugs. 2002 , 93, 79-98	253
1682	The origin of transformed cells. studies of spontaneous and induced cell transformation in cell cultures from marsupials, a snail, and human amniocytes. 2002 , 133, 45-54	43
1681	Role of P53 functionality in the genotoxicity of metronidazole and its hydroxy metabolite. 2002 , 501, 57-67	12
1680	A randomized trial of the effect of a plant-based dietary pattern on additional breast cancer events and survival: the Women's Healthy Eating and Living (WHEL) Study. 2002 , 23, 728-56	225
1679	Basal levels and patterns of anticancer drug-induced activation of nuclear factor-kappaB (NF-kappaB), and its attenuation by tamoxifen, dexamethasone, and curcumin in carcinoma cells. 2002 , 63, 1709-16	143
1678	Evasion from proteasomal degradation by mutated Fos proteins expressed from FBJ-MSV and FBR-MSV osteosarcomatogenic retroviruses. 2002 , 64, 957-61	5
1677	Chromosome-mediated alterations of the MYC gene in human cancer. 2002 , 6, 151-9	73

1676	Elevated levels of IGF-1 receptor convey invasive and metastatic capability in a mouse model of pancreatic islet tumorigenesis. 2002 , 1, 339-53	235
1675	Thinking beyond the tumor cell: Nf1 haploinsufficiency in the tumor environment. 2002 , 1, 408-10	28
1674	The RB and p53 pathways in cancer. 2002 , 2, 103-12	1281
1673	Stable suppression of tumorigenicity by virus-mediated RNA interference. 2002 , 2, 243-7	971
1672	salvador--The persistence of proliferation. 2002 , 2, 171-3	3
1671	Telomerase: a target for cancer therapeutics. 2002 , 2, 257-65	285
1670	Transformation of normal human cells in the absence of telomerase activation. 2002 , 2, 401-13	137
1669	Focus on embryonal malignancies. 2002 , 2, 447-50	58
1668	Matrix metalloproteinases in tumor-host cell communication. 2002 , 70, 561-73	316
1667	Motility cues in the tumor microenvironment. 2002 , 70, 590-8	28
1666	Epithelial carcinogenesis: dynamic interplay between neoplastic cells and their microenvironment. 2002 , 70, 610-23	68
1665	Targeting of RCC1 to chromosomes is required for proper mitotic spindle assembly in human cells. 2002 , 12, 1442-7	95
1664	RECKing MMP function: implications for cancer development. 2002 , 12, 209-11	91
1663	Tumor progression: a brief historical perspective. 2002 , 12, 261-6	104
1662	Implication of direct host-tumor intercellular interactions in non-immune host resistance to neoplastic growth. 2002 , 12, 267-76	13
1661	Laminin isoforms in tumor invasion, angiogenesis and metastasis. 2002 , 12, 197-207	289
1660	Global high-throughput screens for cellular function. 2002 , 30, 381-7	12
1659	Clinical implications of antigen transfer mechanisms from malignant to dendritic cells. exploiting cross-priming. 2002 , 30, 1355-64	32

1658	Contributions of Myc to tumorigenesis. 2002 , 1602, 61-71	79
1657	Recent advances in cancer research: mouse models of tumorigenesis. 2002 , 1602, 97-113	22
1656	Tec kinase pathways in lymphocyte development and transformation. 2002 , 1602, 162-7	3
1655	Pharmacogenomics in cancer drug discovery and development: inhibitors of the Hsp90 molecular chaperone. 2002 , 26, 405-10	21
1654	Transgenic systems in drug discovery: from target identification to humanized mice. 2002 , 7, 461-70	37
1653	The protein kinase B/Akt signalling pathway in human malignancy. 2002 , 14, 381-95	1302
1652	Expression of plasma membrane calcium pump isoform mRNAs in breast cancer cell lines. 2002 , 14, 1015-22	47
1651	Cluster analysis of an extensive human breast cancer cell line protein expression map database. 2002 , 2, 212-23	44
1650	Adrenomedullin functions as an important tumor survival factor in human carcinogenesis. 2002 , 57, 110-9	43
1649	Derangement of growth and differentiation control in oncogenesis. 2002 , 24, 83-90	24
1648	The dynamics of cell cycle regulation. 2002 , 24, 1095-109	236
1647	Defects in G1-S cell cycle control in head and neck cancer: a review. 2002 , 24, 694-704	18
1646	Wnt/beta-catenin signaling suppresses apoptosis in low serum medium and induces morphologic change in rodent fibroblasts. 2002 , 99, 681-8	30
1645	Stromelysin-3 expression by mammary tumor-associated fibroblasts under in vitro breast cancer cell induction. 2002 , 99, 792-9	15
1644	Characterization of XAGE-1b, a short major transcript of cancer/testis-associated gene XAGE-1, induced in melanoma metastasis. 2002 , 97, 195-204	43
1643	Merging bottom-up and top-down approaches to study prostate cancer biology. 2002 , 7, 22-30	5
1642	Mechanisms of cytotoxicity induced by horseradish peroxidase/indole-3-acetic acid gene therapy. 2002 , 87, 221-32	25
1641	Does p53 affect organismal aging?. 2002 , 192, 23-33	131

1640	P2P-R protein overexpression restricts mitotic progression at prometaphase and promotes mitotic apoptosis. 2002 , 193, 199-207	23
1639	Tobacco smoke carcinogens and breast cancer. 2002 , 39, 119-26	160
1638	Aberrant expression of cell-cycle regulator cyclin D1 in breast cancer is related to chromosomal genomic instability. 2002 , 34, 276-84	34
1637	Tyrosine kinase inhibitors: a clinical perspective. 2002 , 4, 9-19	36
1636	New approaches to lung cancer prevention. 2002 , 4, 487-94	15
1635	New molecular targets of breast cancer therapy. 2002 , 178, 123-33	17
1634	Genomische Analyse von Melanomen und melanozytären Nävi. 2002 , 53, 499-509	2
1633	An RCAS-TVA-based approach to designer mouse models. 2002 , 13, 543-7	56
1632	Tumor escape from killing: role of killer inhibitory receptors and acquisition of tumor resistance to cell death. 2002 , 60, 273-81	27
1631	Mast cells and angiogenesis. 2002 , 110, 355-71	287
1630	Stomach cancer highly expresses both initiator and effector caspases; an immunohistochemical study. 2002 , 110, 825-32	38
1629	5.3 Global challenges in research and strategic planning. 2002 , 6 Suppl 3, 179-84	11
1628	GM-CSF-based cancer vaccines. 2002 , 188, 147-54	227
1627	A view to a kill: ligands for Bcl-2 family proteins. 2002 , 6, 479-85	40
1626	Immune recognition and tumor protection. 2002 , 14, 161-164	16
1625	Telomerase in cancer and aging. 2002 , 41, 29-40	124
1624	Cell-surface proteolysis, growth factor activation and intercellular communication in the progression of melanoma. 2002 , 44, 1-15	42
1623	Intracellular signal transduction of cells in response to carcinogenic metals. 2002 , 42, 105-21	92

1622	Symposium 23B: Molecular diagnosis of bladder cancer. 2002 , 41, 403-423	2
1621	Symposium 29: New approaches in cytopathology. 2002 , 41, 493-505	
1620	The phosphatidylinositol 3-kinase/Akt signal pathway is involved in interleukin-6-mediated Mcl-1 upregulation and anti-apoptosis activity in basal cell carcinoma cells. 2002 , 119, 1121-7	38
1619	Life and death signaling pathways contributing to skin cancer. 2002 , 7, 27-35	65
1618	Histologic and immunohistochemical analysis of tissue response to adenovirus-mediated herpes simplex thymidine kinase gene therapy of ovarian cancer. 2002 , 12, 66-73	14
1617	Methylation is an inactivating mechanism of the p16 gene in multiple myeloma associated with high plasma cell proliferation and short survival. 2002 , 118, 1034-40	68
1616	Targeting molecular mechanisms in cancer. 2002 , 72, 760-3	1
1615	Mechanisms of TGF-beta signaling in regulation of cell growth and differentiation. 2002 , 82, 85-91	415
1614	Transcription factors and cancer: an overview. 2002 , 181-182, 131-41	56
1613	Apoptosis resistance of neuroendocrine phenotypes in prostatic adenocarcinoma. 2002 , 53, 118-23	60
1612	Gene therapy of melanoma pulmonary metastasis by intramuscular injection of plasmid DNA encoding tissue inhibitor of metalloproteinases-1. 2002 , 9, 126-32	10
1611	Cancer: The Evolutionary Legacy. 2002 , 88, 219-219	
1610	Bis(1H-2-indolyl)-1-methanones as inhibitors of the hematopoietic tyrosine kinase Flt3. 2002 , 16, 1528-34	37
1609	Differential sensitivity of cancer cells to inhibitors of the epidermal growth factor receptor family. 2002 , 21, 119-27	76
1608	Downregulating PKC delta provides a PI3K/Akt-independent survival signal that overcomes apoptotic signals generated by c-Src overexpression. 2002 , 21, 1071-8	43
1607	Differential protein expression, DNA binding and interaction with SV40 large tumour antigen implicate the p63-family of proteins in replicative senescence. 2002 , 21, 981-9	18
1606	The class II tumour suppressor gene H-REV107-1 is a target of interferon-regulatory factor-1 and is involved in IFNgamma-induced cell death in human ovarian carcinoma cells. 2002 , 21, 2829-39	38
1605	Phospholipase D overcomes cell cycle arrest induced by high-intensity Raf signaling. 2002 , 21, 3651-8	33

1604	Dominant negative PDGF-C inhibits growth of Ewing family tumor cell lines. 2002 , 21, 3847-54	49
1603	Sequential extension of proliferative lifespan in human fibroblasts induced by over-expression of CDK4 or 6 and loss of p53 function. 2002 , 21, 4277-88	33
1602	Syntenin is overexpressed and promotes cell migration in metastatic human breast and gastric cancer cell lines. 2002 , 21, 4080-8	100
1601	Molecular diagnosis of colorectal tumors by expression profiles of 50 genes expressed differentially in adenomas and carcinomas. 2002 , 21, 4120-8	145
1600	Identification of novel candidates for replicative senescence by functional proteomics. 2002 , 21, 4403-13	28
1599	Adenovirus encoding HIV-1 Vpr activates caspase 9 and induces apoptotic cell death in both p53 positive and negative human tumor cell lines. 2002 , 21, 4613-25	55
1598	Novel colon cancer cell lines leading to better understanding of the diversity of respective primary cancers. 2002 , 21, 4646-62	55
1597	Modeling cancer in mice. 2002 , 21, 5504-14	33
1596	Methylation reveals a niche: stem cell succession in human colon crypts. 2002 , 21, 5441-9	92
1595	DNA methylation and breast carcinogenesis. 2002 , 21, 5462-82	386
1594	MLL5, a homolog of Drosophila trithorax located within a segment of chromosome band 7q22 implicated in myeloid leukemia. 2002 , 21, 4849-54	84
1593	Inhibition of Rel/Nuclear Factor-kappaB signaling in skin results in defective DNA damage-induced cell cycle arrest and Ha-ras- and p53-independent tumor development. 2002 , 21, 4969-77	40
1592	BRCA2 and Smad3 synergize in regulation of gene transcription. 2002 , 21, 5660-4	22
1591	Tobacco smoke carcinogens, DNA damage and p53 mutations in smoking-associated cancers. 2002 , 21, 7435-51	815
1590	Repression of IRF-4 target genes in human T cell leukemia virus-1 infection. 2002 , 21, 6751-65	26
1589	Down-regulation of caspase 3 in breast cancer: a possible mechanism for chemoresistance. 2002 , 21, 8843-51	319
1588	Inflammation and cancer. 2002 , 420, 860-7	10561
1587	Conceptual biology: unearthing the gems. 2002 , 416, 373	50

1586	On the offensive. 2002 , 416, 470-4	14
1585	Cancer. The silence of the genes. 2002 , 419, 572-3	11
1584	Monitoring post-translational modification of proteins with allosteric ribozymes. 2002 , 20, 810-5	56
1583	Distinct roles for cyclins E and A during DNA replication complex assembly and activation. 2002 , 4, 523-8	246
1582	Tsc tumour suppressor proteins antagonize amino-acid-TOR signalling. 2002 , 4, 699-704	561
1581	Molecular portraits and the family tree of cancer. 2002 , 32 Suppl, 533-40	223
1580	Suppression of the p53- or pRB-mediated G1 checkpoint is required for E2F-induced S-phase entry. 2002 , 31, 190-4	74
1579	Human securin interacts with p53 and modulates p53-mediated transcriptional activity and apoptosis. 2002 , 32, 306-11	158
1578	Cancer immunoediting: from immunosurveillance to tumor escape. 2002 , 3, 991-8	3444
1577	Gene-expression profiles predict survival of patients with lung adenocarcinoma. 2002 , 8, 816-24	1597
1576	Cytoplasmic relocalization and inhibition of the cyclin-dependent kinase inhibitor p27(Kip1) by PKB/Akt-mediated phosphorylation in breast cancer. 2002 , 8, 1136-44	601
1575	Hypoxia--a key regulatory factor in tumour growth. 2002 , 2, 38-47	4026
1574	Specialization of tumour vasculature. 2002 , 2, 83-90	574
1573	Oncogenic resistance to growth-limiting conditions. 2002 , 2, 221-5	82
1572	New functions for the matrix metalloproteinases in cancer progression. 2002 , 2, 161-74	4764
1571	Death and anti-death: tumour resistance to apoptosis. 2002 , 2, 277-88	1525
1570	Conditional mouse models of sporadic cancer. 2002 , 2, 251-65	242
1569	Scatter-factor and semaphorin receptors: cell signalling for invasive growth. 2002 , 2, 289-300	630

1568	NF-kappaB in cancer: from innocent bystander to major culprit. 2002 , 2, 301-10	2149
1567	Modelling the molecular circuitry of cancer. 2002 , 2, 331-41	759
1566	Gli and hedgehog in cancer: tumours, embryos and stem cells. 2002 , 2, 361-72	632
1565	The Bcl2 family: regulators of the cellular life-or-death switch. 2002 , 2, 647-56	3082
1564	Clinical translation of angiogenesis inhibitors. 2002 , 2, 727-39	1299
1563	Transcription factors as targets for cancer therapy. 2002 , 2, 740-9	941
1562	Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. 2002 , 1, 287-99	1177
1561	Angiogenesis modulation in cancer research: novel clinical approaches. 2002 , 1, 415-26	144
1560	Dual-specificity phosphatases as targets for antineoplastic agents. 2002 , 1, 961-76	120
1559	Analysis of the cytochrome c-dependent apoptosis apparatus in cells from human pancreatic carcinoma. 2002 , 86, 893-8	18
1558	Gene expression profiles of bladder cancers: evidence for a striking effect of in vitro cell models on gene patterns. 2002 , 86, 1283-9	19
1557	Serological identification and expression analysis of gastric cancer-associated genes. 2002 , 86, 1824-30	61
1556	Targeting the cell cycle for cancer therapy. 2002 , 87, 129-33	113
1555	N-acetylgalactosaminyl transferase-3 is a potential new marker for non-small cell lung cancers. 2002 , 87, 751-5	38
1554	Horizontal transfer of DNA by the uptake of apoptotic bodies. 2002 , 83 Suppl 1, 305-6	31
1553	Multiple degradation pathways for Fos family proteins. 2002 , 973, 426-34	27
1552	Apoptosis modulation of Epstein-Barr virus-encoded latent membrane protein 1 in the epithelial cell line HeLa is stimulus-dependent. 2002 , 304, 330-41	22
1551	Cellular senescence and tissue aging in vivo. 2002 , 57, B251-6	59

1550	Growth factors: Setting the framework. 2002 , 225-255	2
1549	Childhood leukaemia. 2002 , 324, 283-7	208
1548	Signal transduction targets in invasion. 2002 , 19, 265-73	29
1547	NF- κ B, a pivotal transcription factor in silica-induced diseases. 2002 , 234/235, 169-176	26
1546	Decreased expression of intercellular adhesion molecule-1 (ICAM-1) and urokinase-type plasminogen activator receptor (uPAR) is associated with tumor cell spreading in vivo. 2002 , 19, 437-44	11
1545	TNF-related apoptosis inducing ligand (TRAIL) and its receptors in tumor surveillance and cancer therapy. 2002 , 7, 449-59	109
1544	Antiangiogenesis therapeutic strategies in prostate cancer. 2002 , 21, 93-106	6
1543	Antisense therapy: current status in prostate cancer and other malignancies. 2002 , 21, 79-92	32
1542	Proteomics in studies of signal transduction in epithelial cells. 2002 , 7, 359-71	17
1541	Mechanisms in epithelial plasticity and metastasis: insights from 3D cultures and expression profiling. 2002 , 7, 415-32	50
1540	Molecular and genetic defects in colorectal tumorigenesis. 2002 , 16, 171-85	22
1539	Cancer gene therapy: Part 2. Candidate transgenes and their clinical development. 2002 , 14, 148-69	9
1538	Understanding cancer: from the gene to the organism. Conference on genes and cancer. 2002 , 3, 415-9	2
1537	Designed transcription factors as structural, functional and therapeutic probes of chromatin in vivo. Fourth in review series on chromatin dynamics. 2002 , 3, 610-5	20
1536	The retinoblastoma gene product interacts with maintenance human DNA (cytosine-5) methyltransferase and modulates its activity. 2002 , 21, 779-88	93
1535	Functional proteomics of transforming growth factor-beta1-stimulated Mv1Lu epithelial cells: Rad51 as a target of TGFbeta1-dependent regulation of DNA repair. 2002 , 21, 1219-30	99
1534	Aberrantly expressed c-Jun and JunB are a hallmark of Hodgkin lymphoma cells, stimulate proliferation and synergize with NF-kappa B. 2002 , 21, 4104-13	270
1533	"Super p53" mice exhibit enhanced DNA damage response, are tumor resistant and age normally. 2002 , 21, 6225-35	431

1532	Smad4 transcriptional pathways and angiogenesis. 2002 , 31, 47-59	35
1531	Recent developments in antiangiogenic therapy. 2002 , 2, 953-66	11
1530	Molecular genetic alterations in adrenal and extra-adrenal pheochromocytomas and paragangliomas. 2003 , 14, 329-50	21
1529	NF-kappaB in pancreatic cancer. 2003 , 33, 15-26	44
1528	Telomere-based crisis: functional differences between telomerase activation and ALT in tumor progression. 2003 , 17, 88-100	136
1527	Genetic Defects as Tumor Markers. 2003 , 37, 159-169	9
1526	Concomitant differentiation and partial proteasome inhibition trigger apoptosis in neuroblastoma cells. 2003 , 63, 15-23	5
1525	Inhibition of invasion and metastasis by glypican-3 in a syngeneic breast cancer model. 2003 , 80, 221-32	73
1524	Involvement of TGF-beta(s)/T(beta)Rs system in tumor progression of murine mammary adenocarcinomas. 2003 , 80, 287-301	7
1523	The biology of antihormone failure in breast cancer. 2003 , 80 Suppl 1, S29-34; discussion S35	44
1522	Autocrine signalling through erbB receptors promotes constitutive activation of protein kinase B/Akt in breast cancer cell lines. 2003 , 81, 117-28	47
1521	Matrix metalloproteinases (MMP), EMMPRIN (extracellular matrix metalloproteinase inducer) and mitogen-activated protein kinases (MAPK): co-expression in metastatic serous ovarian carcinoma. 2003 , 20, 621-31	57
1520	The role of altered cell-cell communication in melanoma progression. 2004 , 35, 309-18	116
1519	Laser capture microdissection and advanced molecular analysis of human breast cancer. 2003 , 8, 335-45	37
1518	Hunting for tumor suppressor genes in liver cancer. 2003 , 37, 739-41	11
1517	Cholangiocarcinoma: current concepts and insights. 2003 , 37, 961-9	214
1516	PDK1 and PKB/Akt: ideal targets for development of new strategies to structure-based drug design. 2003 , 55, 117-26	35
1515	p53 activates ICAM-1 (CD54) expression in an NF-kappaB-independent manner. 2003 , 22, 1567-78	75

1514	The magnitude of hedgehog signaling activity defines skin tumor phenotype. 2003 , 22, 2741-51	113
1513	EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer. 2003 , 22, 5323-35	894
1512	scribble mutants cooperate with oncogenic Ras or Notch to cause neoplastic overgrowth in <i>Drosophila</i> . 2003 , 22, 5769-79	432
1511	Specific keynote: molecular therapeutics in ovarian cancer. 2003 , 88, S88-92; discussion S93-6	21
1510	Antisense to apoptosis inhibitors facilitates chemotherapy and TRAIL-induced death signaling. 2003 , 1002, 90-4	41
1509	Clusterin and IGFBPs as antisense targets in prostate cancer. 2003 , 1002, 95-104	36
1508	Chemosensitization and radiosensitization of human cancer by antisense anti-MDM2 oligonucleotides: in vitro and in vivo activities and mechanisms. 2003 , 1002, 217-35	47
1507	An introduction to the molecular mechanisms of apoptosis. 2003 , 1010, 1-8	54
1506	Differentiation Antigens: Dependence on Carcinogenesis Mechanisms and Tumor Progression (A Hypothesis). 2003 , 37, 2-8	7
1505	Distinct patterns of gene expression induced by viral oncogenes in human embryonic brain cells. 2003 , 23, 27-42	7
1504	Overexpression of autocrine motility factor receptor (AMFR) in NIH3T3 fibroblasts induces cell transformation. 2003 , 20, 51-8	19
1503	Angiogenesis and the role of epigenetics in metastasis. 2003 , 20, 215-27	18
1502	Translational control and metastatic progression: enhanced activity of the mRNA cap-binding protein eIF-4E selectively enhances translation of metastasis-related mRNAs. 2003 , 20, 265-73	177
1501	The molecular perspective: VEGF and angiogenesis. 2003 , 21, 118-9	35
1500	M-CSF targeting into LCL nucleus behaves as a malignancy promotor. 2003 , 15, 262-268	
1499	Global gene expression profiling in the study of multiple myeloma. 2003 , 77, 213-25	15
1498	Biologic directed therapies in gynecologic oncology. 2003 , 5, 459-67	3
1497	Molecular targets in therapy for human soft-tissue and bone sarcomas. 2003 , 5, 295-303	5

1496	The opportunities and challenges of personalized genome-based molecular therapies for cancer: targets, technologies, and molecular chaperones. 2003 , 52 Suppl 1, S45-56	45
1495	Pharmacogenomic applications in clinical drug development. 2003 , 52 Suppl 1, S57-60	5
1494	Development and differentiation of the intestinal epithelium. 2003 , 60, 1322-32	253
1493	Redefining tumour suppressor genes: exceptions to the two-hit hypothesis. 2003 , 60, 2147-63	45
1492	Progranulin (granulin-epithelin precursor, PC-cell-derived growth factor, acrogranin) mediates tissue repair and tumorigenesis. 2003 , 81, 600-12	377
1491	Expression of MUC 1 and Ep-CAM in Merkel cell carcinomas: implications for immunotherapy. 2003 , 295, 146-54	14
1490	Molecular markers and staging of early esophageal cancer. 2003 , 388, 77-82	7
1489	The impact of anti-angiogenic agents on cancer therapy. 2003 , 129, 607-20	20
1488	Profiling cancer. 2003 , 15, 213-20	12
1487	Sniffers, buzzers, toggles and blinkers: dynamics of regulatory and signaling pathways in the cell. 2003 , 15, 221-31	1165
1486	The structure of telomeric DNA. 2003 , 13, 275-83	378
1485	Molecular pathogenesis of thyroid cancer. 2003 , 12, 69-90	66
1484	Insulin/IGF and target of rapamycin signaling: a TOR de force in growth control. 2003 , 13, 79-85	457
1483	Apoptosis, proliferation, differentiation: in search of the order. 2003 , 13, 97-105	43
1482	Defects in the apoptotic machinery of cancer cells: role in drug resistance. 2003 , 13, 125-34	53
1481	Restoring apoptosis as a strategy for cancer gene therapy: focus on p53 and mda-7. 2003 , 13, 169-78	57
1480	MicroRNAs and cancer. 2003 , 13, 253-8	329
1479	Ras interference as cancer therapy. 2003 , 13, 267-73	39

1478 Oncogenomics: opportunities to integrate basic and clinical research. **2003**, 2, 162-168

1477	Use of random ribozyme libraries for the rapid screening of apoptosis- and metastasis-related genes. 2003 , 2, 191-200	13
1476	Loss of pVHL is sufficient to cause HIF dysregulation in primary cells but does not promote tumor growth. 2003 , 3, 75-88	133
1475	PTEN tumor suppressor regulates p53 protein levels and activity through phosphatase-dependent and -independent mechanisms. 2003 , 3, 117-30	415
1474	Ras modulates Myc activity to repress thrombospondin-1 expression and increase tumor angiogenesis. 2003 , 3, 219-31	290
1473	Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. 2003 , 3, 347-61	1111
1472	Protein microarrays: meeting analytical challenges for clinical applications. 2003 , 3, 317-25	400
1471	Physiological levels of tumstatin, a fragment of collagen IV alpha3 chain, are generated by MMP-9 proteolysis and suppress angiogenesis via alphaV beta3 integrin. 2003 , 3, 589-601	463
1470	Perturbation of Ikaros isoform selection by MLV integration is a cooperative event in Notch(IC)-induced T cell leukemogenesis. 2003 , 3, 551-64	122
1469	Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. 2003 , 4, 209-21	852
1468	The tumor-suppressive functions of the human INK4A locus. 2003 , 4, 311-9	173
1467	Progressive vascular changes in a transgenic mouse model of squamous cell carcinoma. 2003 , 4, 383-91	194
1466	Modeling transformation and metastasis in Drosophila. 2003 , 4, 333-5	11
1465	Genetische Diagnostik hereditärer Kolonkarzinome. 2003 , 27, 114-121	
1464	Cyclooxygenase enzymes and prostaglandins in reproductive tract physiology and pathology. 2003 , 71, 97-117	58
1463	The cell cycle, chromatin and cancer: mechanism-based therapeutics come of age. 2003 , 8, 793-802	45
1462	Oral cancer: reviewing the present understanding of its molecular mechanism and exploring the future directions for its effective management. 2003 , 39, 213-21	84
1461	Acquisition of anoikis resistance is a critical step in the progression of oral tongue cancer. 2003 , 39, 648-55	37

1460	Cellular senescence and apoptosis: how cellular responses might influence aging phenotypes. 2003 , 38, 5-11	170
1459	Dietary fish oil reduces oxidative DNA damage in rat colonocytes. 2003 , 35, 149-59	40
1458	Autophagy: a barrier or an adaptive response to cancer. 2003 , 1603, 113-28	131
1457	Raf proteins and cancer: B-Raf is identified as a mutational target. 2003 , 1653, 25-40	170
1456	Studies with ZD1839 in preclinical models. 2003 , 30, 12-20	75
1455	Phase I studies of ZD1839 in patients with common solid tumors. 2003 , 30, 21-9	63
1454	New directions for ZD1839 in the treatment of solid tumors. 2003 , 30, 49-55	104
1453	The tumor microenvironment: a critical determinant of neoplastic evolution. 2003 , 82, 539-48	192
1452	Signaling by carcinogenic metals and metal-induced reactive oxygen species. 2003 , 533, 183-200	109
1451	The potential contributions of chronic inflammation to lung carcinogenesis. 2003 , 5, 46-62	152
1450	Modulation of mitogen-activated protein kinases by 6-nitro-7-hydroxycoumarin mediates apoptosis in renal carcinoma cells. 2003 , 481, 159-67	46
1449	Involvement of nuclear transcription factor-kappa B in low-dose doxorubicin-induced drug resistance of cervical carcinoma cells. 2003 , 66, 25-33	34
1448	Turning cell cycle controller genes into cancer drugs. A role for an antiproliferative cytokine (betaGBP). 2003 , 66, 1563-9	10
1447	Mesenchymal progenitor cell-mediated inhibition of tumor growth in vivo and in vitro in gelatin matrix. 2003 , 75, 248-55	147
1446	Regulation of cell survival by atypical protein kinase C isozymes. 2003 , 43, 213-28	14
1445	Role of KRAS and BRAF gene mutations in mucinous ovarian carcinoma. 2003 , 90, 378-81	177
1444	Mitogen-activated protein kinases (MAPK) as predictors of clinical outcome in serous ovarian carcinoma in effusions. 2003 , 91, 160-72	53
1443	Molecular defects in the pathogenesis of pituitary tumours. 2003 , 24, 94-127	57

1442	A human tissue and data resource: an overview of opportunities, challenges, and development of a provider/researcher partnership model. 2003 , 70, 137-50	9
1441	Long term in vitro-cultured plant cells show typical neoplastic features at the cytological level. 2003 , 95, 357-64	18
1440	A new science-business paradigm in anticancer drug development. 2003 , 21, 103-6	27
1439	Near-diploid and near-triploid human sporadic colorectal adenocarcinomas differ for KRAS2 and TP53 mutational status. 2003 , 37, 207-13	17
1438	Genetic hits and mutation rate in colorectal tumorigenesis: versatility of Knudson's theory and implications for cancer prevention. 2003 , 38, 382-8	26
1437	Stromal factors involved in prostate carcinoma metastasis to bone. 2003 , 97, 739-47	158
1436	Genetic heterogeneity in lung and colorectal carcinoma as revealed by microsatellite analysis in plasma or tumor tissue DNA. 2003 , 97, 2308-17	8
1435	Expression of c-ABL, c-KIT, and platelet-derived growth factor receptor-beta in ovarian serous carcinoma and normal ovarian surface epithelium. 2003 , 98, 758-64	97
1434	The TP53 gene, tobacco exposure, and lung cancer. 2003 , 21, 229-39	229
1433	Familial risk of cancer by site and histopathology. 2003 , 103, 105-9	77
1432	Cannabinoids inhibit gap junctional intercellular communication and activate ERK in a rat liver epithelial cell line. 2003 , 104, 12-8	34
1431	Overexpression of cadherins suppresses pulmonary metastasis of osteosarcoma in vivo. 2003 , 104, 147-54	101
1430	Cytotoxicity, apoptosis induction and downregulation of MDR-1 expression by the anti-topoisomerase II agent, salvicine, in multidrug-resistant tumor cells. 2003 , 106, 108-15	61
1429	Expression profiles of angiogenic growth factors in squamous cell carcinomas of the head and neck. 2003 , 106, 34-44	98
1428	Aberrant methylation of TMS1 in small cell, non small cell lung cancer and breast cancer. 2003 , 106, 198-204	76
1427	Induction of apoptosis and chemosensitization of mesothelioma cells by Bcl-2 and Bcl-xL antisense treatment. 2003 , 106, 160-6	60
1426	Esophageal cancer risk in relation to GGC and CAG trinucleotide repeat lengths in the androgen receptor gene. 2003 , 107, 38-45	28
1425	Green tea catechins inhibit VEGF-induced angiogenesis in vitro through suppression of VE-cadherin phosphorylation and inactivation of Akt molecule. 2003 , 106, 871-8	106

1424	Expression of CCL5/RANTES by Hodgkin and Reed-Sternberg cells and its possible role in the recruitment of mast cells into lymphomatous tissue. 2003 , 107, 197-201	99
1423	Relaxin-like peptides in cancer. 2003 , 107, 513-9	58
1422	Cyclic AMP inhibits TGFbeta1-induced cell-scattering and invasiveness in murine-transformed keratinocytes. 2003 , 107, 715-20	18
1421	Gene transfer of alpha1,3-fucosyltransferase increases tumor growth of the PC-3 human prostate cancer cell line through enhanced adhesion to prostatic stromal cells. 2003 , 107, 949-57	23
1420	Apoptosis and lung cancer: a review. 2003 , 88, 885-98	169
1419	Functional imaging of angiogenesis in an orthotopic model of pancreatic cancer. 2003 , 90, 492-501	13
1418	Endothelial cell functions. 2003 , 196, 430-43	479
1417	Quantifying cell scattering: the blob algorithm revisited. 2003 , 51, 119-26	6
1416	Microarray analysis of xenograft-derived cancer cell lines representing multiple experimental models of human prostate cancer. 2003 , 37, 209-21	19
1415	Changes in gene expression during chemical-induced nephrocarcinogenicity in the Eker rat. 2003 , 38, 141-54	12
1414	Lymphangiogenesis in tumors: what do we know?. 2003 , 60, 171-80	45
1413	Dlg, Scribble and Lgl in cell polarity, cell proliferation and cancer. 2003 , 25, 542-53	234
1412	Collective specification of cellular development. 2003 , 25, 897-903	25
1411	Biological mechanism profiling using an annotated compound library. 2003 , 10, 881-92	79
1410	Natural mechanisms protecting against cancer. 2003 , 90, 103-22	142
1409	Aptamer-based biosensor arrays for detection and quantification of biological macromolecules. 2003 , 319, 244-50	230
1408	Chloroform, carbon tetrachloride and glutathione depletion induce secondary genotoxicity in liver cells via oxidative stress. 2003 , 187, 101-15	88
1407	Molecular and cellular mechanisms of cadmium carcinogenesis. 2003 , 192, 95-117	1113

1406	The relationship between aging and carcinogenesis: a critical appraisal. 2003 , 45, 277-304	75
1405	Angiogenesis in hematologic malignancies. 2003 , 45, 227-44	95
1404	Therapeutic approaches to bladder cancer: identifying targets and mechanisms. 2003 , 46 Suppl, S67-83	40
1403	Development and characterization of nonpeptidic small molecule inhibitors of the XIAP/caspase-3 interaction. 2003 , 10, 759-67	115
1402	Current and potential uses for DNA microarrays in transplantation medicine: lessons from other disciplines. 2003 , 62, 93-103	2
1401	Growth regulatory factors and signalling proteins in testicular germ cell tumours. 2003 , 111, 212-24; discussion 224	30
1400	Immunohistochemical analysis of Omi/HtrA2 expression in stomach cancer. 2003 , 111, 586-90	22
1399	Mutational analysis of salvador gene in human carcinomas. 2003 , 111, 595-8	4
1398	Mutational analysis of Noxa gene in human cancers. 2003 , 111, 599-604	18
1397	Immunohistochemical analysis of Smac/DIABLO expression in human carcinomas and sarcomas. 2003 , 111, 382-8	43
1396	[Melanoma-stroma interactions and melanoma progression]. 2003 , 1, 773-6	2
1395	Overview of the clinical efficacy of investigational anticancer drugs. 2003 , 253, 46-75	67
1394	Tazarotene-induced gene 3 is suppressed in basal cell carcinomas and reversed in vivo by tazarotene application. 2003 , 121, 902-9	33
1393	Mutations of the BRAF gene in benign and malignant melanocytic lesions. 2003 , 121, 1160-2	172
1392	An N-terminal 80 kDa recombinant fragment of human thrombospondin-2 inhibits vascular endothelial growth factor induced endothelial cell migration in vitro and tumor growth and angiogenesis in vivo. 2003 , 121, 1536-43	38
1391	[Carcinogenesis: defect control systems and options for molecular therapy]. 2003 , 1, 444-9	0
1390	Chemoprevention of gastrointestinal malignancies. 2003 , 73, 680-6	9
1389	Human papillomavirus DNA in cervical lesions from Morocco and its implications for cancer control. 2003 , 9, 144-8	16

1388	Review article: molecular basis of gastric carcinogenesis. 2003 , 17 Suppl 2, 75-81	50
1387	Basal cell carcinoma: a dermatopathological and molecular biological update. 2003 , 148, 195-202	144
1386	Tyrosine phosphate in melanoma progression. 2003 , 149, 289-95	7
1385	Mouse models for genetic dissection of polygenic gastrointestinal diseases. 2003 , 33, 155-60	9
1384	Signal Transduction and Communication in Cancer Cells□117th Advanced Course of the International School of Medical Science. 2003 , 3, NA-NA	
1383	Absence of lymphangiogenesis and intratumoural lymph vessels in human metastatic breast cancer. 2003 , 200, 195-206	175
1382	Translational research in ovarian cancer: a must. 2003 , 13 Suppl 2, 220-30	5
1381	Targeted therapy for epithelial ovarian cancer: current status and future prospects. 2003 , 13, 701-34	39
1380	Topical application of the immunosuppressant tacrolimus accelerates carcinogenesis in mouse skin. 2003 , 149, 960-7	103
1379	Acute mutation of retinoblastoma gene function is sufficient for cell cycle re-entry. 2003 , 424, 223-8	461
1378	Mitogenesis by ligands of nuclear receptors: an attractive model for the study of the molecular mechanisms implicated in liver growth. 2003 , 10 Suppl 1, S19-21	39
1377	Antiandrogen-induced cell death in LNCaP human prostate cancer cells. 2003 , 10, 761-71	46
1376	Lymphoma development in Bax transgenic mice is inhibited by Bcl-2 and associated with chromosomal instability. 2003 , 10, 740-8	24
1375	Cancer gene therapy: an awkward adolescence. 2003 , 10, 501-8	57
1374	Bone marrow-derived, endothelial progenitor-like cells as angiogenesis-selective gene-targeting vectors. 2003 , 10, 647-56	75
1373	Chronic myelogenous leukemia as a paradigm of early cancer and possible curative strategies. 2003 , 17, 1211-62	83
1372	Treatment by design in leukemia, a meeting report, Philadelphia, Pennsylvania, December 2002. 2003 , 17, 2358-82	6
1371	p27 deficiency desensitizes Rb ^{-/-} cells to signals that trigger apoptosis during pituitary tumor development. 2003 , 22, 361-9	26

1370	Type 1 insulin-like growth factor regulates MT1-MMP synthesis and tumor invasion via PI 3-kinase/Akt signaling. 2003 , 22, 974-82	141
1369	Trans-activation of heparanase promoter by ETS transcription factors. 2003 , 22, 919-23	50
1368	Induction of hepatocyte proliferation and death by modulation of T-Antigen expression. 2003 , 22, 2515-30	8
1367	Loss of p27(Kip1) cooperates with cyclin E in T-cell lymphomagenesis. 2003 , 22, 1724-9	27
1366	A novel mechanism of tumor suppression by destabilizing AU-rich growth factor mRNA. 2003 , 22, 3554-61	102
1365	Phenoxodiol--an isoflavone analog--induces apoptosis in chemoresistant ovarian cancer cells. 2003 , 22, 2611-20	157
1364	Apoptosis and melanoma chemoresistance. 2003 , 22, 3138-51	669
1363	Function and regulation of melanoma-stromal fibroblast interactions: when seeds meet soil. 2003 , 22, 3162-71	144
1362	Angiogenesis, lymphangiogenesis, and melanoma metastasis. 2003 , 22, 3172-9	183
1361	GM-CSF-secreting melanoma vaccines. 2003 , 22, 3188-92	141
1360	Understanding the progression of melanocytic neoplasia using genomic analysis: from fields to cancer. 2003 , 22, 3081-6	100
1359	Hepatitis B virus-related insertional mutagenesis occurs frequently in human liver cancers and recurrently targets human telomerase gene. 2003 , 22, 3911-6	246
1358	Inhibitor of apoptosis protein (IAP) survivin is upregulated by oncogenic c-H-Ras. 2003 , 22, 4266-80	82
1357	Profiling, comparison and validation of gene expression in gastric carcinoma and normal stomach. 2003 , 22, 4287-300	62
1356	Inactivating mutations of CASPASE-7 gene in human cancers. 2003 , 22, 8048-52	80
1355	Adipocyte-secreted factors synergistically promote mammary tumorigenesis through induction of anti-apoptotic transcriptional programs and proto-oncogene stabilization. 2003 , 22, 6408-23	278
1354	Axis of evil: molecular mechanisms of cancer metastasis. 2003 , 22, 6524-36	479
1353	Tyrosine kinase oncoprotein, RET/PTC3, induces the secretion of myeloid growth and chemotactic factors. 2003 , 22, 4569-77	60

1352	Cancer epigenetics. 2003 , 22, 6479-83	236
1351	Differential regulation of TGF-beta signaling through Smad2, Smad3 and Smad4. 2003 , 22, 6748-63	110
1350	Expression profiling of epithelial plasticity in tumor progression. 2003 , 22, 7155-69	249
1349	Cisplatin: mode of cytotoxic action and molecular basis of resistance. 2003 , 22, 7265-79	2433
1348	Alterations in the apoptotic machinery and their potential role in anticancer drug resistance. 2003 , 22, 7414-30	228
1347	Genetic and epigenetic alterations as hallmarks of the intricate road to cancer. 2003 , 22, 6472-8	72
1346	AS602868, a pharmacological inhibitor of IKK2, reveals the apoptotic potential of TNF-alpha in Jurkat leukemic cells. 2003 , 22, 8187-94	69
1345	The inhibitors of apoptosis: there is more to life than Bcl2. 2003 , 22, 8568-80	375
1344	The Bcl-2 family: roles in cell survival and oncogenesis. 2003 , 22, 8590-607	1232
1343	The death effector domain protein family. 2003 , 22, 8634-44	84
1342	Survivin, versatile modulation of cell division and apoptosis in cancer. 2003 , 22, 8581-9	756
1341	Silibinin upregulates the expression of cyclin-dependent kinase inhibitors and causes cell cycle arrest and apoptosis in human colon carcinoma HT-29 cells. 2003 , 22, 8271-82	198
1340	Dysregulation of DNA repair pathways in a transforming growth factor alpha/c-myc transgenic mouse model of accelerated hepatocarcinogenesis. 2003 , 83, 643-54	31
1339	Cancer: More than skin deep. 2003 , 421, 594-5	8
1338	Correction. 2003 , 421, 595-595	
1337	Biomechanics: Are fast-moving elephants really running?. 2003 , 422, 493-4	98
1336	Cell biology: Developmental predisposition to cancer. 2003 , 422, 494	69
1335	Cell biology: metabolism meets death. 2003 , 424, 896-7	36

1334	Chemical discovery and global gene expression analysis in zebrafish. 2003 , 21, 879-83	126
1333	Chromosome aberrations in solid tumors. 2003 , 34, 369-76	603
1332	Predicting hepatitis B virus-positive metastatic hepatocellular carcinomas using gene expression profiling and supervised machine learning. 2003 , 9, 416-23	701
1331	Senescence, apoptosis and therapy--cutting the lifelines of cancer. 2003 , 3, 286-95	252
1330	Cancer and ageing: rival demons?. 2003 , 3, 339-49	398
1329	Vasculogenic mimicry and tumour-cell plasticity: lessons from melanoma. 2003 , 3, 411-21	681
1328	Tumorigenesis and the angiogenic switch. 2003 , 3, 401-10	2667
1327	Basement membranes: structure, assembly and role in tumour angiogenesis. 2003 , 3, 422-33	1290
1326	Stem-cell hierarchy in skin cancer. 2003 , 3, 434-43	239
1325	The emerging role of lysophosphatidic acid in cancer. 2003 , 3, 582-91	903
1324	Origins of chromosome translocations in childhood leukaemia. 2003 , 3, 639-49	560
1323	Genomic instability--the engine of tumorigenesis?. 2003 , 3, 701-8	265
1322	New tools for functional mammalian cancer genetics. 2003 , 3, 781-9	247
1321	AP-1: a double-edged sword in tumorigenesis. 2003 , 3, 859-68	1568
1320	Opinion: Comparative biology of mouse versus human cells: modelling human cancer in mice. 2003 , 3, 952-9	441
1319	Screening for lung cancer: in pursuit of pre-metastatic disease. 2003 , 3, 65-73	36
1318	Between genotype and phenotype: protein chaperones and evolvability. 2003 , 4, 263-74	229
1317	Sequence-based cancer genomics: progress, lessons and opportunities. 2003 , 4, 409-18	52

1316	Cancer susceptibility in the mouse: genetics, biology and implications for human cancer. 2003 , 4, 721-34	136
1315	Diverse cellular and molecular mechanisms contribute to epithelial plasticity and metastasis. 2003 , 4, 657-65	561
1314	ADAMTS1: a matrix metalloprotease with angioinhibitory properties. 2003 , 995, 183-90	87
1313	Chromatin as a tool for the study of genome function in cancer. 2003 , 983, 5-21	21
1312	DNA methylation as a cancer-specific biomarker: from molecules to populations. 2003 , 983, 286-97	30
1311	Changes in biomarkers from space radiation may reflect dose not risk. 2003 , 31, 1505-12	19
1310	Proteomic analysis of a neoplastic mouse lung epithelial cell line whose tumorigenicity has been abrogated by transfection with the gap junction structural gene for connexin 43, Gja1. 2003 , 24, 651-7	28
1309	Studies in polyphenol chemistry and bioactivity. 4.(1) Synthesis of trimeric, tetrameric, pentameric, and higher oligomeric epicatechin-derived procyanidins having all-4beta,8-interflavan connectivity and their inhibition of cancer cell growth through cell cycle arrest. 2003 , 68, 1641-58	105
1308	Molecular genetics of lung cancer. 2003 , 54, 73-87	250
1307	Overview of novel anticancer drug targets. 2003 , 85, 3-28	
1306	Epigenetic theories of cancer initiation. 2003 , 90, 209-30	33
1305	Prostate cancer biomarkers: a current perspective. 2003 , 3, 459-70	13
1304	Inactivating mutations of caspase-8 gene in colorectal carcinomas. 2003 , 125, 708-15	192
1303	Gene silencing in cancer in association with promoter hypermethylation. 2003 , 349, 2042-54	2694
1302	Invasion and metastasis in pancreatic cancer. 2003 , 2, 14	156
1301	Prognostic and predictive indicators in operable breast cancer. 2003 , 3, 381-90	28
1300	Inhibiting Ras signaling in the therapy of breast cancer. 2003 , 3, 405-16; discussion 417-20	28
1299	Mammalian target of rapamycin: a new molecular target for breast cancer. 2003 , 4, 126-37	111

1298	Molecular pathogenesis of malignant mesothelioma and its relationship to simian virus 40. 2003 , 5, 177-81	55
1297	Expression of the leukotriene D4 receptor CysLT1, COX-2, and other cell survival factors in colorectal adenocarcinomas. 2003 , 124, 57-70	148
1296	The not-so innocent bystander: the microenvironment as a therapeutic target in cancer. 2003 , 7, 71-88	42
1295	Determinants of substrate recognition in nonreceptor tyrosine kinases. 2003 , 36, 393-400	59
1294	Sequence-selective DNA cleavage by a chimeric metallopeptide. 2003 , 125, 6656-62	97
1293	Potent and selective inhibition of membrane-type serine protease 1 by human single-chain antibodies. 2003 , 42, 892-900	40
1292	Mutation analysis of the BRAF, ARAF and RAF-1 genes in human colorectal adenocarcinomas. 2004 , 25, 527-33	224
1291	Future directions in control in an information-rich world. 2003 , 23, 20-33	205
1290	Carcinogenic and systemic health effects associated with arsenic exposure--a critical review. 2003 , 31, 575-88	249
1289	Synthesis and biological activity of photoactivatable N-ras peptides and proteins. 2003 , 125, 12749-58	51
1288	Retroviral insertional mutagenesis: tagging cancer pathways. 2003 , 88, 53-99	102
1287	Multiple mutations and cancer. 2003 , 100, 776-81	557
1286	An overview of the mechanisms of mutagenesis and carcinogenesis. 2003 , 544, 99-106	93
1285	On the association of succinate dehydrogenase mutations with hereditary paraganglioma. 2003 , 14, 453-9	87
1284	p53 haploinsufficiency profoundly accelerates the onset of tongue tumors in mice lacking the xeroderma pigmentosum group A gene. 2003 , 163, 1729-33	29
1283	Expression profiling of mouse endometrial cancers microdissected from ethanol-fixed, paraffin-embedded tissues. 2003 , 162, 755-62	29
1282	Dystroglycan expression is frequently reduced in human breast and colon cancers and is associated with tumor progression. 2003 , 162, 849-60	96
1281	Quantitative assessment of angiogenic responses by the directed in vivo angiogenesis assay. 2003 , 162, 1431-9	108

1280	Apoptosis genes and resistance to cancer therapy: what does the experimental and clinical data tell us?. 2003 , 2, 477-90	110
1279	Role of telomeres and telomerase in the pathogenesis of human cancer. 2003 , 21, 2034-43	110
1278	Activities of MAP-kinase pathways in normal uroepithelial cells and urothelial carcinoma cell lines. 2003 , 282, 48-57	64
1277	STI-571: an anticancer protein-tyrosine kinase inhibitor. 2003 , 309, 709-17	83
1276	Restoration of thrombospondin 1 expression in tumor cells harbouring mutant ras oncogene by treatment with low doses of doxycycline. 2003 , 310, 109-14	18
1275	An in vitro evaluation of the effects of homocysteine thiolactone on key steps of angiogenesis and tumor invasion. 2003 , 311, 649-53	10
1274	The basic biology of malignant melanoma: molecular mechanisms of disease progression and comparative aspects. 2003 , 17, 760-72	38
1273	Lignan precursors from flaxseed or rye bran do not protect against the development of intestinal neoplasia in ApcMin mice. 2003 , 45, 203-10	24
1272	Murine models of colorectal cancer: studying the role of oncogenic K-ras. 2003 , 60, 495-506	7
1271	Evidence for the isolation, growth, and characterization of malignant cells in primary cultures of human tumors. 2003 , 39, 63-70	18
1270	Association of endostatin D104N with leukemia. 2003 , 19, 1-5	6
1269	Serum anti-p53 autoantibodies in pleural malignant mesothelioma, lung cancer and non-neoplastic lung diseases. 2003 , 39, 165-72	20
1268	Dissecting the genetic alterations involved in lung carcinogenesis. 2003 , 40, 111-21	30
1267	Clinical studies with non-irreversible EGFR tyrosine kinase inhibitors. 2003 , 41 Suppl 1, S43-8	26
1266	Design and characterization of a hyperstable p16INK4a that restores Cdk4 binding activity when combined with oncogenic mutations. 2003 , 327, 285-97	18
1265	Schizosaccharomyces pombe Int6 and Ras homologs regulate cell division and mitotic fidelity via the proteasome. <i>Cell</i> , 2003 , 112, 207-17	56.2 74
1264	DOCK4, a GTPase activator, is disrupted during tumorigenesis. <i>Cell</i> , 2003 , 112, 673-84	56.2 193
1263	MTA3, a Mi-2/NuRD complex subunit, regulates an invasive growth pathway in breast cancer. <i>Cell</i> , 2003 , 113, 207-19	56.2 426

1262	Switch-of-function mutants based on morphology classification of Ras superfamily small GTPases. <i>Cell</i> , 2003 , 113, 315-28	56.2	90
1261	Multiple tumor suppressor pathways negatively regulate telomerase. <i>Cell</i> , 2003 , 113, 881-9	56.2	359
1260	Metastatic potential: generic predisposition of the primary tumor or rare, metastatic variants-or both?. <i>Cell</i> , 2003 , 113, 821-3	56.2	139
1259	Membrane type I matrix metalloproteinase usurps tumor growth control imposed by the three-dimensional extracellular matrix. <i>Cell</i> , 2003 , 114, 33-45	56.2	563
1258	How clinicians add to knowledge of development. 2003 , 362, 477-84		13
1257	Chemical basis of inflammation-induced carcinogenesis. 2003 , 417, 3-11		528
1256	Cell adhesion aside from integrin system can abrogate anoikis in rat liver cells by down-regulation of FasL expression, not by activation of PI-3K/Akt and ERK signaling pathway. 2003 , 300, 201-8		16
1255	Homocysteine inhibits the proliferation and invasive potential of HT-1080 human fibrosarcoma cells. 2003 , 301, 540-4		12
1254	Uncoupling of protein kinase D from suppression of EGF-dependent c-Jun phosphorylation in cancer cells. 2003 , 302, 800-4		13
1253	Homocysteine is a potent inhibitor of human tumor cell gelatinases. 2003 , 303, 572-5		11
1252	Bcl-2 promotes premature senescence induced by oncogenic Ras. 2003 , 303, 800-7		36
1251	Induction of apoptosis by takrisodokyeum through generation of hydrogen peroxide and activation of caspase-3 in HL-60 cells. 2003 , 73, 1895-906		10
1250	The ErbB receptors and their role in cancer progression. 2003 , 284, 99-110		516
1249	Recruitment of human umbilical vein endothelial cells and human primary fibroblasts into experimental tumors growing in SCID mice. 2003 , 287, 28-38		24
1248	Regulation of endothelial cell differentiation and transformation by H-Ras. 2003 , 291, 189-200		6
1247	Stochastic model of autocrine and paracrine signals in cell culture assays. 2003 , 85, 3659-65		52
1246	Cyclin A1 is highly expressed in aggressive testicular germ cell tumors. 2003 , 190, 89-95		35
1245	Genetic alterations in cancer as a result of breakage at fragile sites. 2003 , 192, 1-17		89

1244	Telomerase and tumorigenesis. 2003 , 194, 163-72	54
1243	Common malignancy-associated regions of transcriptional activation (MARTA) in human prostate, breast, ovarian, and colon cancers are targets for DNA amplification. 2003 , 201, 67-77	17
1242	Oral metastases: report of 24 cases. 2003 , 41, 3-6	206
1241	Cellular pH regulators: potentially promising molecular targets for cancer chemotherapy. 2003 , 29, 541-9	497
1240	Telomerase inhibition and telomere erosion: a two-pronged strategy in cancer therapy. 2003 , 24, 328-31	11
1239	Adrenomedullin and cancer. 2003 , 112, 175-83	116
1238	Positional control of cell fate through joint integrin/receptor protein kinase signaling. 2003 , 19, 173-206	302
1237	Selective recognition of G-qQuadruplex telomeric DNA by a bis(quinacridine) macrocycle. 2003 , 125, 4732-40	164
1236	Mouse cancer models as a platform for performing preclinical therapeutic trials. 2003 , 13, 84-9	18
1235	Sonic hedgehog in normal and neoplastic proliferation: insight gained from human tumors and animal models. 2003 , 13, 34-42	118
1234	New directions in testicular cancer; molecular determinants of oncogenesis and treatment success. 2003 , 39, 147-56	29
1233	Exploiting the hallmarks of cancer: the future conquest of breast cancer. 2003 , 39, 1668-75	102
1232	Molecular prognostication in bladder cancer--a current perspective. 2003 , 39, 1501-10	32
1231	Is there a link between environmental factors and a genetic predisposition to cancer? A lesson from a familial cluster of gastric cancers. 2003 , 39, 1619-24	14
1230	OncoloGIST, BioloGIST, RadioloGIST: the big impact on the field of oncology of a molecularly-targeted therapy designed to treat a rare disease. 2003 , 39, 1976-7	6
1229	Drug resistance reversal--are we getting closer?. 2003 , 39, 2450-61	116
1228	Hallmarks of radiation carcinogenesis: ignored concepts. 2003 , 1258, 31-36	3
1227	Biological advances for new treatment approaches. 2003 , 19, 162-8	3

1226	Myeloid differentiation (MyD) primary response genes in hematopoiesis. 2003 , 31, 213-28	41
1225	p53- and Mdm2-independent repression of NF-kappa B transactivation by the ARF tumor suppressor. 2003 , 12, 15-25	184
1224	The promotion of tumor metastasis by surgery and stress: immunological basis and implications for psychoneuroimmunology. 2003 , 17 Suppl 1, S27-36	172
1223	Molecular detection of human papillomavirus in 594 uterine cervix samples from Moroccan women (147 biopsies and 447 swabs). 2003 , 27, 286-95	13
1222	Tumour necrosis factor alpha: a potential target for the therapy of solid tumours. 2003 , 4, 565-73	310
1221	Cancer immunoprevention: tracking down persistent tumor antigens. 2003 , 24, 62-6	57
1220	Cancer prevention -- the potential for diet to modulate molecular signalling. 2003 , 9, 11-8	167
1219	Recent advances in understanding apoptosis: new therapeutic opportunities in cancer chemotherapy. 2003 , 9, 251-5	31
1218	Targeting cancer cells by exploiting their resistance. 2003 , 9, 307-12	46
1217	Anchor cell invasion into the vulval epithelium in <i>C. elegans</i> . 2003 , 5, 21-31	106
1216	Metastatic Bladder Cancer: Role of Chemotherapy and New Agents. 2003 , 1, 108-117	5
1215	Molecular approaches to the diagnosis of sporadic and nevoid basal cell carcinoma syndrome-associated odontogenic keratocysts. 2003 , 15, 447-61	10
1214	Emerging role of endothelin-1 in tumor angiogenesis. 2003 , 14, 44-50	108
1213	The ErbB receptors and their role in cancer progression. 2003 , 103-114	1
1212	Cytokines and cancer. 2003 , 1213-1232	1
1211	Essentials of Apoptosis. 2003 ,	3
1210	Malignancy-associated regions of transcriptional activation: gene expression profiling identifies common chromosomal regions of a recurrent transcriptional activation in human prostate, breast, ovarian, and colon cancers. 2003 , 5, 218-28	26
1209	Chemical carcinogens as foreign bodies and some pitfalls regarding cancer immune surveillance. 2003 , 90, 179-207	30

1208	Cyclooxygenase-2 in lung cancer. 2003 , 37, 138-62	37
1207	Wnt signalling via the epidermal growth factor receptor: a role in breast cancer?. 2004 , 6, 65-8	29
1206	Models of breast cancer: quo vadis, animal modeling?. 2004 , 6, 31-8	49
1205	Models of breast cancer: is merging human and animal models the future?. 2004 , 6, 22-30	55
1204	Conditional mouse models demonstrate oncogene-dependent differences in tumor maintenance and recurrence. 2003 , 5, 202-5	10
1203	C766T low-density lipoprotein receptor-related protein 1 (LRP1) gene polymorphism and susceptibility to breast cancer. 2003 , 5, R77-81	27
1202	The prolyl isomerase Pin1 in breast development and cancer. 2003 , 5, 76-82	63
1201	Profiling of pathway-specific changes in gene expression following growth of human cancer cell lines transplanted into mice. 2003 , 4, R46	38
1200	Microarray-based identification of differentially expressed growth- and metastasis-associated genes in pancreatic cancer. 2003 , 60, 1180-99	107
1199	Erlotinib: a new therapeutic approach for non-small cell lung cancer. 2003 , 12, 1395-401	64
1198	Mechanisms in Carcinogenesis and Cancer Prevention. 2003 ,	
1197	Looking beyond morphology: cancer gene expression profiling using DNA microarrays. 2003 , 21, 937-49	38
1196	UVB-induced mutations in human key gatekeeper genes governing signalling pathways and consequences for skin tumourigenesis. 2003 , 2, 825-34	39
1195	Small molecule tyrosine kinase inhibitors: clinical development of anticancer agents. 2003 , 12, 51-64	113
1194	From latent disseminated cells to overt metastasis: genetic analysis of systemic breast cancer progression. 2003 , 100, 7737-42	517
1193	Transforming growth factor beta-1 induces snail transcription factor in epithelial cell lines: mechanisms for epithelial mesenchymal transitions. 2003 , 278, 21113-23	489
1192	Lung Cancer. 2003 ,	11
1191	Fumonisin: Abiogenic Conversions of an Environmental Tumor Promoter and Common Food Contaminant. 2003 , 22, 591-616	14

1190	Applications of positron emission tomography in the development of molecular targeted cancer therapeutics. 2003 , 17, 339-54	16
1189	Yeast genetic methods for the detection of membrane protein interactions: potential use in drug discovery. 2003 , 17, 413-24	15
1188	DNA methylation patterns in cancer: novel prognostic indicators?. 2003 , 3, 245-60	17
1187	Hepatocellular carcinoma: are we making progress?. 2003 , 21, 418-28	48
1186	Induction of a senescent-like phenotype does not confer the ability of bovine immortal cells to support the development of nuclear transfer embryos. 2003 , 69, 301-9	76
1185	Ascorbic acid suppresses drug-induced apoptosis in human colon cancer cells by scavenging mitochondrial superoxide anions. 2004 , 25, 703-12	76
1184	Oncology drug discovery applications using the FMAT 8100 HTS system. 2003 , 8, 81-8	14
1183	Abolition of cyclin-dependent kinase inhibitor p16Ink4a and p21Cip1/Waf1 functions permits Ras-induced anchorage-independent growth in telomerase-immortalized human fibroblasts. 2003 , 23, 2859-70	67
1182	Parkin, a gene implicated in autosomal recessive juvenile parkinsonism, is a candidate tumor suppressor gene on chromosome 6q25-q27. 2003 , 100, 5956-61	246
1181	Novel p27(kip1) C-terminal scatter domain mediates Rac-dependent cell migration independent of cell cycle arrest functions. 2003 , 23, 216-28	185
1180	Clinical application of cDNA microarrays in oncology. 2003 , 8, 252-8	64
1179	p27Kip1 inhibition of GRB2-SOS formation can regulate Ras activation. 2003 , 23, 3735-52	60
1178	Human papillomavirus type 16 E6 activates TERT gene transcription through induction of c-Myc and release of USF-mediated repression. 2003 , 77, 9852-61	122
1177	Hepatocyte growth factor/scatter factor mediates angiogenesis through positive VEGF and negative thrombospondin 1 regulation. 2003 , 100, 12718-23	293
1176	Lung cancer. 9: Molecular biology of lung cancer: clinical implications. 2003 , 58, 892-900	86
1175	Macrophage migration inhibitory factor deficiency is associated with altered cell growth and reduced susceptibility to Ras-mediated transformation. 2003 , 278, 11078-85	52
1174	Impaired regulation of tumor suppressor p53 caused by mutations in the xeroderma pigmentosum DDB2 gene: mutual regulatory interactions between p48(DDB2) and p53. 2003 , 23, 7540-53	65
1173	Genetische Diagnostik hereditärer Kolonkarzinome/Genetic Diagnostics for Hereditary Colon Cancer. 2003 , 27, 114-121	

1172	Caspase- and serine protease-dependent apoptosis by the death domain of FADD in normal epithelial cells. 2003 , 14, 67-77	31
1171	Posttranscriptional and posttranslational regulation of C/EBP delta in G0 growth-arrested mammary epithelial cells. 2003 , 278, 11246-55	24
1170	Pattern recognition in gene expression profiling using DNA array: a comparative study of different statistical methods applied to cancer classification. 2003 , 12, 823-36	38
1169	Regulation of Cdc25A half-life in interphase by cyclin-dependent kinase 2 activity. 2003 , 278, 31838-42	13
1168	Crossing the cancer cell membrane to improve clinical outcomes. 2003 , 8 Suppl 3, 1-4	1
1167	High magnification bronchovideoscopy combined with narrow band imaging could detect capillary loops of angiogenic squamous dysplasia in heavy smokers at high risk for lung cancer. 2003 , 58, 989-95	148
1166	Lack of BRAF mutation in primary uveal melanoma. 2003 , 44, 2876-8	111
1165	Hypoxia inducible factor activates the transforming growth factor-alpha/epidermal growth factor receptor growth stimulatory pathway in VHL(-/-) renal cell carcinoma cells. 2003 , 278, 44966-74	147
1164	A constitutively active NFATc1 mutant induces a transformed phenotype in 3T3-L1 fibroblasts. 2003 , 278, 17246-54	103
1163	Mutation of B-Raf in human choroidal melanoma cells mediates cell proliferation and transformation through the MEK/ERK pathway. 2003 , 278, 42409-18	88
1162	E2F3 loss has opposing effects on different pRB-deficient tumors, resulting in suppression of pituitary tumors but metastasis of medullary thyroid carcinomas. 2003 , 23, 6542-52	79
1161	Rb function in extraembryonic lineages suppresses apoptosis in the CNS of Rb-deficient mice. 2003 , 100, 6546-51	116
1160	Interferon-alpha is implicated in the transcriptional regulation of vascular endothelial growth factor. 2003 , 95, 420-1	6
1159	Signal events: Cell signal transduction and its inhibition in cancer. 2003 , 8 Suppl 3, 5-17	53
1158	The Drosophila Ste20 family kinase dMST functions as a tumor suppressor by restricting cell proliferation and promoting apoptosis. 2003 , 17, 2514-9	303
1157	p53 represses cyclin D1 transcription through down regulation of Bcl-3 and inducing increased association of the p52 NF-kappaB subunit with histone deacetylase 1. 2003 , 23, 4713-27	201
1156	The population genetics of multistage carcinogenesis. 2003 , 270, 1183-91	32
1155	Oncogenic and invasive potentials of human macrophage-stimulating protein receptor, the RON receptor tyrosine kinase. 2003 , 24, 1291-300	114

1154	Optical systems for in vivo molecular imaging of cancer. 2003 , 2, 491-504	167
1153	Immunotherapy of malignant diseases. Challenges and strategies. 2003 , 132, 294-309	29
1152	Regulation of the activity of p38 mitogen-activated protein kinase by Akt in cancer and adenoviral protein E1A-mediated sensitization to apoptosis. 2003 , 23, 6836-48	95
1151	The formin-homology-domain-containing protein FHOD1 enhances cell migration. 2003 , 116, 1745-55	65
1150	Clefts, grooves, and (small) pockets: the structure of the retinoblastoma tumor suppressor in complex with its cellular target E2F unveiled. 2003 , 100, 2165-7	7
1149	A novel ubiquitin fusion system bypasses the mitochondria and generates biologically active Smac/DIABLO. 2003 , 278, 7494-9	41
1148	Increased expression of Bcl-xL and c-Myc is associated with transformation by Abelson murine leukemia virus. 2003 , 278, 50915-22	10
1147	Arrest of mammalian fibroblasts in G1 in response to actin inhibition is dependent on retinoblastoma pocket proteins but not on p53. 2003 , 161, 67-77	52
1146	Overcoming drug resistance in multiple myeloma: the emergence of therapeutic approaches to induce apoptosis. 2003 , 21, 4239-47	72
1145	o-Nitrotoluene-induced large intestinal tumors in B6C3F1 mice model human colon cancer in their molecular pathogenesis. 2004 , 25, 605-12	12
1144	EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. 2003 , 100, 11606-11	1295
1143	N-(4-hydroxyphenyl)retinamide inhibits retinoblastoma growth through reactive oxygen species-mediated cell death. 2003 , 63, 565-73	42
1142	Activation of the ERK1/2 signaling pathway promotes phosphorylation and proteasome-dependent degradation of the BH3-only protein, Bim. 2003 , 278, 18811-6	480
1141	Loss of p16INK4a results in increased glucocorticoid receptor activity during fibrosarcoma development. 2003 , 100, 3113-8	6
1140	Driving the cell cycle to cancer. 2003 , 532, 1-11	28
1139	Glucocorticoids inhibit apoptosis during fibrosarcoma development by transcriptionally activating Bcl-xL. 2003 , 278, 18022-9	59
1138	Quantitation of membrane type serine protease 1 (MT-SP1) in transformed and normal cells. 2003 , 384, 257-66	21
1137	Antitumor capacity of a dominant-negative RET proto-oncogene mutant in a medullary thyroid carcinoma model. 2003 , 14, 971-82	36

1136	Morphology transitions induced by chemotherapy in carcinomas in situ. 2003 , 67, 051914	31
1135	Multistep Carcinogenesis: A Chain Reaction of Aneuploidizations. 2003 , 2, 201-209	122
1134	Large-scale delineation of secreted protein biomarkers overexpressed in cancer tissue and serum. 2003 , 100, 3410-5	363
1133	In vitro selectivity, in vivo biodistribution and tumour uptake of annexin V radiolabelled with a positron emitting radioisotope. 2003 , 89, 1327-33	50
1132	"Man's best friend": a new model system for cancer therapeutics?. 2003 , 7, 144-5	4
1131	Spatial Evolutionary Games of Interaction among Generic Cancer Cells. 2003 , 5, 47-58	28
1130	Tumor Suppressor Genes. 2003 ,	
1129	3-Bromophenyl 6-acetoxymethyl-2-oxo-2H-1-benzopyran-3-carboxylate inhibits cancer cell invasion in vitro and tumour growth in vivo. 2003 , 88, 1111-8	82
1128	Genetic alterations in primary osteosarcoma from 54 children and adolescents by targeted allelotyping. 2003 , 88, 1925-31	30
1127	Functional evaluation of the apoptosome in renal cell carcinoma. 2003 , 89, 2147-54	10
1126	Vascular invasion in thyroid and gastric carcinomas. 2003 , 27, 41-8	1
1125	HMGB1 inhibits cell death in yeast and mammalian cells and is abundantly expressed in human breast carcinoma. 2003 , 17, 1295-7	166
1124	Cytokines and BCR-ABL mediate suppression of TRAIL-induced apoptosis through inhibition of forkhead FOXO3a transcription factor. 2003 , 100, 6523-8	124
1123	Spike, a novel BH3-only protein, regulates apoptosis at the endoplasmic reticulum. 2003 , 17, 696-8	67
1122	c-Jun N-terminal kinase contributes to apoptotic synergy induced by tumor necrosis factor-related apoptosis-inducing ligand plus DNA damage in chemoresistant, p53 inactive mesothelioma cells. 2003 , 278, 25461-7	49
1121	Nitric oxide levels in human preneoplastic colonocytes determine their susceptibility toward antineoplastic agents. 2003 , 64, 1494-502	17
1120	Pro-collagen I COOH-terminal trimer induces directional migration and metalloproteinases in breast cancer cells. 2003 , 278, 3639-47	12
1119	Human growth hormone-regulated HOXA1 is a human mammary epithelial oncogene. 2003 , 278, 7580-90	112

1118	Exposure of human primary colon carcinoma cells to anti-Fas interactions influences the emergence of pre-existing Fas-resistant metastatic subpopulations. 2003 , 171, 4164-74	27
1117	An experimental platform for studying growth and invasiveness of tumor cells within teratomas derived from human embryonic stem cells. 2003 , 100, 13507-12	58
1116	Identification of a unique core domain of par-4 sufficient for selective apoptosis induction in cancer cells. 2003 , 23, 5516-25	143
1115	Airway stents provide symptomatic relief. 2003 , 58, 900-900	78
1114	Telomerase: a potential diagnostic and therapeutic tool in canine oncology. 2003 , 40, 1-7	54
1113	Paternal and maternal genomes confer opposite effects on proliferation, cell-cycle length, senescence, and tumor formation. 2003 , 100, 13344-9	74
1112	Beta-catenin inversely regulates vascular endothelial growth factor-D mRNA stability. 2003 , 278, 44650-6	30
1111	Gene expression profiles of human breast cancer progression. 2003 , 100, 5974-9	722
1110	Tumor Suppressor Genes. 2003 ,	1
1109	Identification of target genes of the p16INK4A-pRB-E2F pathway. 2003 , 278, 46124-37	93
1108	Regulation of survivin function by Hsp90. 2003 , 100, 13791-6	282
1107	Survivin and apoptosis control. 2003 , 88, 31-52	109
1106	The systemic progression of human cancer: a focus on the individual disseminated cancer cell--the unit of selection. 2003 , 89, 35-67	48
1105	Immune enhancement of skin carcinogenesis by CD4+ T cells. 2003 , 197, 1017-28	150
1104	Idiopathic Pulmonary Fibrosis. Proceedings of the 1st Annual Pittsburgh International Lung Conference. October 2002. 2003 , 29, S1-105	28
1103	In situ zymography: a molecular pathology technique to localize endogenous protease activity in tissue sections. 2003 , 40, 227-36	49
1102	Metastatic melanoma in pregnancy: risk of transplacental metastases in the infant. 2003 , 21, 2179-86	230
1101	Loss of HSulf-1 up-regulates heparin-binding growth factor signaling in cancer. 2003 , 278, 23107-17	195

1100	Receptor tyrosine kinase signaling in gliomagenesis: pathobiology and therapeutic approaches. 2003 , 2, 330-42	45
1099	Histone methyltransferases in tumor suppression. 2003 , 2, 491-9	29
1098	Functional mutants of the sequence-specific transcription factor p53 and implications for master genes of diversity. 2003 , 100, 9934-9	137
1097	Catalase protects HepG2 cells from apoptosis induced by DNA-damaging agents by accelerating the degradation of p53. 2003 , 278, 4660-7	73
1096	Base excision repair intermediates induce p53-independent cytotoxic and genotoxic responses. 2003 , 278, 39951-9	140
1095	Hyaluronidase 2 negatively regulates RON receptor tyrosine kinase and mediates transformation of epithelial cells by jaagsiekte sheep retrovirus. 2003 , 100, 4580-5	82
1094	The LMO2 T-cell oncogene is activated via chromosomal translocations or retroviral insertion during gene therapy but has no mandatory role in normal T-cell development. 2003 , 23, 9003-13	104
1093	Normal and leukemic hematopoiesis: are leukemias a stem cell disorder or a reacquisition of stem cell characteristics?. 2003 , 100 Suppl 1, 11842-9	510
1092	Adhesion-dependent activation of the ERK1/2 cascade is by-passed in melanoma cells. 2003 , 278, 34548-54	45
1091	The phase III trial in the era of targeted therapy: unraveling the "go or no go" decision. 2003 , 21, 3683-95	99
1090	Nonredundant role of Bax and Bak in Bid-mediated apoptosis. 2003 , 23, 4701-12	99
1089	Cyclin D1 repression of peroxisome proliferator-activated receptor gamma expression and transactivation. 2003 , 23, 6159-73	184
1088	Progressive alterations in global and GC-rich DNA methylation during tumorigenesis. 2003 , 75, 289-99	22
1087	Combined-modality treatment of solid tumors using radiotherapy and molecular targeted agents. 2003 , 21, 2760-76	115
1086	Transcriptional regulation of the telomerase hTERT gene as a target for cellular and viral oncogenic mechanisms. 2003 , 24, 1167-76	176
1085	Chemopreventive n-3 fatty acids activate RXRalpha in colonocytes. 2003 , 24, 1541-8	85
1084	Akt activation disrupts mammary acinar architecture and enhances proliferation in an mTOR-dependent manner. 2003 , 163, 315-26	124
1083	Re: Microarray studies challenge theories of metastasis. 2003 , 95, 829	10

1082	Molecular biology of prostate cancer. 2003 , 9, 437-48	36
1081	Role of the Retinoblastoma Protein in Differentiation and Senescence. 2003 , 2, 124-130	85
1080	Cell Immortality and Hallmarks of Cancer. 2003 , 2, 295-298	14
1079	More than one road to kill tumor cells--why are they not always successful?. 2003 , 2, 31-3	5
1078	Gene Expression Phenotypes of Oncogenic Signaling Pathways. 2003 , 2, 414-416	11
1077	INT6: A Link Between the Proteasome and Tumorigenesis. 2003 , 2, 80-82	11
1076	The Low Molecular Weight Isoforms of Cyclin E Deregulate the Cell Cycle of Mammary Epithelial Cells. 2003 , 2, 459-464	30
1075	Death ligands and bisindolylmaleimide: a killer combination. 2003 , 2, 271	1
1074	Conceptual research and phenomenology--harmonizing slices. 2003 , 2, 3-4	1
1073	Why Iressa failed: toward novel use of kinase inhibitors (outlook). 2003 , 2, 137-40	21
1072	Biological parameters for lung cancer in mathematical models of carcinogenesis. 2003 , 104, 357-66	5
1071	Mitogen-activated protein kinase activation in UV-induced signal transduction. 2003 , 2003, RE2	170
1070	The LNT model is the best we can do--today. 2003 , 23, 263-8	29
1069	Activation and suppression of the TRAIL death-receptor pathway in chemotherapy sensitive and resistant follicular lymphoma cells. 2003 , 2, 534-40	9
1068	Chemokines and breast cancer: a gateway to revolutionary targeted cancer treatments?. 2003 , 10, 579-92	25
1067	Blocking survivin to kill cancer cells. 2003 , 223, 533-42	10
1066	Overview: translating Hsp90 biology into Hsp90 drugs. 2003 , 3, 297-300	125
1065	New analogues of the anticancer E7070: synthesis and pharmacology. 2003 , 18, 89-94	4

1064	Altered HOX gene expression in human skin and breast cancer cells. 2003 , 2, 518-23	42
1063	The MYC oncogene as a cancer drug target. 2003 , 3, 163-75	104
1062	Biological Stoichiometry: An Ecological Perspective on Tumor Dynamics. 2003 , 53, 1112	25
1061	Functional genomics in lung cancer and biomarker detection. 2003 , 29, 153-6	12
1060	The role of apoptosis in tumor progression and metastasis. 2003 , 3, 631-42	78
1059	Tumor suppression through angiogenesis inhibition. 2003 , 223, 249-70	1
1058	Genes and proteins governing the cellular sensitivity to HSP90 inhibitors: a mechanistic perspective. 2003 , 3, 331-41	45
1057	Tumor suppressor genes in lung cancer. 2003 , 222, 97-115	11
1056	Emerging roles of targeted small molecule protein-tyrosine kinase inhibitors in cancer therapy. 2004 , 14, 175-225	68
1055	The tissue microenvironment as an epigenetic tumor modifier. 2003 , 223, 315-47	12
1054	The role of chemotherapy in the treatment of unresectable stage III and IV nonsmall cell lung cancer. 2003 , 9, 207-36	15
1053	Tissue-specific gene expression of head and neck squamous cell carcinoma in vivo by complementary DNA microarray analysis. 2003 , 129, 760-70	43
1052	Nutrition and cancer prevention: diet-gene interactions. 2003 , 62, 605-10	17
1051	Anti-cancer effects of butyrate: use of micro-array technology to investigate mechanisms. 2003 , 62, 107-15	123
1050	Cell cycle control, DNA damage checkpoints and cancer. 2003 , 35, 391-7	44
1049	Neovastat--a novel antiangiogenic drug for cancer therapy. 2003 , 14, 91-6	43
1048	CD44s adhesive function spontaneous and PMA-inducible CD44 cleavage are regulated at post-translational level in cells of melanocytic lineage. 2003 , 13, 325-37	38
1047	26th Lauriston S. Taylor Lecture: developing mechanistic data for incorporation into cancer and genetic risk assessments: old problems and new approaches. 2003 , 85, 4-12	1

1046	Microsatellite analysis of synchronous and metachronous tumors: a tool for double primary tumor and metastasis assessment. 2003 , 12, 151-9	24
1045	Advances in gene therapy and immunotherapy for brain tumors. 2003 , 16, 665-670	19
1044	NOX5 NAD(P)H oxidase regulates growth and apoptosis in DU 145 prostate cancer cells. 2003 , 285, C353-69	208
1043	Heterogeneity of chemosensitivity of colorectal adenocarcinoma determined by a modified ex vivo ATP-tumor chemosensitivity assay (ATP-TCA). 2003 , 14, 369-75	31
1042	Can resistant starch and/or aspirin prevent the development of colonic neoplasia? The Concerted Action Polyp Prevention (CAPP) 1 Study. 2003 , 62, 51-7	15
1041	Potential anticancer effects of statins: fact or fiction?. 2003 , 10, 49-58	26
1040	Mitogenic signaling cascades in glial tumors. 2003 , 52, 1425-34; discussion 1434-5	52
1039	Expression of angiogenic growth factors in acoustic neurinoma. 2003 , 123, 1040-5	31
1038	Extracellular matrix-regulated p53 expression and nuclear localization in cultured Detroit 562 cells derived from pharyngeal carcinoma. 2003 , 66, 419-28	4
1037	Cellular Assays in Drug Discovery. 2003 , 1-47	
1036	Therapeutic potential of selective cyclooxygenase-2 inhibitors in the management of tumor angiogenesis. 2003 , 37, 179-92	94
1035	Tumour Suppressor Genes. 2003 ,	1
1034	B lymphoid neoplasms of mice: characteristics of naturally occurring and engineered diseases and relationships to human disorders. 2003 , 81, 97-121	15
1033	References. 2003 , 765-949	
1032	Advances in Biology and Therapy of Multiple Myeloma. 2003 , 2003, 248-278	52
1031	Back Matter. 2003 , 91-102	
1030	Constitutive exclusion of Csk from Hck-positive membrane microdomains permits Src kinase-dependent proliferation of Theileria-transformed B lymphocytes. 2003 , 101, 1874-81	49
1029	The human herpes virus 8-encoded viral FLICE inhibitory protein protects against growth factor withdrawal-induced apoptosis via NF-kappa B activation. 2003 , 101, 1956-61	73

1028	Inhibition of STAT3 signaling induces apoptosis and decreases survivin expression in primary effusion lymphoma. 2003 , 101, 1535-42	386
1027	Cell context-specific effects of the BCR-ABL oncogene monitored in hematopoietic progenitors. 2003 , 101, 4088-97	29
1026	Bcl-2 activates a programme of premature senescence in human carcinoma cells. 2003 , 375, 263-74	51
1025	The angiogenic regulator CD13/APN is a transcriptional target of Ras signaling pathways in endothelial morphogenesis. 2003 , 101, 1818-26	89
1024	History of the Baylor Charles A. Sammons Cancer Center. 2003 , 16, 30-58	9
1023	Demystified...tissue microarray technology. 2003 , 56, 198-204	93
1022	Nulliparous CCAAT/enhancer binding protein delta (C/EBPdelta) knockout mice exhibit mammary gland ductal hyperplasia. 2003 , 228, 278-85	36
1021	Targeted drugs in oncology: New names, new mechanisms, new paradigm. 2003 , 60, 1233-1243	6
1020	Pancreatic and hepatobiliary cancer. 2003 , 178-189	
1019	Expression of EphB4 in Head and Neck Squamous Cell Carcinoma. 2003 , 82, 866-887	18
1018	Molecular targets of the oncogenic transcription factor jun. 2003 , 3, 41-55	48
1017	Aging and cancer in transgenic and mutant mice. 2003 , 8, s883-902	13
1016	The adenine nucleotide translocator: a new potential chemotherapeutic target. 2003 , 4, 517-24	26
1015	[Oncology 2003: new therapeutic perspectives]. 2003 , 19, 131	0
1014	Tomato and soy polyphenols reduce insulin-like growth factor-I-stimulated rat prostate cancer cell proliferation and apoptotic resistance in vitro via inhibition of intracellular signaling pathways involving tyrosine kinase. 2003 , 133, 2367-76	91
1013	Classical and molecular cytogenetic analysis in head and neck squamous cell carcinomas. 2003 , 26, 121-128	4
1012	HPV e carcinogênese oral: revisão bibliográfica. 2003 , 69, 553-559	5
1011	Cancer Invasion: Watch Your Neighbourhood!. 2003 , 89, 343-348	22

1010	Application of in vivo electroporation to cancer gene therapy. 2003 , 3, 59-64	24
1009	Viral and cellular cytokines as therapeutic targets in AIDS-related lymphoproliferative disorders. 2003 , 3, 81-96	1
1008	Regulation of endothelial cell integrin function and angiogenesis by COX-2, cAMP and Protein Kinase A. 2003 , 90, 577-85	39
1007	Establishment and characterization of clonal cell lines derived from a fibrosarcoma of the H2-K/V-JUN transgenic mouse. A model of H2-K/V-JUN mediated tumorigenesis. 2003 , 24, 176-84	2
1006	[Oncogenes and mitotic regulators: a change in perspective of our view of neoplastic processes]. 2003 , 19, 187-99	0
1005	Advances in molecular therapies in patients with brain tumors. 2003 , 10, 125-37	50
1004	Vascular endothelial growth factor as a therapeutic target in cancer. 2004 , 61, S4-11	28
1003	Molecular Basis of Pancreatic Carcinogenesis: Which Concepts May Be Clinically Relevant?. 351-358	
1002	Notre patrimoine r�troviral. 2004 , 198, 399-412	2
1001	Molecular imaging in oncology. 2004 , 4, 162-73	4
1000	Molecular-targeted agents in pancreatic cancer. 2004 , 11, 32-8	23
999	Carotenoids and Modulation of Cancer: Molecular Targets. 2004 , 2, 35-45	11
998	Mast cell-derived angiopoietin-1 plays a critical role in the growth of plasma cell tumors. 2004 , 114, 1317-25	100
997	Invasive growth: a genetic program. 2004 , 48, 451-6	31
996	. 2004 ,	3
995	Angiogenesis: a target for cancer therapy. 2004 , 10, 11-26	61
994	Cell death signaling in malignancy. 2003 , 115, 319-43	11
993	Protein Transduction Strategies for Target and Mechanism Validation. 2004 , 91-118	1

992	Novel technologies and recent advances in metastasis research. 2004 , 48, 573-81	27
991	. 2004 ,	1
990	Detection of tumor markers with ProteinChip technology. 2004 , 5, 45-67	101
989	Contributions. 2004 , 37-278	
988	Use of recombinant congenic strains in mapping disease-modifying genes. 2004 , 19, 105-9	6
987	Association of chromosomal alterations with arsenite-induced tumorigenicity of human HaCaT keratinocytes in nude mice. 2004 , 112, 1704-10	34
986	Rasputin, more promiscuous than ever: a review of G3BP. 2004 , 48, 1065-77	113
985	Cancer Genetics and Drug Target Selection. 2004 , 41-53	
984	Gene Microarray Technologies for Cancer Drug Discovery and Development. 2004 , 141-186	
983	Evidence for potential mechanisms for the effect of conjugated linoleic acid on tumor metabolism and immune function: lessons from n-3 fatty acids. 2004 , 79, 1190S-1198S	74
982	Therapeutic Strategies to Improve the Efficacy of Oxaliplatin in Gastrointestinal Tumors. 2004 , 19, 183-189	1
981	Antiangiogenic therapy in hematologic malignancies. 2004 , 10, 1221-34	27
980	Ras Signaling, Deregulation of Gene Expression and Oncogenesis. 2004 , 189-208	22
979	Thresholds for the effects of 2-acetylaminofluorene in rat liver. 2004 , 32 Suppl 2, 85-91	33
978	Alternagin-C, a disintegrin-like protein, induces vascular endothelial cell growth factor (VEGF) expression and endothelial cell proliferation in vitro. 2004 , 279, 18247-55	53
977	Activation of Ras-Ral pathway attenuates p53-independent DNA damage G2 checkpoint. 2004 , 279, 36382-9	16
976	The molecular pathogenesis of cholangiocarcinoma. 2004 , 24, 127-37	90
975	Saw palmetto extract suppresses insulin-like growth factor-I signaling and induces stress-activated protein kinase/c-Jun N-terminal kinase phosphorylation in human prostate epithelial cells. 2004 , 145, 3205-14	24

974	Cancer risk in people with epilepsy: the role of antiepileptic drugs. 2005 , 128, 7-17	66
973	Oncogenes as regulators of tissue factor expression in cancer: implications for tumor angiogenesis and anti-cancer therapy. 2004 , 30, 21-30	46
972	Signal transduction inhibitors in cellular function. 2004 , 284, 15-36	5
971	Combination epidermal growth factor receptor inhibition and radical radiotherapy for NSCLC. 2004 , 4, 569-83	5
970	Signaling multiplex of the epidermal growth factor receptor. 2004 , 4, 1145-56	2
969	Cancer and Inflammation. 2004 ,	2
968	Functional antagonism between NF-kappaB and nuclear receptors: implications in carcinogenesis and strategies for optimal cancer chemopreventive interventions. 2004 , 4, 337-44	7
967	Acute ablation of survivin uncovers p53-dependent mitotic checkpoint functions and control of mitochondrial apoptosis. 2004 , 279, 2077-84	102
966	Contribution of the hemostatic system to angiogenesis in cancer. 2004 , 30, 5-20	50
965	The tumour specific pro-apoptotic factor apoptin (Vp3) from chicken anaemia virus. 2004 , 5, 179-90	25
964	Specific and redundant functions of histone deacetylases in regulation of cell cycle and apoptosis. 2004 , 3, 1240-2	38
963	Signal Transducing Kinases and Cancer. 2004 , 25, 177-182	
962	Telomerase is not required for experimental tumorigenesis of human and bovine adrenocortical cells. 2004 , 30, 555-65	4
961	Identifying interventional and pathogenic mechanisms by generative inverse modeling of gene expression profiles. 2004 , 11, 1135-48	8
960	Carcinogen derived biomarkers: applications in studies of human exposure to secondhand tobacco smoke. 2004 , 13 Suppl 1, i48-56	54
959	PI3K/PTEN/Akt Pathway. 2004 , 145-167	148
958	Principles of Molecular Oncology. 2004 ,	6
957	Early phase I data on an irreversible pan-erb inhibitor: CI-1033. What did we learn?. 2004 , 16 Suppl 4, 44-8	14

956	Signature of a silent killer: expression profiling in epithelial ovarian cancer. 2004 , 4, 157-67	25
955	Dynamic conformational heterogeneities of carcinogen-DNA adducts and their mutagenic relevance. 2004 , 22, 57-90	48
954	Down-regulation of Betaig-h3 gene is involved in the tumorigenesis in human bronchial epithelial cells induced by heavy-ion radiation. 2004 , 162, 655-9	25
953	Too old to care?. 2004 , 9, 343-52	43
952	Quantitative multiplex methylation-specific PCR assay for the detection of promoter hypermethylation in multiple genes in breast cancer. 2004 , 64, 4442-52	223
951	Targeted disruption of the 3p12 gene, Dutt1/Robo1, predisposes mice to lung adenocarcinomas and lymphomas with methylation of the gene promoter. 2004 , 64, 6432-7	56
950	A protective role for matrix metalloproteinase-3 in squamous cell carcinoma. 2004 , 64, 6965-72	118
949	The minimal active domain of endostatin is a heparin-binding motif that mediates inhibition of tumor vascularization. 2004 , 64, 9012-7	47
948	Apoptosis protease activator protein-1 expression is dispensable for response of human melanoma cells to distinct proapoptotic agents. 2004 , 64, 7386-94	47
947	MUC4 is increased in high grade intraepithelial neoplasia in Barrett's oesophagus and is associated with a proapoptotic Bax to Bcl-2 ratio. 2004 , 57, 1267-72	23
946	Degradation of p53, not telomerase activation, by E6 is required for bypass of crisis and immortalization by human papillomavirus type 16 E6/E7. 2004 , 78, 5698-706	29
945	HER1/EGFR targeting: refining the strategy. 2004 , 9, 58-67	91
944	Tobacco-specific nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone promotes functional cooperation of Bcl2 and c-Myc through phosphorylation in regulating cell survival and proliferation. 2004 , 279, 40209-19	99
943	Inactivating mutations of proapoptotic Bad gene in human colon cancers. 2004 , 25, 1371-6	62
942	Role of the dependence receptor DCC in colorectal cancer pathogenesis. 2004 , 22, 3420-8	88
941	Transforming growth factor-beta pathway serves as a primary tumor suppressor in CD8+ T cell tumorigenesis. 2004 , 64, 6524-9	29
940	DNA methylation profiles of lymphoid and hematopoietic malignancies. 2004 , 10, 2928-35	57
939	Transforming growth factor beta-induced cell cycle arrest of human hematopoietic cells requires p57KIP2 up-regulation. 2004 , 101, 15231-6	196

938	Hepatocyte growth factor sensitizes human ovarian carcinoma cell lines to paclitaxel and cisplatin. 2004 , 64, 1744-50	44
937	Endometriosis and the neoplastic process. 2004 , 127, 293-304	160
936	Expression of N-acetylglucosaminyltransferase v is associated with prognosis and histology in non-small cell lung cancers. 2004 , 10, 1773-9	56
935	Involvement of insulin receptor substrate 2 in mammary tumor metastasis. 2004 , 24, 9726-35	98
934	The Zimmerman-McLean-Foster hypothesis: 25 years later. 2004 , 88, 962-7	69
933	Histone-Deacetylase Inhibitors for the Treatment of Cancer. 2004 , 3, 777-786	110
932	Nuclear factor-kappaB is an important modulator of the altered gene expression profile and malignant phenotype in squamous cell carcinoma. 2004 , 64, 6511-23	149
931	GW112, a novel antiapoptotic protein that promotes tumor growth. 2004 , 64, 2474-81	116
930	Immunological prevention of a multigene cancer syndrome. 2004 , 64, 8428-34	16
929	The RB protein family in retinal development and retinoblastoma: new insights from new mouse models. 2004 , 26, 417-34	16
928	Direct test of potential roles of EIIIA and EIIB alternatively spliced segments of fibronectin in physiological and tumor angiogenesis. 2004 , 24, 8662-70	84
927	Anti-invasive, antitumoral, and antiangiogenic efficacy of a pyrimidine-2,4,6-trione derivative, an orally active and selective matrix metalloproteinases inhibitor. 2004 , 10, 4038-47	134
926	Green fluorescent protein tagging of extracellular signal-regulated kinase and p38 pathways reveals novel dynamics of pathway activation during primary and metastatic growth. 2004 , 64, 7336-45	140
925	Genetic analysis of macrophage characteristics as a tool to identify tumor susceptibility genes: mapping of three macrophage-associated risk inflammatory factors, marif1, marif2, and marif3. 2004 , 64, 3458-64	17
924	Minireview: Cyclin D1: normal and abnormal functions. 2004 , 145, 5439-47	768
923	Hedgehog signaling promotes prostate xenograft tumor growth. 2004 , 145, 3961-70	239
922	Phase I trial of the cyclin-dependent kinase inhibitor flavopiridol in combination with docetaxel in patients with metastatic breast cancer. 2004 , 10, 5038-47	62
921	Human papillomavirus type 16 E6 amino acid 83 variants enhance E6-mediated MAPK signaling and differentially regulate tumorigenesis by notch signaling and oncogenic Ras. 2004 , 78, 5934-45	107

920	Hath1, down-regulated in colon adenocarcinomas, inhibits proliferation and tumorigenesis of colon cancer cells. 2004 , 64, 6050-7	101
919	Down-regulation of the receptor for advanced glycation end-products (RAGE) supports non-small cell lung carcinoma. 2005 , 26, 293-301	114
918	Antitumor effects of thalidomide analogs in human prostate cancer xenografts implanted in immunodeficient mice. 2004 , 10, 4192-7	45
917	Heat shock protein 90 regulates the metaphase-anaphase transition in a polo-like kinase-dependent manner. 2004 , 64, 5106-12	61
916	Induction of androgen receptor-dependent apoptosis in prostate cancer cells by the retinoblastoma protein. 2004 , 64, 1377-85	19
915	Telomere maintenance in childhood primitive neuroectodermal brain tumors. 2004 , 6, 1-8	22
914	Tissue-wide expression profiling using cDNA subtraction and microarrays to identify tumor-specific genes. 2004 , 64, 844-56	190
913	Phospholipase D elevates the level of MDM2 and suppresses DNA damage-induced increases in p53. 2004 , 24, 5677-86	55
912	Inhibition of NF-kappa B activation by peptides targeting NF-kappa B essential modulator (nemo) oligomerization. 2004 , 279, 54248-57	49
911	Impact of proteomics on bladder cancer research. 2004 , 5, 381-94	34
910	Suppression of PTEN expression by NF-kappa B prevents apoptosis. 2004 , 24, 1007-21	207
909	Nuclear localization of apoptosis protease activating factor-1 predicts survival after tumor resection in early-stage non-small cell lung cancer. 2004 , 10, 5665-9	25
908	The FUTURE of ErbB-1 and ErbB-2 pathway inhibition in breast cancer: targeting multiple receptors. 2004 , 9 Suppl 3, 1-3	15
907	Caspase inhibition during apoptosis causes abnormal signalling and developmental aberrations in Drosophila. 2004 , 131, 5591-8	249
906	Myocardial ischemia, fluorodeoxyglucose, and severity of coronary artery stenosis: the complexities of metabolic remodeling in hibernating myocardium. 2004 , 109, e167-70; author reply e167-70	10
905	Hypoxia and defective apoptosis drive genomic instability and tumorigenesis. 2004 , 18, 2095-107	190
904	Cytokine stimulation of aerobic glycolysis in hematopoietic cells exceeds proliferative demand. 2004 , 18, 1303-5	144
903	Spontaneous mutations in digestive tract of old mice show tissue-specific patterns of genomic instability. 2004 , 64, 6919-23	25

902	Beta-catenin up-regulates the expression of the urokinase plasminogen activator in human colorectal tumors. 2004 , 64, 1209-14	79
901	High level HPV-16 E7 oncoprotein expression correlates with reduced pRb-levels in cervical biopsies. 2004 , 18, 1120-2	52
900	Loss of nuclear factor-kappaB is tumor promoting but does not substitute for loss of p53. 2004 , 64, 4415-8	26
899	Activation of antioxidant pathways in ras-mediated oncogenic transformation of human surface ovarian epithelial cells revealed by functional proteomics and mass spectrometry. 2004 , 64, 4577-84	114
898	A fragment of histidine-rich glycoprotein is a potent inhibitor of tumor vascularization. 2004 , 64, 599-605	73
897	Epigenetics and cancer. 2004 , 18, 2315-35	352
896	14-3-3sigma mediation of cell cycle progression is p53-independent in response to insulin-like growth factor-I receptor activation. 2004 , 279, 34353-60	27
895	Chemoresistance: impact of nuclear factor (NF)-kappaB inhibition by small interfering RNA. Commentary re J. Guo et al., Enhanced chemosensitivity to irinotecan by RNA interference-mediated down-regulation of the NF-kappaB p65 subunit. Clin Cancer Res 2004 , 10, 3333-3341. 2004 , 10, 3262-4	24
894	Specific recognition and killing of glioblastoma multiforme by interleukin 13-zetakine redirected cytolytic T cells. 2004 , 64, 9160-6	291
893	Cysteine cathepsins are central contributors of invasion by cultured adenosylmethionine decarboxylase-transformed rodent fibroblasts. 2004 , 64, 8831-8	45
892	Caspase-mediated Cleavage of Insulin Receptor Substrate. 2004 , 279, 25149-56	11
891	TIMP-1 alters susceptibility to carcinogenesis. 2004 , 64, 952-61	60
890	Re-expression of detachment-inducible chloride channel mCLCA5 suppresses growth of metastatic breast cancer cells. 2004 , 279, 41634-41	28
889	Oral silibinin inhibits lung tumor growth in athymic nude mice and forms a novel chemocombination with doxorubicin targeting nuclear factor kappaB-mediated inducible chemoresistance. 2004 , 10, 8641-7	104
888	c-Myc interacts with hypoxia to induce angiogenesis in vivo by a vascular endothelial growth factor-dependent mechanism. 2004 , 64, 6563-70	80
887	PPAR gamma signaling exacerbates mammary gland tumor development. 2004 , 18, 528-40	143
886	Exploiting different ways to die. 2004 , 18, 1223-6	70
885	The ras/mitogen-activated protein kinase pathway inhibitor and likely tumor suppressor proteins, sprouty 1 and sprouty 2 are deregulated in breast cancer. 2004 , 64, 6127-36	145

884	Conditional expression of K-ras in an epithelial compartment that includes the stem cells is sufficient to promote squamous cell carcinogenesis. 2004 , 64, 8804-7	107
883	Nuclear factor-kappaB is constitutively activated in prostate cancer in vitro and is overexpressed in prostatic intraepithelial neoplasia and adenocarcinoma of the prostate. 2004 , 10, 5501-7	142
882	Cancer and Genetics: Part II. 2004 , 31, 35-36	
881	Telomerase expression predicts unfavorable outcome in osteosarcoma. 2004 , 22, 3790-7	80
880	Cyclophilin D, a component of the permeability transition-pore, is an apoptosis repressor. 2004 , 64, 85-93	101
879	Clustering of minimal deleted regions reveals distinct genetic pathways of human hepatocellular carcinoma. 2004 , 64, 3030-6	36
878	herg1 gene and HERG1 protein are overexpressed in colorectal cancers and regulate cell invasion of tumor cells. 2004 , 64, 606-11	178
877	An integrated view of copy number and allelic alterations in the cancer genome using single nucleotide polymorphism arrays. 2004 , 64, 3060-71	447
876	Cell-type-specific responses to chemotherapeutics in breast cancer. 2004 , 64, 4218-26	307
875	DNA polymerase beta interacts with TRF2 and induces telomere dysfunction in a murine mammary cell line. 2004 , 64, 3830-7	31
874	Utilization of bone marrow-derived endothelial cell precursors in spontaneous prostate tumors varies with tumor grade. 2004 , 64, 6137-43	78
873	Detection of residual subclinical ovarian carcinoma after completion of adjuvant chemotherapy. 2004 , 10, 2681-6	2
872	Oral cavity and esophageal carcinogenesis modeled in carcinogen-treated mice. 2004 , 10, 301-13	248
871	Design of a real time quantitative PCR assay to assess global mRNA amplification of small size specimens for microarray hybridisation. 2004 , 57, 1278-87	4
870	Destructive cycles: the role of genomic instability and adaptation in carcinogenesis. 2004 , 25, 2033-44	49
869	Hunting drug targets by systems-level modeling of gene expression profiles. 2004 , 3, 180-91	5
868	Malignancy in renal transplantation. 2004 , 15, 1582-8	168
867	Cancer therapeutics: understanding the mechanism of action. 2004 , 32 Suppl 1, 116-21	18

866	Bim is a suppressor of Myc-induced mouse B cell leukemia. 2004 , 101, 6164-9	407
865	A cleaved form of MAGE-A4 binds to Miz-1 and induces apoptosis in human cells. 2004 , 279, 15505-14	43
864	Epigallocatechin-3-gallate inhibits epidermal growth factor receptor signaling pathway. Evidence for direct inhibition of ERK1/2 and AKT kinases. 2004 , 279, 12755-62	183
863	Dual regulation of MMP-2 expression by the type 1 insulin-like growth factor receptor: the phosphatidylinositol 3-kinase/Akt and Raf/ERK pathways transmit opposing signals. 2004 , 279, 19683-90	125
862	Concerted activation of ETS protein ER81 by p160 coactivators, the acetyltransferase p300 and the receptor tyrosine kinase HER2/Neu. 2004 , 279, 14909-16	73
861	Identification of interaction partners and substrates of the cyclin A1-CDK2 complex. 2004 , 279, 33727-41	50
860	An alternative transcript derived from the trio locus encodes a guanosine nucleotide exchange factor with mouse cell-transforming potential. 2004 , 279, 43998-4004	41
859	Colon cancer: genomics and apoptotic events. 2004 , 385, 449-64	69
858	Heat shock protein 70 promotes cell survival by inhibiting lysosomal membrane permeabilization. 2004 , 200, 425-35	451
857	Increased expression of Apaf-1 and procaspase-3 and the functionality of intrinsic apoptosis apparatus in non-small cell lung carcinoma. 2004 , 385, 153-68	44
856	Genome coverage and sequence fidelity of phi29 polymerase-based multiple strand displacement whole genome amplification. 2004 , 32, e71	236
855	Telomeres, Telomerase and Cancer: An Endless Search to Target the Ends. 2004 , 3, 1136-1148	22
854	Expression of kinase-defective mutants of c-Src in human metastatic colon cancer cells decreases Bcl-xL and increases oxaliplatin- and Fas-induced apoptosis. 2004 , 279, 46113-21	48
853	Snail and E47 repressors of E-cadherin induce distinct invasive and angiogenic properties in vivo. 2004 , 117, 2827-39	130
852	Low level chromosome instability in embryonic cells of primary aneuploid mice. 2004 , 107, 95-8	3
851	Identification and testing of a gene expression signature of invasive carcinoma cells within primary mammary tumors. 2004 , 64, 8585-94	365
850	Construction of a cyclin D1-Cdk2 fusion protein to model the biological functions of cyclin D1-Cdk2 complexes. 2004 , 279, 47688-98	42
849	Session 2: Inflammation and Cancer: LISA M. COUSSENS, Cancer Research Institute, Department of Pathology and the UCSF Comprehensive Cancer Center, University of California, San Francisco, 2340 Sutter St, Rm. N221, San Francisco, CA 94143. 2004 , 32, 732-732	6

848	Polycomb Group Proteins in Cell Cycle Progression and Cancer. 2004 , 3, 394-398	72
847	Clinical implications of advanced molecular cytogenetics in cancer. 2004 , 4, 71-81	16
846	The cytotoxicity of chemotherapy drugs varies in cervical cancer cells depending on the p53 status. 2004 , 3, 1177-83	24
845	Target selection issues in drug discovery and development. 2004 , 16 Suppl 4, 16-8	2
844	Recent advances in molecular diagnosis and therapy of gastric cancer. 2004 , 22, 380-5	14
843	Production of a novel camel single-domain antibody specific for the type III mutant EGFR. 2004 , 25, 296-305	26
842	Twist induces an epithelial-mesenchymal transition to facilitate tumor metastasis. 2004 , 3, 1058-9	73
841	Guarding the Bcl-2 army. 2004 , 3, 348-50	
840	Do female sex hormones initiate breast cancer? A review of the evidence. 2004 , 7, 120-8	11
839	Genomic instability is associated with lack of telomerase activation in ovarian cancer. 2004 , 3, 1250-3	9
838	Life, death and E2F: linking proliferation control and DNA damage signaling via E2F1. 2004 , 3, 845-6	49
837	Regulation of tumor progression by anti-neoplastic T cell responses. 2004 , 3, 140-6	8
836	Clipped wings: epigenetic inactivation of APC. 2004 , 3, 965-6	
835	The development and application of functional nuclear magnetic resonance to in vivo therapeutic anticancer research: 2002 Sir Godfrey Hounsfield lecture delivered at the President's Day, Manchester. 2004 , 77, 296-307	7
834	Getting back on track, or what to do when apoptosis is de-railed: recoupling oncogenes to the apoptotic machinery. 2004 , 3, 21-8	9
833	Regulation of cyclin E protein levels through E2F-mediated inhibition of degradation. 2004 , 3, 1572-8	11
832	HSP70 and genomic stability. 2004 , 3, 591-2	21
831	ErbB2 and TGF-beta: A Cooperative Role in Mammary Tumor Progression?. 2004 , 3, 595-598	10

830	The ARTS Connection: Role of ARTS in Apoptosis and Cancer. 2004 , 3, 1019-1021	15
829	Molecular targets for cancer therapy and prevention. 2004 , 125, 97S-101S	11
828	Calmodulin-mediated activation of Akt regulates survival of c-Myc-overexpressing mouse mammary carcinoma cells. 2004 , 279, 38903-11	78
827	Lysophosphatidic acid (LPA) in malignant ascites stimulates motility of human pancreatic cancer cells through LPA1. 2004 , 279, 6595-605	144
826	Endothelin-1-induced prostaglandin E2-EP2, EP4 signaling regulates vascular endothelial growth factor production and ovarian carcinoma cell invasion. 2004 , 279, 46700-5	73
825	Roles of stem cell factor/c-Kit and effects of Glivec/STI571 in human uveal melanoma cell tumorigenesis. 2004 , 279, 31769-79	65
824	Cystatin m: a novel candidate tumor suppressor gene for breast cancer. 2004 , 64, 6957-64	74
823	Selecting biomedical data sources according to user preferences. 2004 , 20 Suppl 1, i86-93	13
822	Acquired expression of periostin by human breast cancers promotes tumor angiogenesis through up-regulation of vascular endothelial growth factor receptor 2 expression. 2004 , 24, 3992-4003	260
821	Hsp90 activation and cell cycle regulation. 2004 , 3, 1530-6	129
820	Phosphatidylinositol transfer protein alpha regulates growth and apoptosis of NIH3T3 cells: involvement of a cannabinoid 1-like receptor. 2004 , 45, 1555-64	15
819	The histone deacetylase inhibitor NVP-LAQ824 inhibits angiogenesis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584. 2004 , 64, 6626-34	208
818	PEA-15 is inhibited by adenovirus E1A and plays a role in ERK nuclear export and Ras-induced senescence. 2004 , 279, 46802-9	46
817	Spontaneous DNA damage in <i>Saccharomyces cerevisiae</i> elicits phenotypic properties similar to cancer cells. 2004 , 279, 22585-94	54
816	Activation of the RON receptor tyrosine kinase attenuates transforming growth factor-beta1-induced apoptotic death and promotes phenotypic changes in mouse intestinal epithelial cells. 2005 , 26, 27-36	9
815	High intensity ras signaling induces premature senescence by activating p38 pathway in primary human fibroblasts. 2004 , 279, 1050-9	135
814	Involvement of Ras activation in human breast cancer cell signaling, invasion, and anoikis. 2004 , 64, 4585-92	171
813	Altered expression of metastasis-associated and regulatory molecules in effusions from breast cancer patients: a novel model for tumor progression. 2004 , 10, 7335-46	60

812	Secreted protein acidic, rich in cysteine (SPARC), mediates cellular survival of gliomas through AKT activation. 2004 , 279, 52200-9	92
811	Retinoic acid receptor beta2 hypermethylation: implications for prostate cancer detection, prevention, and therapy. 2004 , 10, 3935-6	7
810	Repression of the Arf tumor suppressor by E2F3 is required for normal cell cycle kinetics. 2004 , 18, 1413-22	139
809	Menin induces apoptosis in murine embryonic fibroblasts. 2004 , 279, 10685-91	67
808	Nicotine: potentially a multifunctional carcinogen?. 2004 , 79, 1-3	40
807	Tobacco carcinogen-induced cellular transformation increases activation of the phosphatidylinositol 3'-kinase/Akt pathway in vitro and in vivo. 2004 , 64, 446-51	118
806	Therapeutic targets for antimetastatic therapy. 2004 , 8, 527-36	22
805	Novel agents in epithelial ovarian cancer. 2004 , 22 Suppl 2, 29-44	14
804	An E1B-19 kDa gene deletion mutant adenovirus demonstrates tumor necrosis factor-enhanced cancer selectivity and enhanced oncolytic potency. 2004 , 9, 786-803	56
803	Reduced Apaf-1 expression in human cutaneous melanomas. 2004 , 91, 1089-95	47
802	Transcriptional silencing of the Dickkopf-3 (Dkk-3) gene by CpG hypermethylation in acute lymphoblastic leukaemia. 2004 , 91, 707-13	90
801	Cellular responses to ErbB-2 overexpression in human mammary luminal epithelial cells: comparison of mRNA and protein expression. 2004 , 90, 173-81	37
800	Anti-tumor efficacy of human angiostatin using liver-mediated adeno-associated virus gene therapy. 2004 , 9, 56-66	31
799	Epidermal growth factor receptor signaling in tissues. 2004 , 24, 53-61	5
798	Oct4 expression in adult human stem cells: evidence in support of the stem cell theory of carcinogenesis. 2005 , 26, 495-502	462
797	Bcr-Abl-mediated protection from apoptosis downstream of mitochondrial cytochrome c release. 2004 , 24, 10289-99	50
796	Tumor cell traffic through the extracellular matrix is controlled by the membrane-anchored collagenase MT1-MMP. 2004 , 167, 769-81	482
795	Molecular Targeting and Signal Transduction. 2004 ,	

794	Upregulation of the Catalytic Telomerase Subunit by the Transcription Factor ER81 and Oncogenic HER2/Neu, Ras, or Raf. 2004 , 24, 25-35	105
793	Invasion of normal human fibroblasts induced by v-Fos is independent of proliferation, immortalization, and the tumor suppressors p16INK4a and p53. 2004 , 24, 1540-59	30
792	Selectively advantageous mutations and hitchhikers in neoplasms: p16 lesions are selected in Barrett's esophagus. 2004 , 64, 3414-27	180
791	Endogenous inhibitors of nuclear factor-kappaB, an opportunity for cancer control. 2004 , 64, 8135-8	27
790	Low-dose radiation and genotoxic chemicals can protect against stochastic biological effects. 2004 , 2, 185-211	12
789	Chromosomal rearrangement as the basis for human tumourigenesis. 2004 , 80, 543-57	11
788	p19Arf suppresses growth, progression, and metastasis of Hras-driven carcinomas through p53-dependent and -independent pathways. 2004 , 2, E242	69
787	A comprehensive screen for chicken proteins that interact with proteins unique to virulent strains of Marek's disease virus. 2004 , 83, 1117-23	35
786	Identification of the apoptosis activation cascade induced in mammary carcinomas by energy restriction. 2004 , 64, 1541-5	31
785	Death receptor signals to mitochondria. 2004 , 3, 1051-7	146
784	Modeling metastasis in vivo. 2005 , 26, 513-23	330
783	Prostate Carcinogenesis is an Endogenous, Hypoxic Process. 2004 , 4, 77-83	
782	Increased expression of calcium-binding protein S100 in human uterine smooth muscle tumours. 2004 , 10, 735-42	41
781	Sensitive, noninvasive detection of lymph node metastases. 2004 , 1, e66	67
780	Increased skin carcinogenesis in a keratinocyte directed thioredoxin-1 transgenic mouse. 2004 , 25, 1983-9	6
779	DNA aneuploidy and integration of human papillomavirus type 16 e6/e7 oncogenes in intraepithelial neoplasia and invasive squamous cell carcinoma of the cervix uteri. 2004 , 10, 3059-63	115
778	Sensitization to the lysosomal cell death pathway upon immortalization and transformation. 2004 , 64, 5301-10	123
777	Risk assessment and risk management of mycotoxins in food. 2004 , 3-31	16

776	c-Myc as a therapeutic target in cancer. 2004 , 4, 289-302	76
775	Handbook of Anticancer Pharmacokinetics and Pharmacodynamics. 2004 ,	7
774	Impact of microarray technology in clinical oncology. 2004 , 22, 312-20	23
773	Dioxin-induced immortalization of normal human keratinocytes and silencing of p53 and p16INK4a. 2004 , 279, 27187-93	67
772	Towards discovery-driven translational research in breast cancer. 2005 , 272, 2-15	42
771	Glomerulosclerosis: a paraneoplastic phenomenon?. 2004 , 9, 387-91	12
770	Mesothelial cell proliferation and apoptosis. 2004 , 9, 292-9	32
769	Molecular medicine: a clinician's primer on microarrays. 2004 , 34, 565-9	1
768	Molecular footprints of human lung cancer progression. 2004 , 95, 197-204	114
767	Transcriptional responses to epigallocatechin-3 gallate in HT 29 colon carcinoma spheroids. 2004 , 9, 661-9	29
766	Assessment of apoptosis by M30 immunoreactivity and the correlation with morphological criteria in normal colorectal mucosa, adenomas and carcinomas. 2004 , 44, 9-17	32
765	DNA ploidy analysis in histopathology. Morphometry and DNA cytometry reproducibility conditions and clinical applications. 2004 , 44, 603-14	13
764	Antiangiogenic effect of metronomic paclitaxel treatment in prostate cancer and non-tumor tissue in the same animals: a quantitative study. 2004 , 112, 201-9	29
763	Mutation of FADD gene is rare in human colon and stomach cancers. 2004 , 112, 595-7	7
762	Expression of adhesion molecules and Ki-67 in female adnexal tumor of probable Wolffian origin (FATWO): report of two cases and review of the literature. 2004 , 112, 390-8	66
761	A genetic progression model of oral cancer: current evidence and clinical implications. 2004 , 33, 317-22	122
760	The T1796A mutation of the BRAF gene is absent in Spitz nevi. 2004 , 31, 266-70	56
759	Morphologically distinct patterns of apoptosis correlate with size and high-grade dysplasia in colonic adenomas. 2004 , 44, 240-6	5

758	The case-only odds ratio as a causal parameter. 2004 , 60, 233-40	11
757	Truncation of activated leukocyte cell adhesion molecule: a gateway to melanoma metastasis. 2004 , 122, 1293-301	51
756	Cytokines in cancer immunity and immunotherapy. 2004 , 202, 275-93	306
755	Polycomb CBX7 has a unifying role in cellular lifespan. 2004 , 6, 67-72	279
754	Senescing human cells and ageing mice accumulate DNA lesions with unrepairable double-strand breaks. 2004 , 6, 168-70	601
753	Functional proteomic screens reveal an essential extracellular role for hsp90 alpha in cancer cell invasiveness. 2004 , 6, 507-14	471
752	Conquering the complexity of p53. 2004 , 36, 7-8	21
751	White meat or dark?. 2004 , 36, 8-10	27
750	Monitoring p53's pulse. 2004 , 36, 113-4	37
749	Close look at gene conversion hot spots. 2004 , 36, 114-5	25
748	Fusion genes and rearranged genes as a linear function of chromosome aberrations in cancer. 2004 , 36, 331-4	255
747	In situ analyses of genome instability in breast cancer. 2004 , 36, 984-8	304
746	Cytokines in cancer pathogenesis and cancer therapy. 2004 , 4, 11-22	1018
745	The proteasome: a suitable antineoplastic target. 2004 , 4, 349-60	1028
744	Hyaluronan: from extracellular glue to pericellular cue. 2004 , 4, 528-39	1586
743	Pathways of apoptotic and non-apoptotic death in tumour cells. 2004 , 4, 592-603	851
742	Hallmarks of 'BRCAness' in sporadic cancers. 2004 , 4, 814-9	1268
741	A vision for the National Cancer Program in the United States. 2004 , 4, 820-8	39

740	Friends or foes - bipolar effects of the tumour stroma in cancer. 2004 , 4, 839-49	1446
739	Gefitinib--a novel targeted approach to treating cancer. 2004 , 4, 956-65	283
738	Development of novel targeted therapies in the treatment of malignant glioma. 2004 , 3, 430-46	187
737	Apoptosis and genomic instability. 2004 , 5, 752-62	234
736	Integrin signalling during tumour progression. 2004 , 5, 816-26	1209
735	Molecular mechanisms of caspase regulation during apoptosis. 2004 , 5, 897-907	1456
734	Life and death decisions by E2F-1. 2004 , 11, 137-42	121
733	Successes and failures of immunotherapy for gastric cancer. 2022 , 27, 103343	0
732	Ionizing radiation protection and the linear No-threshold controversy: Extent of support or counter to the prevailing paradigm. 2022 , 253-254, 106984	0
731	A nonlinear model and an algorithm for identifying cancer driver pathways. 2022 , 129, 109578	0
730	Tumor microenvironment-triggered intratumoral in situ construction of theranostic supramolecular self-assembly. 2022 , 473, 214824	1
729	Cell-penetrating peptides. 2023 , 105-131	0
728	Isatin derived novel Schiff bases: An efficient pharmacophore for versatile biological applications. 2023 , 1271, 134121	0
727	A model and cooperative co-evolution algorithm for identifying driver pathways based on the integrated data and PPI network. 2023 , 212, 118753	0
726	Microfluidics in vascular biology research: a critical review for engineers, biologists, and clinicians. 2022 , 22, 3618-3636	1
725	Optimal treatment strategy of cancers with intratumor heterogeneity. 2022 , 19, 13337-13373	0
724	Characterization and Assessment of Cold Plasma as a New Practical Approach for Cancer Cell Treatment. 2022 ,	0
723	The Role of Nanotechnology for Diagnostic and Therapy Strategies in Lung Cancer. 2022 ,	0

722	Exercise: A Critical Component of Cachexia Prevention and Therapy in Cancer. 2022 , 193-203	o
721	Investigation of early neoplastic transformation and premalignant biology using genetically engineered organoid models. 2022 , 20, 5309-5315	o
720	Metabolic dysregulation in cancer progression. 2022 , 1-39	o
719	Autophagy-inducing nutritional interventions in experimental and clinical oncology. 2022 ,	o
718	Cancer Biology of Molecular Imaging. 2022 , 3-39	o
717	Systematic Integration of Protein Affecting Mutations, Gene Fusions, and Copy Number Alterations Into a Comprehensive Somatic Mutational Profile.	o
716	Gastrointestinal Cancers: What Is the Real Board of Microenvironment and the Role of MicrobiotaImmunity Axis?. 2022 ,	o
715	Introduction. 2022 , 1-20	o
714	Elimination of damaged cells-dependent antiaging strategy. 2022 , 75-111	o
713	Gesunde Marktwirtschaft Das Leben, die ðonomie und das soziale Nerven­geflecht. 2022 , 25-48	o
712	Epigenetics. 2022 , 167-196	o
711	Transmembranproteine und ihre Bedeutung bei der Krebserkrankung. 2022 , 75, 287-296	o
710	Role of tumor-associated macrophages in the breast tumor microenvironment. 2022 , 137-169	3
709	Cell Division/Death: Cell Cycle Cellular Senescence. 2022 ,	o
708	The Immunohistochemical Landscape of the Hypoxia-Related Proteins in Oral Squamous Cell Carcinoma. 2022 ,	o
707	Study of Tumour Induced Vessel Displacement in the Tumour Progression Rate with Advanced Bioinspired Computational Tools. 2022 , 289-308	o
706	What Cancer Is. 2022 , 1-18	o
705	Invertebrate models in translational research. 2022 , 31-48	o

704	SNPs Ability to Influence Disease Risk: Breaking the Silence on Synonymous Mutations in Cancer. 2022 , 77-96	0
703	A General Overview on Causes, Risk Factors, Diagnosis, Treatment, and Role of Oxidative Stress Biomarkers in Colorectal Cancer. 2022 , 3877-3895	0
702	Long Noncoding RNA Acting as Therapeutic Target for Oxidative Stress-Induced Pancreatic Cancer. 2022 , 1525-1557	0
701	Electrospun nanofibers for 3-D cancer models, diagnostics, and therapy.	0
700	Fasting and cancer responses to therapy. 2022 ,	0
699	Multi-label classification for biomedical literature: an overview of the BioCreative VII LitCovid Track for COVID-19 literature topic annotations. 2022 , 2022,	4
698	Introduction to various types of cancers. 2022 , 1-29	2
697	The biology of cancer. 2023 , 35-45	0
696	Fuzzy-Receiver Operating Characteristics (F-ROC) for Fuzzy-Inspired Biosensing Performance Evaluation. 2022 ,	0
695	Activated aggregation strategies to construct size-increasing nanoparticles for cancer therapy.	0
694	Network Dynamics Caused by Genomic Alteration Determine the Therapeutic Response to FGFR Inhibitors for Lung Cancer. 2022 , 12, 1197	0
693	Construction and validation of a novel coagulation-related 7-gene prognostic signature for gastric cancer. 13,	1
692	Enhancing anti-tumour innate immunity by targeting the DNA damage response and pattern recognition receptors in combination with radiotherapy. 12,	0
691	Global research trends in extracellular vesicles based on stem cells from 1991 to 2021: A bibliometric and visualized study. 10,	0
690	Clonal hematopoiesis of indeterminate potential in patients with solid tumor malignancies.	0
689	Disrupting the Interplay between Programmed Cell Death Protein 1 and Programmed Death Ligand 1 with Spherical Nucleic Acids in Treating Cancer. 2022 , 8, 1299-1305	0
688	A Pan-Cancer Assessment of RB1/TP53 Co-Mutations. 2022 , 14, 4199	1
687	Synergistic Lethality Effects of Apatinib and Homoharringtonine in Acute Myeloid Leukemia. 2022 , 2022, 1-13	0


686	Monitoring of Current Cancer Therapy by Positron Emission Tomography and Possible Role of Radiomics Assessment. 2022 , 23, 9394	1
685	Asialoglycoprotein receptor 1 functions as a tumor suppressor in liver cancer via inhibition of STAT3.	0
684	A Supervised Learning Identification System for Prognosis of Breast Cancer. 2022 , 2022, 1-8	0
683	Endogenous TRAIL-R4 critically impacts apoptotic and non-apoptotic TRAIL-induced signaling in cancer cells. 10,	0
682	A mechanistic mathematical model of initiation and malignant transformation in sporadic vestibular schwannoma.	0
681	Current Uses of Mushrooms in Cancer Treatment and Their Anticancer Mechanisms. 2022 , 23, 10502	2
680	Enabling factor for cancer hallmark acquisition: Small nucleolar RNA host gene 17. 12,	0
679	Different Approaches for the Profiling of Cancer Pathway-Related Genes in Glioblastoma Cells. 2022 , 23, 10883	1
678	Most cancers carry a substantial deleterious load due to Hill-Robertson interference. 11,	0
677	The Critical Role of RNA m6A Methylation in Gliomas: Targeting the Hallmarks of Cancer.	0
676	The Dysfunction of Carcinogenesis- and Apoptosis-Associated Genes that Develops in the Hypothalamus under Chronic Social Defeat Stress in Male Mice. 2022 , 87, 1050-1064	0
675	Metabolite-derived protein modifications modulating oncogenic signaling. 12,	0
674	RLIP: A necessary transporter protein for translating oxidative stress into pro-obesity and pro-carcinogenic signaling. 2022 , 1877, 188803	0
673	Small Molecule Assembly Modulators with Pan-Cancer Therapeutic Efficacy.	0
672	The impact of macrophages on endothelial cells is potentiated by cycling hypoxia: Enhanced tumor inflammation and metastasis. 12,	1
671	Nucleoli in epithelial cell collectives respond to tumorigenic, spatial, and mechanical cues. 2022 , 33,	1
670	The role of LncRNA LBX2-AS1 in cancers: functions, mechanisms and potential clinical utility.	0
669	Expression of epithelial-mesenchymal transition-associated proteins and proliferating cell nuclear antigen in dihydropyridine-induced gingival overgrowth fibroblasts: A preliminary study. 2022 ,	0

668	Targeting the USP7/RRM2 axis drives senescence and sensitizes melanoma cells to HDAC/LSD1 inhibitors. 2022 , 40, 111396	0
667	Paracrine HB-EGF signaling reduce enhanced contractile and energetic state of activated decidual fibroblasts by rebalancing SRF-MRTF-TCF transcriptional axis. 10,	1
666	Nuclear morphology and functional characteristics that enable survival of cells in the polyan euploid cancer cell state following cytotoxic chemotherapy.	0
665	The emerging roles and potential applications of circular RNAs in ovarian cancer: a comprehensive review.	0
664	Method to improve the localization accuracy and contrast recovery of lesions in separately acquired X-ray and diffuse optical tomographic breast imaging. 2022 , 13, 5295	1
663	Pou3f1 mediates the effect of Nfatc3 on ulcerative colitis-associated colorectal cancer by regulating inflammation. 2022 , 27,	0
662	Rubiaronol B induces RIPK1-dependent necroptosis via NOX1-derived ROS production.	0
661	E2F1/CKS2/PTEN signaling axis regulates malignant phenotypes in pediatric retinoblastoma. 2022 , 13,	0
660	In ovo model in cancer research and tumor immunology. 13,	2
659	C-reactive protein and cancer risk: a pan-cancer study of prospective cohort and Mendelian randomization analysis. 2022 , 20,	1
658	H2G-Net: A multi-resolution refinement approach for segmentation of breast cancer region in gigapixel histopathological images. 9,	0
657	Individual Genetic Heterogeneity. 2022 , 13, 1626	0
656	Non-Coding RNAs in Hepatocellular Carcinoma. 2022 , 2, 185-213	1
655	Out of the cycle: Impact of cell cycle aberrations on cancer metabolism and metastasis.	0
654	All Roads Lead to Cathepsins: The Role of Cathepsins in Non-Alcoholic Steatohepatitis-Induced Hepatocellular Carcinoma. 2022 , 10, 2351	0
653	Spatio-temporal modelling of phenotypic heterogeneity in tumour tissues and its impact on radiotherapy treatment. 2022 , 111248	0
652	Combinatorial treatments of tamoxifen and SM6Met, an extract from <i>Cyclopia subternata</i> Vogel, are superior to either treatment alone in MCF-7 cells. 13,	0
651	Identification and validation of a signature involving voltage-gated chloride ion channel genes for prediction of prostate cancer recurrence. 13,	0

- 650 Interactome battling of lncRNA CCDC144NL-AS1: Its role in the emergence and ferocity of cancer and beyond. **2022**, ○
- 649 Stimuli-Responsive Aggregation-Induced Emission (AIE)-Active Polymers for Biomedical Applications. ○
- 648 Terminal differentiation and anti-tumorigenic effects of prolactin in breast cancer. 13, ○
- 647 The role of miR-200 family in the regulation of hallmarks of cancer. 12, 1
- 646 Editorial: Novel agents and combinations for treatment of malignant pleural mesothelioma in pre-clinical models. 13, ○
- 645 Therapeutic targeting of DNA damage repair pathways guided by homologous recombination deficiency scoring in ovarian cancers. ○
- 644 Incidence of BRAF V600E Gene Mutation Among Lebanese Population in Melanoma and Colorectal Cancer: A Retrospective Study Between 2010 and 2019. **2022**, ○
- 643 An integrative systems biology approach to overcome venetoclax resistance in acute myeloid leukemia. **2022**, 18, e1010439 ○
- 642 IKZF3 amplification frequently occurs in HER2-positive breast cancer and is a potential therapeutic target. **2022**, 39, ○
- 641 Cancer as a Channelopathy: Appreciation of Complimentary Pathways Provides a Different Perspective for Developing Treatments. **2022**, 14, 4627 ○
- 640 Apoptosis evasion via long non-coding RNAs in colorectal cancer. **2022**, 22, 1
- 639 Binding of Proteins to Copolymers of Varying Charges and Hydrophobicity: A Molecular Mechanism and Computational Strategies. ○
- 638 The role of aging in cancer. **2022**, 16, 3213-3219 ○
- 637 Leader gene identification for digestive system cancers based on human subcellular location and cancer-related characteristics in protein-protein interaction networks. 13, ○
- 636 Allyl Isothiocyanate (AITC) Induces Apoptotic Cell Death In Vitro and Exhibits Anti-Tumor Activity in a Human Glioblastoma GBM8401/luc2 Model. **2022**, 23, 10411 1
- 635 Fusion-negative Rhabdomyosarcoma 3D-organoids as an innovative model to predict resistance to cell death inducers. ○
- 634 Advances in Engineered Biomaterials Targeting Angiogenesis and Cell Proliferation for Cancer Therapy. ○
- 633 A Bioinformatic Approach to Enhance Undergraduate Student Understanding of the Cancer-Immunity Cycle. ○

- 632 Nerves in gastrointestinal cancer: from mechanism to modulations. o
- 631 Breast PET / MRI Hybrid Imaging and Targeted Tracers. o
- 630 PLXDC1 Can Be a Biomarker for Poor Prognosis and Immune Evasion in Gastric Cancer. Volume 15, 5439-5455 o
- 629 Potassium Ion Channels in Malignant Central Nervous System Cancers. **2022**, 14, 4767 1
- 628 ZFP36 Inhibits Tumor Progression of Human Prostate Cancer by Targeting CDK6 and Oxidative Stress. **2022**, 2022, 1-24 o
- 627 Variant calling enhances the identification of cancer cells in single-cell RNA sequencing data. **2022**, 18, e1010576 o
- 626 Colon cancer and colorectal cancer: Prevention and treatment by potential natural products. **2022**, 110170 5
- 625 Cancer is a devastating disease, but also an eye-opener and window into the deep mysteries of life and its origins. **2022**, o
- 624 Proteomics and phosphoproteomics profiling of the co-formulation of type I and II interferons, HeberFERON, in the glioblastoma-derived cell line U-87 MG. o
- 623 Repurposing an Antiepileptic Drug for the Treatment of Glioblastoma. 1
- 622 Transcriptional regulation and repressive condensates modulate a proliferative-invasive cellular switch in vivo. o
- 621 Multimodal microscale mechanical mapping of cancer cells in complex microenvironments. **2022**, 121, 3586-3599 1
- 620 Comprehensive landscape of the functions and prognostic value of RNA binding proteins in uterine corpus endometrial carcinoma. 9, o
- 619 The endoplasmic reticulum membrane protein Sec62 as potential therapeutic target in SEC62 overexpressing tumors. 13, o
- 618 Non-genomic activation of the AKT-mTOR pathway by the mitochondrial stress response in thyroid cancer. o
- 617 Basic Research on Bullfrog Egg-derived Sialic Acid-binding Lectin for Cancer Treatment. **2022**, 142, 1045-1053 o
- 616 Human papillomavirus-related neoplasia of the ocular adnexa. **2022**, 100, 3-33 o
- 615 Targeted therapy in oncology. **2022**, 222-228 o

- 614 CDK4/6 initiates Rb inactivation and CDK2 activity coordinates cell-cycle commitment and G1/S transition. **2022**, 12, 1
- 613 Bioelectronic medicines: Therapeutic potential and advancements in next-generation cancer therapy. **2022**, 188808 0
- 612 Hesperetin induces apoptosis in A549 cells via the Hsp70-mediated activation of Bax. **2022**, 61, 0
- 611 Obesity, inflammation, and cancer in dogs: Review and perspectives. 9, 1
- 610 EMT mechanism in breast cancer metastasis and drug resistance: Revisiting molecular interactions and biological functions. **2022**, 155, 113774 0
- 609 Multifunctional stimuli-responsive hybrid nanogels for cancer therapy: Current status and challenges. **2022**, 351, 476-503 0
- 608 3D in vitro cancer models for drug screening: A study of glucose metabolism and drug response in 2D and 3D culture models. **2021**, 0
- 607 Cytotoxicity Studies of Eugenol Amino Alcohols Derivatives. 0
- 606 Reprogramming Carbohydrate Metabolism in Cancer and Its Role in Regulating the Tumor Microenvironment. **2022**, 3-65 0
- 605 An overview on macrophage targeting-A promising approach. **2022**, 0
- 604 AKT Isoforms as a Target in Cancer and Immunotherapy. **2022**, 409-436 0
- 603 Practical Aspects of NMR-Based Metabolomics. **2022**, 0
- 602 Effects of pectins on colorectal cancer: targeting hallmarks as a support for future clinical trials. 0
- 601 Breast MRI: Multiparametric and Advanced Techniques. **2022**, 231-257 0
- 600 Quaternary Ru(II) Complexes of Terpyridines, Saccharin and 1, 2-Azoles: Effect of Substituents on Molecular Structure, Speciation, Photoactivity, and Photocytotoxicity. 0
- 599 Prinzipien der zellulären Tumorgenese und -progression. **2022**, 835-849 0
- 598 The use of adenoviral vectors in gene therapy and vaccine approaches. **2022**, 45, 1
- 597 ???RNA?????????????. **2022**, 0

596	Cell-Free Filtrates (CFF) as Vectors of a Transmissible Pathologic Tissue Memory Code: A Hypothetical and Narrative Review. 2022 , 23, 11575	0
595	Phase III Prospectively Randomized Trial of Perioperative 5-FU After Curative Resection for Colon Cancer: An Intergroup Trial of the ECOG-ACRIN Cancer Research Group (E1292).	0
594	Super-enhancers in esophageal carcinoma: Transcriptional addictions and therapeutic strategies. 12,	0
593	Unraveling the Potential Role of NEDD4-like E3 Ligases in Cancer. 2022 , 23, 12380	1
592	The Biological Relevance of Papaverine in Cancer Cells. 2022 , 11, 3385	1
591	From Cold to Hot: Changing Perceptions and Future Opportunities for Quantitative Systems Pharmacology (QSP) Modeling in Cancer Immunotherapy.	1
590	LncRNA ALMS1-IT1 is a novel prognostic biomarker and correlated with immune infiltrates in colon adenocarcinoma. 2022 , 101, e31314	0
589	The efficacy of applying some plants and herbs in cancer therapy for humans and animals  comprehensive review. 2022 ,	0
588	Emerging role of mRNA methylation in regulating the hallmarks of cancer. 2022 ,	0
587	Evaluating the relevance of surgical margins. Part one: The problems with current methodology.	1
586	Antibody therapeutics for epithelial ovarian cancer.	0
585	Hallmarks of Cancer Expression in Oral Lichen Planus: A Scoping Review of Systematic Reviews and Meta-Analyses. 2022 , 23, 13099	0
584	Druggable Metabolic Vulnerabilities Are Exposed and Masked during Progression to Castration Resistant Prostate Cancer. 2022 , 12, 1590	0
583	Live or Heat-Killed Lactobacillus rhamnosus Aerosolization Decreases Adenomatous Lung Cancer Development in a Mouse Carcinogen-Induced Tumor Model. 2022 , 23, 12748	0
582	Functional Modulation of Human Macrophages by Secreted Phospholipases A2: Implications in Cancer. 2022 , 10, 2763	0
581	Reprogramming of glycolysis by chemical carcinogens during tumor development. 2022 ,	0
580	Mechanosensitive Ion Channel PIEZO1 Signaling in the Hall-Marks of Cancer: Structure and Functions. 2022 , 14, 4955	1
579	Pancreatic Cancer Research beyond DNA Mutations. 2022 , 12, 1503	0

- 578 HCP5 prevents ubiquitination-mediated UTP3 degradation to inhibit apoptosis by activating c-Myc transcriptional activity. **2022**, ○
- 577 The thioredoxin system: balancing redox responses in immune cells and tumors. ○
- 576 An off-the-shelf multi-well scaffold-supported platform for tumour organoid-based tissues. **2022**, 121883 1
- 575 A New Manganese Superoxide Dismutase Mimetic Improves Oxaliplatin-Induced Neuropathy and Global Tolerance in Mice. **2022**, 23, 12938 ○
- 574 Induction of Breast Cancer Cell Apoptosis by TRAIL and Smac Mimetics: Involvement of RIP1 and cFLIP. **2022**, 44, 4803-4821 ○
- 573 Hypoxia and ER Transcriptional Crosstalk Is Associated with Endocrine Resistance in Breast Cancer. **2022**, 14, 4934 ○
- 572 Imaging Hallmarks of Sarcoma Progression Via X-ray Computed Tomography: Beholding the Flower of Evil. **2022**, 14, 5112 ○
- 571 Heterocyclic Compounds as Hsp90 Inhibitors: A Perspective on Anticancer Applications. **2022**, 14, 2220 ○
- 570 Suppression Effects of Excessively Expressed Gene BCL-2 in Cell Lines of Prostate Cancer. **2022**, ○
- 569 Replicative Instability Drives Cancer Progression. **2022**, 12, 1570 1
- 568 Association between Immunologic Markers and Cirrhosis in Individuals from a Prospective Chronic Hepatitis C Cohort. **2022**, 14, 5280 1
- 567 Counteracting Immunosuppression in the Tumor Microenvironment by Oncolytic Newcastle Disease Virus and Cellular Immunotherapy. **2022**, 23, 13050 1
- 566 Expression level comparison of marker genes related to early embryonic development and tumor growth. **2022**, 24, ○
- 565 Modulation of signaling cross-talk between pJNK and pAKT generates optimal apoptotic response. **2022**, 18, e1010626 ○
- 564 Caspase 3 and Cleaved Caspase 3 Expression in Tumorigenesis and Its Correlations with Prognosis in Head and Neck Cancer: A Systematic Review and Meta-Analysis. **2022**, 23, 11937 1
- 563 Investigating Two Modes of Cancer-Associated Antigen Heterogeneity in an Agent-Based Model of Chimeric Antigen Receptor T-Cell Therapy. **2022**, 11, 3165 ○
- 562 Decoding the Impact of Genetic Variants in Gastric Cancer Patients Based on High-Dimensional Copy Number Variation Data Using Next-Generation Knowledge Discovery Methods. **2022**, 12, 10053 ○
- 561 FOXP3+ regulatory T cells and the immune escape in solid tumours. 13, ○

560	The salivary exosomal microRNA as a potential biomarker in patients with periodontitis and oral cancers.	0
559	Expression and Signaling Pathways of Nerve Growth Factor (NGF) and Pro-NGF in Breast Cancer: A Systematic Review. 2022 , 29, 8103-8120	0
558	HDLBP Promotes Hepatocellular Carcinoma Proliferation and Sorafenib Resistance by Suppressing Trim71-dependent RAF1 Degradation. 2022 ,	0
557	Capric Acid Behaves Agonistic Effect on Calcitriol to Control Inflammatory Mediators in Colon Cancer Cells. 2022 , 27, 6624	0
556	The Interplay between the Cellular Response to DNA Double-Strand Breaks and Estrogen. 2022 , 11, 3097	0
555	Searching for the Metabolic Signature of Cancer: A Review from Warburg's Time to Now. 2022 , 12, 1412	2
554	Transcriptome and morphological analysis on the heart in gestational protein-restricted aging male rat offspring. 10,	2
553	Inflammation and Cancer. 1-9	0
552	CIMT 2022: Report on the 19th Annual Meeting of the Association for Cancer Immunotherapy.	0
551	Identification of novel a chromatin regulator signature predicting overall survival for breast cancer.	0
550	Managing the TME to improve the efficacy of cancer therapy. 13,	0
549	Tumor-derived ARHGAP35 mutations enhance the G13-Rho signaling axis in human endometrial cancer.	0
548	Reimagining Cancer: Moving from the Cellular to the Tissue Level.	0
547	Tumor-targeted miRNA nanomedicine for overcoming challenges in immunity and therapeutic resistance.	0
546	Redeployment of Placental Gene Programming: Can Invasive Placentation Molecular Switches Complement the Hallmarks of Cancer?.	0
545	STIM1 signals through NFAT independently of Orai1 and SOCE to regulate breast cancer cell migration.	0
544	Molecular Mechanisms of Anti-Estrogen Therapy Resistance and Novel Targeted Therapies. 2022 , 14, 5206	1
543	CREAMMIST: an integrative probabilistic database for cancer drug response prediction.	0

542	Current and emerging anti-angiogenic therapies in gastrointestinal and hepatobiliary cancers. 12,	o
541	Case report: MicroRNA-10b as a therapeutic target in feline metastatic mammary carcinoma and its implications for human clinical trials. 12,	o
540	Developing a Nomogram for Preoperative Prediction of Cervical Cancer Lymph Node Metastasis by Multiplex Immunofluorescence.	o
539	Molecular Targeting of the Most Functionally Complex Gene in Precision Oncology: p53. 2022 , 14, 5176	o
538	Systems Biology and Genomics. 1-11	o
537	Cancer and Cell Death. 1-16	o
536	Three-Dimensional in Vitro Models: A Promising Tool To Scale-Up Breast Cancer Research.	1
535	Long non-coding RNAs and microRNAs as regulators of stress in cancer (Review). 2022 , 26,	1
534	Modern approaches to treating cancer with oncolytic viruses. 2022 , 9, 91-112	o
533	Development of genomic instability-associated long non-coding RNA signature: A prognostic risk model of clear cell renal cell carcinoma. 12,	o
532	Loss of thyroid gland circadian PER2 rhythmicity in aged mice and its potential association with thyroid cancer development. 2022 , 13,	o
531	What Are the Reasons for Continuing Failures in Cancer Therapy? Are Misleading/Inappropriate Preclinical Assays to Be Blamed? Might Some Modern Therapies Cause More Harm than Benefit?. 2022 , 23, 13217	2
530	Loss of long-range co-expression is a common trait in cancer.	o
529	Tumor Microenvironment Characterization in Breast Cancer Identifies Prognostic Pathway Signatures. 2022 , 13, 1976	o
528	Indole-3-Carbinol Stabilizes p53 to Induce miR-34a, Which Targets LDHA to Block Aerobic Glycolysis in Liver Cancer Cells. 2022 , 15, 1257	o
527	Biological Hallmarks of Cancer. 1-10	o
526	Targeting the regulation of aberrant protein production pathway in gastrointestinal cancer treatment. 12,	o
525	Tumor Angiogenesis. 1-30	o

524	PIM3 kinase promotes tumor metastasis in hepatoblastoma by upregulating cell surface expression of chemokine receptor cxcr4.	0
523	Evo-devo perspectives on cancer.	1
522	Periostin: biology and function in cancer. 2022 , 22,	0
521	The Role of Iron in DNA and Genomic Instability in Cancer, a Target for Iron Chelators That Can Induce ROS. 2022 , 12, 10161	0
520	Role of ABC Transporters in Cancer Development and Malignant Alteration. 2022 , 142, 1201-1225	0
519	Filter inference: A scalable nonlinear mixed effects inference approach for snapshot time series data.	0
518	lncRNA EGFEM1P promotes thyroid cancer progression by acting as an miR-369-3p sponge and upregulating TCF4. 2022 , 24,	0
517	Targeting the tumor stroma for cancer therapy. 2022 , 21,	3
516	Warburg effect in colorectal cancer: the emerging roles in tumor microenvironment and therapeutic implications. 2022 , 15,	3
515	Chemokine Physiology in Cancer.	0
514	Role of Non-Coding RNAs in Lung Cancer.	0
513	FOXK2 transcription factor and its roles in tumorigenesis (Review). 2022 , 24,	0
512	The role of transcription factors in the acquisition of the four latest proposed hallmarks of cancer and corresponding enabling characteristics. 2022 , 86, 1203-1215	0
511	The competition of ecological resonances in the quantum metabolic model of cancer: Potential energetic interventions. 2022 , 222, 104798	0
510	Transgenic mice harboring direct repeat substrates reveal key underlying causes of homologous recombination in vivo. 2022 , 120, 103419	0
509	Role of ginsenoside Rh2 in tumor therapy and tumor microenvironment immunomodulation. 2022 , 156, 113912	1
508	Multi-scale gene regulation mechanism: Spatiotemporal transmission of genetic information. 2022 , 77, 102487	0
507	Current perspectives and trend of nanomedicine in cancer: A review and bibliometric analysis. 2022 , 352, 211-241	2

- 506 Cancer. **2023**, 249-284 o
- 505 Targeting emerging cancer hallmarks by transition metal complexes: Epigenetic reprogramming and epitherapies. Part II. **2023**, 475, 214899 o
- 504 Targeted therapy and molecular genetics. **2023**, 464-488.e11 o
- 503 The malignant phenotype. **2006**, 116, o
- 502 STRATEGIE WALKI ZE ZJAWISKIEM OPORNOŚCI WIELOLEKOWEJ NOWOTWORÓW. **2012**, 10, 1-8 o
- 501 Machine Learning Using Gene-Sets to Infer miRNA Function. **2022**, 229-240 o
- 500 Anticancer Natural Alkaloids as Drug Bank Targeting Biomolecules. **2022**, 559-589 o
- 499 Regulation of Immune Cells by microRNAs and microRNA-Based Cancer Immunotherapy. **2022**, 75-108 1
- 498 Epigenetic-Mediated Regulation of Gene Expression for Biological Control and Cancer: Cell and Tissue Structure, Function, and Phenotype. **2022**, 339-373 o
- 497 Voltage-Gated Calcium Channels as Key Regulators of Cancer Progression. **2022**, 635-657 o
- 496 Antitumor activity of a pexidartinib bioisostere inhibiting CSF1 production and CSF1R kinase activity in human hepatocellular carcinoma. **2023**, 369, 110255 o
- 495 Investigation of the effects of isoeugenol-based phenolic compounds on migration and proliferation of HT29 colon cancer cells at cellular and molecular level. **2023**, 130, 106230 o
- 494 Prostate cancer resistance leads to a global deregulation of translation factors and unconventional translation. **2022**, 4, o
- 493 Placing human gene families into their evolutionary context. **2022**, 16, o
- 492 Novel pyrazole-based COX-2 inhibitors as potential anticancer agents: Design, synthesis, cytotoxic effect against resistant cancer cells, cell cycle arrest, apoptosis induction and dual EGFR/Topo-1 inhibition. **2022**, 106273 o
- 491 Editorial: Hallmark of cancer: Resisting cell death. 12, o
- 490 Small Non-Coding RNAs in Human Cancer. **2022**, 13, 2072 1
- 489 Evaluation of molecular signatures in the urinary bladder and upper tract urothelial carcinomas: a prospective controlled clinical study. **2022**, 34, o

488	Roles of TGF- β in cancer hallmarks and emerging onco-therapeutic design. 1-44	0
487	Latifolin, a Natural Flavonoid, Isolated from the Heartwood of <i>Dalbergia odorifera</i> Induces Bioactivities through Apoptosis, Autophagy, and Necroptosis in Human Oral Squamous Cell Carcinoma. 2022 , 23, 13629	3
486	Traveling wave speed and profile of a glioma or glioblastoma multiforme model. 2022 , 107008	0
485	Innate lymphoid cells: potential targets for cancer therapeutics. 2022 ,	0
484	Lessons learned from the discovery and development of the sesquiterpene lactones in cancer therapy and prevention.	0
483	Stochastic differential equation modelling of cancer cell migration and tissue invasion.	0
482	The Role of WRAP53 in Cell Homeostasis and Carcinogenesis Onset. 2022 , 44, 5498-5515	0
481	LRRC8A Is a Promising Prognostic Biomarker and Therapeutic Target for Pancreatic Adenocarcinoma. 2022 , 14, 5526	0
480	Emerging roles of long noncoding and circular RNAs in pancreatic ductal adenocarcinoma. 13,	0
479	The role of LOXL2 induced by glucose metabolism-activated NF- κ B in maintaining drug resistance through EMT and cancer stemness in gemcitabine-resistant pancreatic cancer.	0
478	BENZOATE GROUP ATTACHMENT TO TEMPO PROVIDES ENHANCED DISCRIMINATION OF LIPOSOMES FABRICATED USING HUMAN LUNG NORMAL AND CARCINOMA CELLS. 2022 , 7, 261-267	0
477	Targeting the MITF/APAF-1 axis as salvage therapy for MAPK inhibitors in resistant melanoma. 2022 , 41, 111601	0
476	Regression of Lung Cancer in Mice by Intranasal Administration of SARS-CoV-2 Spike S1. 2022 , 14, 5648	3
475	Anti-cancer effect of targeting fibroblast activation protein alpha in glioblastoma through remodeling macrophage phenotype and suppressing tumor progression.	0
474	A Pan-Cancer Atlas of Differentially Interacting Hallmarks of Cancer Proteins. 2022 , 12, 1919	1
473	Glutamine metabolism and radiosensitivity: Beyond the Warburg effect. 12,	0
472	Multi-Omics Alleviates the Limitations of Panel Sequencing for Cancer Drug Response Prediction. 2022 , 14, 5604	0
471	Modeling Cutaneous Squamous Cell Carcinoma for Laboratory Research.	0

- 470 Targeting intra-tumoral heterogeneity of human brain tumors with in vivo imaging: A roadmap for imaging genomics from multiparametric MR signals. o
- 469 QSER1 preserves the suppressive status of the pro-apoptotic genes to prevent apoptosis. o
- 468 Binding selectivity-dependent molecular mechanism of inhibitors towards CDK2 and CDK6 investigated by multiple short molecular dynamics and free energy landscapes. **2023**, 38, 84-99 3
- 467 Accurate Characterization of Bladder Cancer Cells with Intraoperative Flow Cytometry. **2022**, 14, 5440 o
- 466 Gold nanoparticles as antiangiogenic and antimetastatic agents. **2022**, 103438 o
- 465 ATRX modulates the escape from a telomere crisis. **2022**, 18, e1010485 o
- 464 Cell-Free DNA in the Pathogenesis and Therapy of Non-Infectious Inflammations and Tumors. **2022**, 10, 2853 1
- 463 A systems biology approach towards oral cancer using computational tools and techniques. **2022**, 231, 104709 o
- 462 Transient Receptor Potential (TRP) Channels in Tumor Vascularization. **2022**, 23, 14253 o
- 461 Systemic Metabolomic Changes Associated with Chemotherapy: Role in Personalized Therapy. **2022**, 811-839 o
- 460 High Throughput Transcriptomics to Understand Chemical Drivers of Racial Disparities in Breast Cancer. o
- 459 Tumor proliferation and invasion are coupled through cell-extracellular matrix friction. o
- 458 Biological effects of the loss of homochirality in a multicellular organism. **2022**, 13, 1
- 457 The non-apoptotic function of Caspase-8 in negatively regulating the CDK9-mediated Ser2 phosphorylation of RNA polymerase II in cervical cancer. **2022**, 79, o
- 456 Metabolic Reprogramming in Cancer. **2022**, 841-892 o
- 455 Marsdenia tenacissima extract activates FoxO3a nuclear translocation to promote apoptosis via inhibiting autophagy in prostate cancer. **2022**, 154560 o
- 454 An Automatized Workflow to Study Mechanistic Indicators for Driver Gene Prediction with Moonlight. o
- 453 Realising the Full Potential of Biosimilars: Interviews with Three Key Opinion Leaders. 2-9 o

- 452 RNA-binding motif 4 promotes angiogenesis in HCC by selectively activating VEGF-A expression. **2023**, 187, 106593 o
- 451 Inflammasomes as integral components of PANoptosomes in the regulation of cell death. **2023**, 525-538 o
- 450 Structurally diverse G-quadruplexes as the noncanonical nucleic acid drug target for live cell imaging and antibacterial study. o
- 449 Polylactic acid based polymeric nanoparticle mediated co-delivery of navitoclax and decitabine for cancer therapy. **2023**, 47, 102627 o
- 448 Ligand-based modelling for screening natural compounds targeting Minichromosome Maintenance Complex Component-7 for potential anticancer effects. **2023**, 36, 101152 o
- 447 Inhibition of Lonp1 induces mitochondrial remodeling and autophagy suppression in cervical cancer cells. **2023**, 125, 151986 1
- 446 Towards achieving a modern science-based paradigm for agrochemical carcinogenicity assessment. **2023**, 137, 105301 o
- 445 G-quadruplex-mediated specific recognition, stabilization and transcriptional repression of bcl-2 by small molecule. **2023**, 734, 109483 o
- 444 Novel thiazolidines of potential anti-proliferation properties against esophageal squamous cell carcinoma via ERK pathway. **2023**, 246, 114909 o
- 443 Genetic and epigenetic characteristics of patients with colorectal cancer from Uruguay. **2023**, 241, 154264 o
- 442 IFITM proteins: Understanding their diverse roles in viral infection, cancer, and immunity. **2023**, 299, 102741 o
- 441 p53 as a potential target for treatment of cancer: A perspective on recent advancements in small molecules with structural insights and SAR studies. **2023**, 247, 115020 o
- 440 Optimization of antitumor radiotherapy fractionation via mathematical modeling with account of 4 RB of radiobiology. **2023**, 558, 111371 1
- 439 Targeting emerging cancer hallmarks by transition metal complexes: Cancer stem cells and tumor microbiome. Part I. **2023**, 477, 214923 o
- 438 Data synthesis and adversarial networks: A review and meta-analysis in cancer imaging. **2023**, 84, 102704 o
- 437 Multiplex substrate profiling by mass spectrometry for proteases. **2022**, o
- 436 The Tumor Microenvironment in Hepatocellular Carcinoma. **2022**, o
- 435 Possible relationship between the somatic mutations and the formation of cancers. **2022**, 55, 01009 o

- 434 Immunogenic Effect of Modulated Electro-hyperthermia (mEHT) in Solid Tumors. **2022**, ○
- 433 Mass cytometry to characterize the immune lung cancer microenvironment. **2022**, ○
- 432 Chapter 5. Mimicking Chemical Features of the Tumor Microenvironment. **2022**, 97-140 ○
- 431 FDA Should Re-evaluate All mRNA Vaccines and Revoke Their Use Authorizations (The Short Version).. **2022**, 4, 16-66 ○
- 430 A Cancer Theory: The Central Nervous System's Adaptive Changes Make Chronic Diseases Incurable. **2019**, 1, 38-62 ○
- 429 Indução de adenocarcinoma de cólon em Rattus norvegicus Wistar. **2022**, 17, 1-9 ○
- 428 INVESTIGATION OF THE CLINICOPATHOLOGICAL IMPORTANCE OF NEUTROPHIL-TO-LYMPHOCYTE RATIO AND PLATELET-TO-LYMPHOCYTE RATIO IN BREAST CANCER. ○
- 427 Study on molecular biological mechanism of Chinese herbal medicines for the treatment of gastric precancerous lesions based on data mining and network pharmacology. **2022**, 51, 573-584 ○
- 426 Immunotoxicity of nanomaterials in health and disease: Current challenges and emerging approaches for identifying immune modifiers in susceptible populations. **2022**, 14, ○
- 425 A mathematical model with aberrant growth correction in tissue homeostasis and tumor cell growth. **2023**, 86, ○
- 424 Hallmarks of cancer: The insulin-like growth factors perspective. 12, ○
- 423 Microglia-Derived Olfactomedin-like 3 Is a Potent Angiogenic Factor in Primary Mouse Brain Endothelial Cells: A Novel Target for Glioblastoma. **2022**, 23, 14613 ○
- 422 Involvement of Small Non-Coding RNA and Cell Antigens in Pathogenesis of Extramedullary Multiple Myeloma. **2022**, 23, 14765 ○
- 421 New chimeric HDAC inhibitors for the treatment of colorectal cancer. ○
- 420 Biology and medicine in the landscape of quantum advantages. **2022**, 19, ○
- 419 Inhibiting the inhibitors: development of the IAP inhibitor xevinapant for the treatment of locally advanced squamous cell carcinoma of the head and neck. **2022**, 102492 ○
- 418 Collagen III deposition and basement membrane integrity alterations: possible predictive markers in metastatic prostate cancer. ○
- 417 Cancer Segmentation by Entropic Analysis of Ordered Gene Expression Profiles. **2022**, 24, 1744 ○

416	Hubbing the Cancer Cell. 2022 , 14, 5924	0
415	Checkpoint Kinase 1 (CHK1) Functions as Both a Diagnostic Marker and a Regulator of Epithelial-to-Mesenchymal Transition (EMT) in Triple-Negative Breast Cancer. 2022 , 44, 5848-5865	0
414	Cold-induced RNA-binding Protein and RNA-binding Motif Protein 3: Two RNA Molecular Chaperones Closely Related to Reproductive Development and Reproductive System Diseases.. 2022 , 30,	0
413	Integrative Approaches to the Treatment of Cancer. 2022 , 14, 5933	2
412	Deep tumor-penetrating nano-delivery strategy to improve diagnosis and therapy in patient-derived xenograft (PDX) oral cancer model and patient tissue.	0
411	LncRNA DIRC1 is a novel prognostic biomarker and correlated with immune infiltrates in stomach adenocarcinoma. 2022 , 101, e31839	0
410	HLA-BAT1 alters migration, invasion and pro-inflammatory cytokines in prostate cancer. 12,	0
409	The coming decade in precision oncology: six riddles. 2023 , 23, 43-54	1
408	Protection of the human gene research literature from contract cheating organizations known as research paper mills. 2022 , 50, 12058-12070	0
407	Suppression of Calcium Entry Modulates the Expression of TRP and Runx2 in Thyroid Cancer Cells, Two Transcription Factors That Regulate Invasion, Proliferation and Thyroid-Specific Protein Levels. 2022 , 14, 5838	0
406	Recent Advances of Organ-on-a-Chip in Cancer Modeling Research. 2022 , 12, 1045	1
405	Synthetic lethality between CCNE1 hyperactivity and PARG inhibition in breast cancer.	0
404	An Epigenetic LINE-1-Based Mechanism in Cancer. 2022 , 23, 14610	0
403	CircRNAs: Roles in regulating head and neck squamous cell carcinoma. 12,	1
402	Antiproliferative Activity of Buddleja saligna (Willd.) against Melanoma and In Vivo Modulation of Angiogenesis. 2022 , 15, 1497	0
401	Cell polarity signalling at the birth of multicellularity: What can we learn from the first animals. 10,	0
400	Identification of Altered Primary Immunodeficiency-Associated Genes and Their Implications in Pediatric Cancers. 2022 , 14, 5942	0
399	Comment on Prognostic value of preoperative enhanced computed tomography as a quantitative imaging biomarker in pancreatic cancer[28, 6310-6313	0

- 398 Genetic Network of Breast Cancer Metastasis in Lymph Nodes via Information Theory Algorithms. **2022**, 0
- 397 High expression of caspase-8 as a predictive factor of poor prognosis in patients with esophageal cancer. 0
- 396 A remarkable adaptive paradigm of heart performance and protection emerges in response to the constitutive challenge of marked cardiac-specific overexpression of adenylyl cyclase type 8. 11, 1
- 395 Artificial intelligence to guide precision anticancer therapy with multitargeted kinase inhibitors. **2022**, 22, 0
- 394 Growth Signaling Autonomy in Circulating Tumor Cells Aids Metastatic Seeding. 1
- 393 Transcriptomics indicate nuclear division and cell adhesion not recapitulated in MCF7 and MCF10A compared to luminal A breast tumours. **2022**, 12, 0
- 392 UCP2 as a Cancer Target through Energy Metabolism and Oxidative Stress Control. **2022**, 23, 15077 0
- 391 AtlasGrabber: a software facilitating the high throughput analysis of the human protein atlas online database. **2022**, 23, 0
- 390 Exploring the Potential of PEG-Heparin Hydrogels To Support Long-term Ex Vivo Culture of Patient-derived Breast Explant Tissues. 2202202 0
- 389 Current Status of Novel Agents for the Treatment of B Cell Malignancies: What's Coming Next?. **2022**, 14, 6026 0
- 388 Targeting cancer-specific metabolic pathways for developing novel cancer therapeutics. 13, 2
- 387 Anticancer activity of retinoic acid against breast cancer cells derived from an Iraqi patient. **2022**, 0
- 386 SGC-CLK-1 (CAF-170) a chemical probe for the Cdc2-Like kinases CLK1, CLK2, and CLK4. 0
- 385 Defektif Homolog Rekombinasyon DNA Tamiri ve PARP İhhibisyonu Arasındaki Sentetik Letal Etkilem. 2459-2475 0
- 384 Implication of gut microbes and its metabolites in colorectal cancer. 1
- 383 Hypoxia-Inducible Factor-1: A Novel Therapeutic Target for the Management of Cancer, Drug Resistance, and Cancer-Related Pain. **2022**, 14, 6054 1
- 382 Analysis of m7G methylation modification patterns and pulmonary vascular immune microenvironment in pulmonary arterial hypertension. 13, 0
- 381 SMoRe ParS: A novel methodology for bridging modeling modalities and experimental data applied to 3D vascular tumor growth. 9, 0

- 380 Cancer-associated fibroblasts in acute leukemia. 12, o
- 379 A Rare Case of Childhood Adrenocortical Carcinoma in a 4-years-old female child presented with features of Cushing Syndrome: Case report and Literature review. o
- 378 Resistance of MMTV-NeuT/ATTAC mice to anti-PD-1 immune checkpoint therapy is associated with macrophage infiltration and Wnt pathway expression. **2022**, 13, 1350-1358 o
- 377 Spatial biology of cancer evolution. 4
- 376 Wnt activation-induced disturbance of cell competition causes diffuse invasion of transformed cells through upregulation of NF- κ B-mediated MMP21. o
- 375 Proteomics and Phospho-Proteomics Profiling of the Co-Formulation of Type I and II Interferons, HeberFERON, in the Glioblastoma-Derived Cell Line U-87 MG. **2022**, 11, 4068 o
- 374 HS3ST3A1 and CAPN8 Serve as Immune-Related Biomarkers for Predicting the Prognosis in Thyroid Cancer. **2022**, 2022, 1-14 o
- 373 Activation of OSM-STAT3 Epigenetically Regulates Tumor-Promoting Transcriptional Programs in Cervical Cancer. **2022**, 14, 6090 o
- 372 Modeling and Predicting Cancer Clonal Evolution with Reinforcement Learning. o
- 371 The underexplored links between cancer and the internal body climate: Implications for cancer prevention and treatment. 12, o
- 370 CRAC and SK Channels: Their Molecular Mechanisms Associated with Cancer Cell Development. **2023**, 15, 101 o
- 369 TissueGrinder, a novel technology for rapid generation of patient-derived single cell suspensions from solid tumors by mechanical tissue dissociation. 9, o
- 368 Structural variant analysis of a cancer reference cell line sample using multiple sequencing technologies. **2022**, 23, o
- 367 Emerging roles of intratumor microbiota in cancer metastasis. **2022**, o
- 366 Markers associated with genomic instability, immunogenicity and immune therapy responsiveness in Metaplastic carcinoma of the breast: Expression of H2AX, pRPA2, P53, PD-L1 and tumor infiltrating lymphocytes in 76 cases. **2022**, 22, o
- 365 Succinylation and redox status in cancer cells. 12, o
- 364 Mathematical Model of Triple-Negative Breast Cancer in Response to Combination Chemotherapies. **2023**, 85, o
- 363 PCSK9 in Liver Cancers at the Crossroads between Lipid Metabolism and Immunity. **2022**, 11, 4132 1

- 362 Immunoregulatory framework and the role of miRNA in the pathogenesis of NSCLC [A systematic review. 12, 0
- 361 Wnt Signaling in the Development of Bone Metastasis. **2022**, 11, 3934 1
- 360 Peptidomimetics in cancer targeting. **2022**, 28, 0
- 359 Systematic Investigation of the Diagnostic and Prognostic Impact of LINC01087 in Human Cancers. **2022**, 14, 5980 0
- 358 Innate immune function during antineoplastic treatment is associated with 12-months survival in non-small cell lung cancer. 13, 0
- 357 R-PTP- η Inhibits Contact-Dependent Cell Growth by Suppressing E2F Activity. **2022**, 10, 3199 0
- 356 Flavonoids and saponins: What have we got or missed?. **2022**, 154580 2
- 355 A novel nomogram model combining CT texture features and urine energy metabolism to differentiate single benign from malignant pulmonary nodule. 12, 0
- 354 The immunological role of mesenchymal stromal cells in patients with myelodysplastic syndrome. 13, 0
- 353 Towards Whole Health Toxicology: In-Silico Prediction of Diseases Sensitive to Multi-Chemical Exposures. **2022**, 10, 764 0
- 352 Peto's paradox revisited: black box vs mechanistic approaches to understanding the roles of mutations and promoting factors in cancer. 0
- 351 *Chiliadenus sericeus* subsp. *virescens* (Maire) Greuter: Phytochemical Assessments, Antimicrobial, Free Radical Scavenging, Antidiabetic, and Antiproliferative Properties. 0
- 350 The Nephrotoxicity of Drugs Used in Causal Oncological Therapies. **2022**, 29, 9681-9694 1
- 349 Targeting hypoxia-inducible factors for breast cancer therapy: A narrative review. 13, 0
- 348 Phytochemicals and mitochondria: Therapeutic allies against gastric cancer. **2022**, 154608 0
- 347 Alterperyleneol as a Novel Thioredoxin Reductase Inhibitor Induces Liver Cancer Cell Apoptosis and Ferroptosis. **2022**, 70, 15763-15775 0
- 346 Neurobiological reduction: From cellular explanations of behavior to interventions. 13, 0
- 345 Editorial: Factors determining long term anti-tumor responses to immune checkpoint blockade therapy. 13, 0

344	Maslinic Acid Exerts Anticancer Effects by Targeting Cancer Hallmarks. 2022 , 154631	0
343	More than Just Antioxidants: Redox-Active Components and Mechanisms Shaping Redox Signalling Network. 2022 , 11, 2403	1
342	Design and Synthesis of Some New Quinoxaline Containing 1,3,4-Oxadiazole Hybrids and Evaluation of Their Anti-Cancer Activity.	0
341	Age- and Stage-Dependent Prostate Cancer Aggressiveness Associated with Differential Notch Signaling. 2023 , 24, 164	0
340	Transcriptomic analysis reveals the promotion of lymph node metastasis by Helicobacter pylori infection via upregulating chemokine (C-X-C motif) receptor 2 expression in gastric carcinoma. 2022 , 11, 1000000	0
339	Frequency of Meningococcal Meningitis Susceptibility Associated TLR4 +896 A/G (rs4986790) Allele in the Saudi Population. 2022 , 16, 2923-2933	0
338	NVL-520 is a selective, TRK-sparing, and brain-penetrant inhibitor of ROS1 fusions and secondary resistance mutations.	1
337	Culture of Continuous Cell Lines. 2023 , 1-61	0
336	The Road to Malignant Cell Transformation after Particulate Matter Exposure: From Oxidative Stress to Genotoxicity. 2023 , 24, 1782	0
335	Host-Microbiome Interactions in Gastrointestinal Cancers. 2023 , 147-161	0
334	Pathway-guided monitoring of the disease course in bladder cancer with longitudinal urine proteomics. 2023 , 3,	0
333	Central Nervous System Neoplasms in Microgravity. 2022 , 107-121	0
332	Antarctic Macroalgae <i>Palmaria decipiens</i> (Rhodophyta, Palmariales) Extracts Present Antioxidant and Antitumor Activity against Colorectal Cancer. 2022 , 12, 274-291	0
331	Dormant cancer cells: programmed quiescence, senescence, or both?.	0
330	Antibody Profiling and In Silico Functional Analysis of Differentially Reactive Antibody Signatures of Glioblastomas and Meningiomas. 2023 , 24, 1411	0
329	The mitophagy receptor BNIP3 is critical for the regulation of metabolic homeostasis and mitochondrial function in the nucleus pulposus cells of the intervertebral disc. 1-23	0
328	Single-cell transcriptome analysis reveals a cancer-associated fibroblast marker gene signature in hepatocellular carcinoma that predicts prognosis. 2023 ,	0
327	RNAi screening reveals a synthetic chemical-genetic interaction between ATP synthase and PFK1 in cancer cells.	1

326	Lactate, histone lactylation and cancer hallmarks. 1-19	0
325	Why is pituitary carcinoma so rare?. 1-3	0
324	Chromatin and Cancer: Implications of Disrupted Chromatin Organization in Tumorigenesis and Its Diversification. 2023 , 15, 466	0
323	IRF8 Regulates Intrinsic Ferroptosis through Repressing p53 Expression to Maintain Tumor Cell Sensitivity to Cytotoxic T Lymphocytes. 2023 , 12, 310	0
322	Identification of MTHFD2 as a prognostic biomarker and ferroptosis regulator in triple-negative breast cancer. 13,	0
321	STEAP1 regulation and its influence modulating the response of LNCaP prostate cancer cells to bicalutamide, enzalutamide and apalutamide. 2023 , 27,	1
320	Effects of plasma-activated Ringer's lactate solution on cancer cells: evaluation of genotoxicity. 2023 , 45,	1
319	The first embryo, the origin of cancer and animal phylogeny. I. A presentation of the neoplastic process and its connection with cell fusion and germline formation. 10,	0
318	When cancer drug resistance meets metabolomics (bulk, single-cell and/or spatial): Progress, potential, and perspective. 12,	0
317	DNA Damage Response Alterations in Ovarian Cancer: From Molecular Mechanisms to Therapeutic Opportunities. 2023 , 15, 448	0
316	Systemic structural analysis of alterations reveals a common structural basis of driver mutations in cancer. 2023 , 5,	0
315	Single-cell sequencing of PIT1-positive pituitary adenoma highlights the pro-tumour microenvironment mediated by IFN- γ -induced tumour-associated fibroblasts remodelling.	0
314	Infiltrating CD8 ⁺ T cells and M2 macrophages are retained in tumor matrix tracks enriched in low tension fibronectin fibers. 2023 ,	0
313	Curcumin-loaded nanofilm generating avascular niche to stabilize in vivo ectopic chondrogenesis of BMSC. 1-18	0
312	Cancer Stem Cell Relationship with Pro-Tumoral Inflammatory Microenvironment. 2023 , 11, 189	1
311	Meta-hallmarks of aging and cancer. 2023 , 35, 12-35	3
310	The Metabolism of Cancer Cells During Metastasis. 2023 , 1-21	0
309	An overview of recent advancements in anticancer Pt(IV) prodrugs: New smart drug combinations, activation and delivery strategies. 2023 , 121388	0

308	Transient loss of Polycomb components induces an epigenetic cancer fate.	0
307	Physical Exercise and the Hallmarks of Breast Cancer: A Narrative Review. 2023 , 15, 324	1
306	RNA splicing dysregulation and the hallmarks of cancer.	1
305	Intersection of immune and oncometabolic pathways drives cancer hyperprogression during immunotherapy. 2023 ,	1
304	The role of the Na ⁺ /Ca ²⁺ -exchanger (NCX) in cancer-associated fibroblasts. 2023 ,	1
303	Analysis of Energy-Driven Leader-Follower Hierarchy During Collective Cancer Cell Invasion. 2023 , 247-262	0
302	Conditional Knockout of Hypoxia-Inducible Factor 1-Alpha in Tumor-Infiltrating Neutrophils Protects against Pancreatic Ductal Adenocarcinoma. 2023 , 24, 753	0
301	Roles of IL-7R Induced by Interactions between Cancer Cells and Macrophages in the Progression of Esophageal Squamous Cell Carcinoma. 2023 , 15, 394	0
300	Transmicron: accurate prediction of insertion probabilities improves detection of cancer driver genes from transposon mutagenesis screens.	0
299	Increased expression of TBC1D10B as a potential prognostic and immunotherapy relevant biomarker in liver hepatocellular carcinoma. 2023 , 13,	0
298	Insight into the relationships of structure and anti-tumor effects of Glucuronomannan oligosaccharides (Gx) and its derivatives on the A549 lung adenocarcinoma cells. 2023 , 102979	0
297	Cancer Stem Cells are Actually Stem Cells with Disordered Differentiation: the Monophyletic Origin of Cancer.	0
296	Chemotherapy-induced tumor immunogenicity is mediated in part by megakaryocyte-erythroid progenitors.	0
295	Piperine Reduces Neoplastic Progression in Cervical Cancer Cells by Downregulating the Cyclooxygenase 2 Pathway. 2023 , 16, 103	0
294	Depression and Cancer: The Inflammatory Bridge. 2023 ,	0
293	Therapeutic targeting of TRAIL death receptors.	1
292	Nerolidol, bioactive compound suppress growth of HCT-116 colorectal cancer cells through cell cycle arrest and induction of apoptosis.	0
291	DeepSom: a CNN-based approach to somatic variant calling in WGS samples without a matched normal. 2023 , 39,	0

- 290 In-silico study of asymmetric remodeling of tumors in response to external biochemical stimuli. **2023**, 13, ○
- 289 PANACEA: Network-based Methods for Pharmacotherapy Prioritization in Personalized Oncology. ○
- 288 Purinergic signaling: Diverse effects and therapeutic potential in cancer. 13, ○
- 287 Characterization of murine isogenic normal and NRF2-KO colon epithelial cells to explore the food contaminants toxicity and oxidative stress involvement.. ○
- 286 Recent advances in small cell lung cancer: the future is now?. **2023**, 47, ○
- 285 Carrimycin, a first in-class anti-cancer agent, targets selenoprotein H to induce nucleolar oxidative stress and inhibit ribosome biogenesis. **2023**, ○
- 284 The Prime and Integral Cause of Cancer in the Post-Warburg Era. **2023**, 15, 540 ○
- 283 Long Non-Coding RNAs Associated with Mitogen-Activated Protein Kinase in Human Pancreatic Cancer. **2023**, 15, 303 ○
- 282 PDT-sensitized ROS-responsive dextran nanosystem for maximizing antitumor potency of multi-target drugs. **2023**, 633, 122567 ○
- 281 Fork-Remodeling Helicase Rad5 Preferentially Reverses Replication Forks with Gaps in the Leading Strand. **2023**, 435, 167946 ○
- 280 Intracellular calprotectin (S100A8/A9) facilitates DNA damage responses and promotes apoptosis in head and neck squamous cell carcinoma. **2023**, 137, 106304 ○
- 279 Cellular-automaton model for tumor growth dynamics: Virtualization of different scenarios. **2023**, 153, 106481 ○
- 278 Heterogeneity of cGMP signalling in tumour cells and the tumour microenvironment: Challenges and chances for cancer pharmacology and therapeutics. **2023**, 242, 108337 ○
- 277 CAP1 (cyclase-associated protein 1) mediates the cyclic AMP signals that activate Rap1 in stimulating matrix adhesion of colon cancer cells. **2023**, 104, 110589 ○
- 276 A review of computational modeling, machine learning and image analysis in cancer metastasis dynamics. **2022**, 3, ○
- 275 The CAM Model & A with Experts. **2023**, 15, 191 1
- 274 High-Throughput Prediction of the Impact of Genetic Variability on Drug Sensitivity and Resistance Patterns for Clinically Relevant Epidermal Growth Factor Receptor Mutations from Atomistic Simulations. **2023**, 63, 321-334 ○
- 273 Melanocytic naevi, melanocytomas and emerging concepts. **2022**, ○

- 272 The hallmarks of cancer in pituitary tumors? o
- 271 Medicinal Utility of Thiosemicarbazones with Special Reference to Mixed Ligand and Mixed Metal Complexes: A Review. **2022**, 48, 877-895 1
- 270 Telomerase and Anticancer Treatment. **2022**, 15, 1881-1888 o
- 269 Editorial: Therapies and influences in urothelial carcinoma. 12, o
- 268 The Role of CXC Chemokines in Cancer Progression. **2023**, 15, 167 o
- 267 Squamous Intraepithelial Lesions of the Uterine Cervix The Long and Winding Road of Our Understanding of Their Morphology, Biology, and the Terminology That Describes Them From First to LAST. **2023**, 42, 109-119 o
- 266 The cytotoxic and apoptotic effects of Thymus vulgaris extracts on human breast cancer cell lines. o
- 265 Introduction on Novel Treatment for Cancer Treatment. **2023**, 1-19 o
- 264 Development of Smart Drug delivery systems for chemo/PDT synergistic treatment. o
- 263 Immunogenic Cell Death in Cancer. **2023**, o
- 262 MYC-mediated resistance to trametinib and HCQ in PDAC is overcome by CDK4/6 and lysosomal inhibition. **2023**, 220, o
- 261 Micronucleus Assay in Lymphocytes for Human Biomonitoring and Clinical Studies. **2023**, 623-646 o
- 260 Altered serum lipid levels are associated with prognosis of diffuse large B cell lymphoma and influenced by utility of rituximab. **2023**, 102, 393-402 o
- 259 Biosensors for cancer biomarker detection. **2023**, 297-336 o
- 258 A multidimensional atlas of human glioblastoma organoids reveals highly coordinated molecular networks and effective drugs. o
- 257 Therapeutic potentials of medicinal plants and significance of computational tools in anti-cancer drug discovery. **2023**, 393-455 o
- 256 Tumor-associated macrophages in prostate cancer: role in progression and therapy. **2023**, 153-180 o
- 255 The tumor-immune ecosystem in shaping metastasis. o

- 254 Cancer: A Complex Problem Requiring Interdisciplinary Research. **2023**, 0
- 253 The Implication of miRNA Signature in the Characteristic Features and Diagnosis of Lung Cancer. **2023**, 0
- 252 Roles of trans-lesion synthesis (TLS) DNA polymerases in tumorigenesis and cancer therapy. **2023**, 5, 1
- 251 NIR luminogen for low-temperature photothermal therapy by triggering HSP90 α down-regulation. 0
- 250 Altered Nucleotide Insertion Mechanisms of Disease-Associated TERT Variants. **2023**, 14, 281 1
- 249 Aptamer-functionalized dendrimers for targeted cancer therapy. **2023**, 255-275 0
- 248 Bodywide ecological interventions on cancer. **2023**, 29, 59-74 1
- 247 Gene Expression Profiles in Cancers and Their Therapeutic Implications. **2023**, 29, 9-14 0
- 246 The Regulatory Effect of Phytochemicals on Chronic Diseases by Targeting Nrf2-ARE Signaling Pathway. **2023**, 12, 236 1
- 245 Hybrid computational models of multicellular tumour growth considering glucose metabolism. **2023**, 21, 1262-1271 0
- 244 Ion Channels in Gliomas: From Molecular Basis to Treatment. **2023**, 24, 2530 0
- 243 Caregivers with Cancer Patients: Focus on Hispanics. **2023**, 15, 626 2
- 242 The Mystery of Cancer Resistance: A Revelation Within Nature. 0
- 241 Carbon nanotubes for anticancer therapy: new trends and innovations. **2023**, 175-204 0
- 240 Molecular mechanisms of resistance to the EGFR monoclonal antibody cetuximab. **2023**, 13-27 0
- 239 Cancer Stem Cells and Their Therapeutic Usage. **2023**, 0
- 238 Karyotyping and Chromosomal Aberrations in Cancer: Molecular and Diagnostic Biomarkers. **2023**, 50-80 0
- 237 The Relationship between Cancer and Dementia: An Updated Review. **2023**, 15, 640 0

- 236 Synthesis and Biological Evaluation of Potential Oncoimmunomodulator Agents. **2023**, 24, 2614 o
- 235 Evaluation of the Small Heat Shock Protein Family Members HSPB2 and HSPB3 in Bladder Cancer Prognosis and Progression. **2023**, 24, 2609 o
- 234 Molecular Genetic Characteristics of FANCI, a Proposed New Ovarian Cancer Predisposing Gene. **2023**, 14, 277 o
- 233 Epigenetics and Circular RNAs in Cancer. **2023**, 1-31 o
- 232 Surface modified iron-oxide based engineered nanomaterials for hyperthermia therapy of cancer cells. 1-47 o
- 231 Long Noncoding RNA LINC01503 Silencing Suppresses KLK4 Expression to Impede Pancreatic Cancer Development as miR-1321 Sponge. **2023**, 2023, 1-12 o
- 230 Ameliorative and protective activity of Silver Nanoparticles (AgNPs) Biosynthesized Using Taraxacum officinale L. leaves Extract against 1, 2-dimethylhydrazine (DMH) Induced Colon Cancer in Rats. **2022**, 14, 34-53 o
- 229 Stability analysis of a multiscale model including cell-cycle dynamics and populations of quiescent and proliferating cells. **2023**, 8, 12342-12372 o
- 228 Innovative strategies to study epigenetic regulation and advance precision medicine. **2023**, o
- 227 Radiolabeled Antibodies for Imaging and Targeted Therapy. **2023**, 533-575 o
- 226 The effect of natural products combination on MCF-7 cells exceeds tamoxifen therapeutic dose effects in vitro. **2023**, 47, 891-904 o
- 225 Beyond genomics and proteomics. **2023**, 191-243 o
- 224 Molecular Imaging in Oncology. **2023**, 303-373 o
- 223 Natural products in conditions associated with inflammatory bowel diseases: Colorectal cancer, diversion colitis, and obesity. **2023**, 415-442 o
- 222 Warburg Effect Revisited: Embodiment of Classical Biochemistry and Organic Chemistry. Current State and Prospects. **2023**, 88, S1-S20 o
- 221 Antiproliferative activity and apoptosis-inducing mechanism of 'Curcuma longa (Turmimax®)' on Hela cell lines. o
- 220 Chromosomal Instability as Enabling Feature and Central Hallmark of Breast Cancer. Volume 15, 189-211 o
- 219 Thanksgiving to Yeast, the HMGB Proteins History from Yeast to Cancer. **2023**, 11, 993 o

- 218 How cancer hijacks the body's homeostasis through the neuroendocrine system. **2023**, 46, 263-275 1
- 217 PGC-1s shape epidermal physiology by modulating keratinocyte proliferation and terminal differentiation. **2023**, 26, 106314 0
- 216 Use of *Arabidopsis thaliana* as a model to understand specific carcinogenic events: Comparison of the molecular machinery associated with cancer-hallmarks in plants and humans. **2023**, 9, e15367 0
- 215 Application of Artificial Intelligence to In Vitro Tumor Modeling and Characterization of the Tumor Microenvironment. 0
- 214 Angelicin impedes the progression of glioblastoma via inactivation of YAP signaling pathway. **2023**, 161, 114462 0
- 213 Oral squamous cell carcinoma-derived EVs promote tumor progression by regulating inflammatory cytokines and the IL-17A-induced signaling pathway. **2023**, 118, 110094 0
- 212 Novel gold(I) complexes induce apoptosis in leukemia cells via the ROS-induced mitochondrial pathway with an upregulation of Harakiri and overcome multi drug resistances in leukemia and lymphoma cells and sensitize drug resistant tumor cells to apoptosis in vitro. **2023**, 161, 114507 0
- 211 Evaluation of the effect of nano-encapsulated lactoferrin on the expression of Bak and Bax genes in gastric cancer cell line AGS and study of the molecular docking of lactoferrin with these proteins. **2023**, 866, 147355 0
- 210 Macrophage CD5L is a target for cancer immunotherapy. **2023**, 91, 104555 0
- 209 T52 attenuates oncogenic STAT3 signaling and suppresses osteosarcoma. **2023**, 114, 154799 0
- 208 The extracellular matrix protein pattern in the canine neoplastic mammary gland. **2023**, 82, 102050 0
- 207 Survey of genomic and physiological characteristics for survival in lymphoma: The NCI genomic data portal. **2023**, 47, 100955 0
- 206 Multi compartmental 3D breast cancer disease model recapitulating tumor complexity in in-vitro. **2023**, 1867, 130361 0
- 205 High-content analysis of testicular toxicity of BPA and its selected analogs in mouse spermatogonial, Sertoli cells, and Leydig cells revealed BPAF induced unique multinucleation phenotype associated with the increased DNA synthesis. **2023**, 89, 105589 0
- 204 Mechanistic correlation between mitochondrial permeability transition pores and mitochondrial ATP dependent potassium channels in ischemia reperfusion. **2023**, 162, 114599 0
- 203 Biology of cancer: Understanding the supracellular control of mitosis in physiological processes and malignancy. **2023**, 92, 42-44 0
- 202 Design and development of novel spiro-oxindoles as potent antiproliferative agents using quantitative structure activity based Monte Carlo method, docking molecular, molecular dynamics, free energy calculations, and pharmacokinetics /toxicity studies. **2023**, 1284, 135404 0
- 201 Pathophysiology of Oral Cancer: An Overview. **2018**, 46, 507-512 0

- 200 Acute inflammatory reaction during anti-angiogenesis therapy combined with immunotherapy as a possible indicator of the therapeutic effect: Three case reports and literature review. 13, ○
- 199 Dexmedetomidine promotes necroptosis by upregulating PARP1 in non-small cell lung cancer. 1-21 ○
- 198 Next generation immuno-oncology tumor profiling using a rapid, non-invasive, computational biophysics biomarker in early-stage breast cancer. 6, ○
- 197 Targeting telomerase utilizing zeolitic imidazole frameworks as non-viral gene delivery agents across different cancer cell types. **2023**, 149, 213420 ○
- 196 From cells to organoids: The evolution of blood-brain barrier technology for modelling drug delivery in brain cancer. **2023**, 196, 114777 ○
- 195 A Novel Approach to Analyse Lung Cancer Progression and Metastasis Using Page Rank Technique. **2022**, 153-161 ○
- 194 Repurposing digoxin for geroprotection in patients with frailty and multimorbidity. **2023**, 86, 101860 ○
- 193 Updates in neuroendocrine neoplasms: From mechanisms to the clinic. **2023**, 84, 291-297 ○
- 192 Albumin-based drug carrier targeting urokinase receptor for cancer therapy. **2023**, 634, 122636 ○
- 191 Cell starvation increases uptake of extracellular Thymosin β and its complexes with calcium. **2023**, 116, 109743 ○
- 190 Cancer Research Trends in Traditional Korean Medical Journals since 2000 - Topic Modeling Using Latent Dirichlet Allocation and Keyword Network Analysis. **2022**, 43, 1075-1088 ○
- 189 Transformation of primary murine peritoneal mast cells by constitutive KIT activation as a result of lostCdkn2a/Arfexpression. ○
- 188 Radiolabeled Biodistribution of Expansile Nanoparticles: Intraperitoneal Administration Results in Tumor Specific Accumulation. **2023**, 17, 2212-2221 ○
- 187 Collective heterogeneity of mitochondrial potential in contact inhibition of proliferation. ○
- 186 Antibodies to calnexin and mutated calreticulin are common in human sera. **2023**, 71, 103380 ○
- 185 A biochemical necroptosis model explains cell-type-specific responses to cell death cues. **2023**, 122, 817-834 ○
- 184 Defining genomic, transcriptomic, proteomic, epigenetic, and phenotypic biomarkers with prognostic capability in male breast cancer: a systematic review. **2023**, 24, e74-e85 ○
- 183 Circadian clocks in health and disease: Dissecting the roles of the biological pacemaker in cancer. 12, 116 ○

- 182 Characterization of the redox status of cancer patients through the d-ROMs and BAP test and correlation of these parameters with blood variables. ○
- 181 Pan-cancer molecular subtypes of metastasis reveal distinct and evolving transcriptional programs. **2023**, 4, 100932 1
- 180 From the Catastrophic Objective Irreproducibility of Cancer Research and Unavoidable Failures of Molecular Targeted Therapies to the Sparkling Hope of Supramolecular Targeted Strategies. **2023**, 24, 2796 ○
- 179 The regulatory mechanisms and inhibitors of isocitrate dehydrogenase 1 in cancer. **2023**, 13, 1438-1466 ○
- 178 The Role of NF- κ B in Endometrial Diseases in Humans and Animals: A Review. **2023**, 24, 2901 1
- 177 Acacetin induces sustained ERK1/2 activation and RIP1-dependent necroptotic death in breast cancer cells. **2023**, 462, 116409 ○
- 176 Hsa_circ_0072309 is a prognostic biomarker and is correlated with immune infiltration in gastric cancer. **2023**, 9, e13191 ○
- 175 Potential miRNA Use as a Biomarker: From Breast Cancer Diagnosis to Metastasis. **2023**, 12, 525 ○
- 174 The Mathematical modeling of Cancer growth and angiogenesis by an individual based interacting system. **2023**, 562, 111432 ○
- 173 Current Status of the Bioactive Properties of Royal Jelly: A Comprehensive Review with a Focus on Its Anticancer, Anti-Inflammatory, and Antioxidant Effects. **2023**, 28, 1510 ○
- 172 Vitamin D metabolism in cancer: potential feasibility of vitamin D metabolism blocking therapy. ○
- 171 Paradoxical activation of oncogenic signaling as a cancer treatment strategy. ○
- 170 Impact of near-infrared fluorescence imaging with indocyanine green on the surgical treatment of pulmonary masses in dogs. 10, ○
- 169 Construction of a three-component regulatory network of transcribed ultraconserved regions for the identification of prognostic biomarkers in gastric cancer. **2023**, 124, 396-408 ○
- 168 Colon Cancer Microbiome Landscaping: Differences in Right- and Left-Sided Colon Cancer and a Tumor Microbiome-Ileal Microbiome Association. **2023**, 24, 3265 ○
- 167 Newly identified form of phenotypic plasticity of cancer: immunogenic mimicry. **2023**, 42, 323-334 ○
- 166 GPR65 as a potential immune checkpoint regulates the immune microenvironment according to pan-cancer analysis. **2023**, 9, e13617 ○
- 165 Hesperidin Induced HePG-2 Cell Apoptosis through ROS-Mediated p53/Bcl-2/Bax and p-mTOR Signaling Pathways. **2023**, 2023, 1-10 ○


- 164 Advances in Molecular Regulation of Prostate Cancer Cells by Top Natural Products of Malaysia. **2023**, 45, 1536-1567 1
- 163 The GenesStemnessSecretome Interplay in Malignant Pleural Mesothelioma: Molecular Dynamics and Clinical Hints. **2023**, 24, 3496 o
- 162 Integration of single sample and population analysis for understanding immune evasion mechanisms of lung cancer. **2023**, 9, o
- 161 Recent advancements to engineer mesenchymal stem cells and their extracellular vesicles for targeting and destroying tumors. **2023**, 178, 1-16 o
- 160 Small molecules as cancer targeting ligands: Shifting the paradigm. **2023**, 355, 417-433 o
- 159 Noncoding RNAs Controlling Oxidative Stress in Cancer. **2023**, 15, 1155 o
- 158 Chorioallantoic Membrane Assay at the Cross-Roads of Adipose-Tissue-Derived Stem Cell Research. **2023**, 12, 592 o
- 157 Daily berry consumption attenuates Eatenin signalling and genotoxicity in colon carcinoma cells exposed to faecal water from healthy volunteers in a clinical trial. **2023**, 102, 105440 o
- 156 Ontology (2) Death Programs and Their Discontents. **2023**, 381-418 o
- 155 Screening MT1-MMP Activity and Inhibition in Three-Dimensional Tumor Spheroids. **2023**, 11, 562 o
- 154 Efficacy of therapies targeting TGF- β in solid tumors: a systematic review and meta-analysis of clinical trials. **2023**, 15, 283-292 o
- 153 An insight into synthesis and antitumor activity of citrate and gallate stabilizing gold nanospheres. **2023**, 13, o
- 152 CD38-Induced Metabolic Dysfunction Primes Multiple Myeloma Cells for NAD⁺-Lowering Agents. **2023**, 12, 494 o
- 151 The effects of lipoic acid on respiratory diseases. **2023**, 116, 109713 o
- 150 The role of redox homeostasis biomarkers in clear cell renal cell carcinoma development and progression. **2022**, 73, 34-39 o
- 149 Cancer immunotherapies: A hope for the incurable?. 3, o
- 148 DNA Methylation and Histone Modification in Low-Grade Gliomas: Current Understanding and Potential Clinical Targets. **2023**, 15, 1342 o
- 147 Polyethylenimine-Conjugated Hydroxyethyl Cellulose for Doxorubicin/Bcl-2 siRNA Co-Delivery Systems. **2023**, 15, 708 o

- 146 A timeline of tumour-associated macrophage biology. **2023**, 23, 238-257 o
- 145 A compilation of bioinformatic approaches to identify novel downstream targets for the detection and prophylaxis of cancer. **2023**, 75-113 o
- 144 Mono-ADP-ribosylation by PARP10 and PARP14 in genome stability. **2023**, 5, o
- 143 On the gene expression landscape of cancer. **2023**, 18, e0277786 o
- 142 Methylation of nonessential genes in cutaneous melanoma [Rule Out hypothesis. Publish Ahead of Print, o
- 141 NFIXing Cancer: The Role of NFIX in Oxidative Stress Response and Cell Fate. **2023**, 24, 4293 o
- 140 Body Mass Index and Cancer Risk: An Umbrella Review of Meta-Analyses of Observational Studies. 1-14 o
- 139 Phenotypic Discovery of Thiocarbohydrazone with Anticancer Properties and Catalytic Inhibition of Human DNA Topoisomerase IIβ **2023**, 16, 341 o
- 138 NETworking with cancer: The bidirectional interplay between cancer and neutrophil extracellular traps. **2023**, 41, 505-526 o
- 137 Omega-Class Glutathione Transferases Protect DNA from Oxidative Stress in Pathogenic Helminth Reproductive Cells. **2023**, 12, 560 o
- 136 Genomics-Driven Precision Medicine in Pediatric Solid Tumors. **2023**, 15, 1418 o
- 135 Direct cellular targets and anticancer mechanisms of the natural product oridonin. **2023**, 2, o
- 134 Delineating the tumour-regulatory roles of EYA4. **2023**, 210, 115466 o
- 133 The caspase-8 and procaspase-3 expression in gastric cancer and non-cancer mucosa in relation to clinico-morphological factors and some apoptosis-associated proteins. **2023**, 68, 94-100 o
- 132 Emerging RNA-Based Therapeutic and Diagnostic Options: Recent Advances and Future Challenges in Genitourinary Cancers. **2023**, 24, 4601 o
- 131 Expression Dynamics of CA IX Epitope in Cancer Cells under Intermittent Hypoxia Correlates with Extracellular pH Drop and Cell Killing by Ureido-Sulfonamide CA IX Inhibitors. **2023**, 24, 4595 o
- 130 Natural Products in Precision Oncology: Plant-Based Small Molecule Inhibitors of Protein Kinases for Cancer Chemoprevention. **2023**, 15, 1192 o
- 129 Machilin D Promotes Apoptosis and Autophagy, and Inhibits Necroptosis in Human Oral Squamous Cell Carcinoma Cells. **2023**, 24, 4576 o

- 128 Carcinogenicity Assessment. **2023**, 125-172 ○
- 127 An Introduction to Human Cancers. **2023**, 3-28 ○
- 126 A circuit for secretion-coupled cellular autonomy in multicellular eukaryotic cells. **2023**, 19, ○
- 125 Cell division cycle-associated 8 is a prognostic biomarker related to immune invasion in hepatocellular carcinoma. ○
- 124 Anti-HER2 scFv-nCyt c -Modified Lipid-Encapsulated Oxygen Nanobubbles Prepared with Bulk Nanobubble Water for Inducing Apoptosis and Improving Photodynamic Therapy. 2206091 ○
- 123 Effects of epigenetic therapy on natural killer cell function and development in hematologic malignancy. ○
- 122 Pan-Cancer Analysis Reveals Functional Similarity of Three lncRNAs across Multiple Tumors. **2023**, 24, 4796 ○
- 121 Glycomic, Glycoproteomic, and Proteomic Profiling of Philippine Lung Cancer and Peritumoral Tissues: Case Series Study of Patients Stages III. **2023**, 15, 1559 ○
- 120 Cell Cycle and Cancer. **2023**, 83-101 ○
- 119 Breast Tumor Microenvironment and CDKs. **2023**, 149-174 ○
- 118 Platelets in the tumor microenvironment and their biological effects on cancer hallmarks. 13, ○
- 117 Antitumor Therapy Targeting the Tumor Microenvironment. **2023**, 2023, 1-16 ○
- 116 Medicinal chemistry perspective of pyrido[2,3-d]pyrimidines as anticancer agents. **2023**, 13, 6872-6908 ○
- 115 Metabolic Rewiring and Stemness: A Critical Attribute of Pancreatic Cancer Progression. ○
- 114 Tumor Metabolism: Challenges and Future Perspectives. **2023**, 1-27 ○
- 113 The Importance of the Fifth Nucleotide in DNA: Uracil. ○
- 112 Cellular response to Amyloid neurotoxicity in Alzheimer's disease and implications in new therapeutics. **2023**, 6, 3-9 ○
- 111 Low-dose metronomic gemcitabine pretreatments overcome the resistance of breast cancer to immune checkpoint therapy. **2023**, 15, 429-442 ○

- 110 A study of indirect action's impact on simulated neutron-induced DNA damage. **2023**, 68, 075014 ○
- 109 An agent-based model of tissue maintenance and self-repair. **2023**, 324, C941-C950 ○
- 108 Bioactive secondary metabolites in sea cucumbers and their potential to use in the functional food industry. **2023**, 26, 69-86 ○
- 107 A Novel Method in Identifying Pyroptosis and Apoptosis Based on the Double Resonator Piezoelectric Cytometry Technology. **2023**, 13, 356 ○
- 106 The role of VEGF in cancer-induced angiogenesis and research progress of drugs targeting VEGF. **2023**, 175586 ○
- 105 Effects of Ecaryophyllene and oxygen availability on cholesterol and fatty acids in breast cancer cells. **2023**, 18, e0281396 ○
- 104 Establishment of a new prognostic risk model of MAPK pathway-related molecules in kidney renal clear cell carcinoma based on genomes and transcriptomes analysis. 13, ○
- 103 Beneficial insights into postbiotics against colorectal cancer. 10, ○
- 102 Selective protection of normal cells from chemotherapy, while killing drug-resistant cancer cells. **2023**, 14, 193-206 ○
- 101 Folik Asitin Kanser Hâreleri ÷erine Etkisi ve Sitotoksisitelerinin De÷rlendirilmesi. ○
- 100 Cancer hallmarks intersect with neuroscience in the tumor microenvironment. **2023**, 41, 573-580 ○
- 99 Role of T Helper 17 in Cancer Pathology: A Double-Edge Sword. **2023**, 1-24 ○
- 98 The Chorioallantoic Membrane Xenograft Assay as a Reliable Model for Investigating the Biology of Breast Cancer. **2023**, 15, 1704 ○
- 97 Stemming Tumoral Growth: A Matter of Grotesque Organogenesis. **2023**, 12, 872 ○
- 96 Activated fibroblasts in cancer: Perspectives and challenges. **2023**, 41, 434-449 ○
- 95 The role of Th-17 cells and IL-17 in the metastatic spread of breast cancer: As a means of prognosis and therapeutic target. 14, ○
- 94 The New Dimension of the Renin-Angiotensin System in the Hallmarks of Cancer. **2023**, 395-413 ○
- 93 Renin-Angiotensin System and Cancer: From Laboratory to Clinics. **2023**, 341-363 ○

- 92 Serrated colonic lesions. Current review. **2023**, 3, 30-37 ○
- 91 Quercetin Nanoparticle-Based Hypoxia-Responsive Probe for Cancer Detection. **2023**, 6, 1546-1555 ○
- 90 New therapies for clear cell ovarian carcinoma. **2023**, 33, 385-393 ○
- 89 Biology of Cancer-Testis Antigens and Their Therapeutic Implications in Cancer. **2023**, 12, 926 ○
- 88 IDriveGenes: Cancer Driver Genes Prediction Using Machine Learning. **2023**, 11, 28439-28453 ○
- 87 Immuntherapie im Kontext anderer Therapiemodalitäten von Kopf-Hals-Tumoren | Highlights der ASCO- und ESMO-Jahrestagung 2022. ○
- 86 Antrodin C Isolated from Antrodia Cinnamomea Induced Apoptosis through ROS/AKT/ERK/P38 Signaling Pathway and Epigenetic Histone Acetylation of TNF α in Colorectal Cancer Cells. **2023**, 12, 764 ○
- 85 Chalcones and Gastrointestinal Cancers: Experimental Evidence. **2023**, 24, 5964 ○
- 84 Extracellular Matrix Dynamics as an Emerging yet Understudied Hallmark of Aging and Longevity. **2022**, 0 ○
- 83 Repurposing fluphenazine to suppress melanoma brain, lung and bone metastasis by inducing G0/G1 cell cycle arrest and apoptosis and disrupting autophagic flux. **2023**, 40, 161-175 ○
- 82 Mechanisms and shapes of causal exposure-response functions for asbestos in mesotheliomas and lung cancers. **2023**, 115607 ○
- 81 Calcium signalling pathways in prostate cancer initiation and progression. ○
- 80 Recent advances in the tumor-penetrating peptide internalizing RGD for cancer treatment and diagnosis. ○
- 79 Potential Pathogenic Impact of Cow Milk Consumption and Bovine Milk-Derived Exosomal MicroRNAs in Diffuse Large B-Cell Lymphoma. **2023**, 24, 6102 ○
- 78 Human umbilical cord mesenchymal stem cells conditioned medium exerts anti-tumor effects on KGN cells in a cell density-dependent manner through activation of the Hippo pathway. **2023**, 14, ○
- 77 Computational Biology Helps Understand How Polyploid Giant Cancer Cells Drive Tumor Success. **2023**, 14, 801 ○
- 76 An actin filament branching surveillance system regulates cell cycle progression, cytokinesis and primary ciliogenesis. **2023**, 14, ○
- 75 Systemic Alterations of Cancer Cells and Their Boost by Polyploidization: Unicellular Attractor (UCA) Model. **2023**, 24, 6196 ○

- 74 The Complex Role of HBeAg and Its Precursors in the Pathway to Hepatocellular Carcinoma. **2023**, 15, 857 ○
- 73 A transcriptomic pan-cancer signature for survival prognostication and prediction of immunotherapy response based on endothelial senescence. **2023**, 30, ○
- 72 Long noncoding RNA SNHG15: A promising target in human cancers. 13, ○
- 71 Nuclear PD-L1 promotes EGR1-mediated angiogenesis and accelerates tumorigenesis. **2023**, 9, ○
- 70 An immunometabolism subtyping system identifies S100A9+ macrophage as an immune therapeutic target in colorectal cancer based on multiomics analysis. **2023**, 4, 100987 ○
- 69 Mitocans induce lipid flip-flop and permeabilize the membrane to signal apoptosis. **2023**, ○
- 68 Concurrent treatment of flavonol with chemotherapeutics potentiates or counteracts the therapeutic implications in cervical cancer cells. **2023**, 35, ○
- 67 Minimal Morphoelastic Models of Solid Tumour Spheroids: A Tutorial. **2023**, 85, ○
- 66 Immunostaining for VEGF and Decorin Predicts Poor Survival and Recurrence in Canine Soft Tissue Sarcoma. **2023**, 10, 256 ○
- 65 GATA-3 expression in breast cancer is related to intratumoral M2 macrophage infiltration and tumor differentiation. **2023**, 18, e0283003 ○
- 64 Development of a scoring function for comparing simulated and experimental tumor spheroids. **2023**, 19, e1010471 ○
- 63 Transformation of primary murine peritoneal mast cells by constitutive KIT activation is accompanied by loss of Cdkn2a/Arf expression. 14, ○
- 62 Anti-cancer potentials of aervine validated through in silico molecular docking, dynamics simulations, pharmacokinetic prediction and in vitro assessment of caspase B in SW480 cell line. **2023**, 49, 799-815 ○
- 61 Polyphenols and Antioxidants. **2023**, 113-136 ○
- 60 Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy for Gastric Cancer with Peritoneal Carcinomatosis: Additional Information Helps to Optimize Patient Selection before Surgery. **2023**, 15, 2089 ○
- 59 Tumor-specific activity of precision medicines in the NCI-MATCH trial. ○
- 58 Oncogene-mediated nuclear accumulation of lactate promotes epigenetic alterations to induce cancer cell proliferation. **2023**, 124, 495-519 ○
- 57  **2017**, 83-88 ○

- 56 Contribution of EpsteinBarr Virus Lytic Proteins to Cancer Hallmarks and Implications from Other Oncoviruses. **2023**, 15, 2120 ○
- 55 Multiscale Modeling of Spheroid Tumors: Effect of Nutrient Availability on Tumor Evolution. ○
- 54 In Vitro High-Throughput Genotoxicity Testing Using H2AX Biomarker, Microscopy and Reproducible Automatic Image Analysis in ImageJ: A Pilot Study with Valinomycin. **2023**, 15, 263 ○
- 53 StructureActivity Relationship Studies Based on Quinazoline Derivatives as EGFR Kinase Inhibitors (2017Present). **2023**, 16, 534 ○
- 52 Intrinsic signalling factors associated with cancer cell-cell fusion. **2023**, 21, ○
- 51 Integrated gene network analysis sheds light on understanding the progression of Osteosarcoma. 10, ○
- 50 Emerging hallmark of gliomas microenvironment in evading immunity: a basic concept. **2023**, 59, ○
- 49 The effects of KIR2DL4 stimulated NK-92 cells on the apoptotic pathways of HER2 + /HER-breast cancer cells. **2023**, 40, ○
- 48 Platinum Engineering on Nanoceria Surface toward High Catalytic Activity for Inducing Tumor Cell Apoptosis and Inhibiting Migration. ○
- 47 Regulation of Autophagy via Carbohydrate and Lipid Metabolism in Cancer. **2023**, 15, 2195 ○
- 46 Turning Cold into Hot: New Insights in Cancer Immunotherapy. **2022**, 1-13 ○
- 45 Rewiring of RNA methylation by the oncometabolite fumarate in renal cell carcinoma. ○
- 44 Hallmarks of an Aging and Malignant Tumor Microenvironment and the Rise of Resilient Cell Subpopulations. **2023**, 113-137 ○
- 43 Netrin-1 inducing antiapoptotic effect of acute myeloid leukemia cells in a concentration-dependent manner through the Unc-5 netrin receptor B-focal adhesion kinase axis. **2023**, 24, ○
- 42 Potential Use of Thalidomide in Glioblastoma Treatment: An Updated Brief Overview. **2023**, 13, 543 ○
- 41 Circular RNAs-mediated angiogenesis in human cancers. ○
- 40 Microfluidics and Cancer Treatment: Emerging Concept of Biomedical Engineering. **2023**, 523-562 ○
- 39 The RNA interactome in the Hallmarks of Cancer. ○

- 38 Proteomics mining of cancer hallmarks on a single-cell resolution. o
- 37 Functions of N6-methyladenosine in cancer metabolism: from mechanism to targeted therapy. **2023**, 11, o
- 36 A tumor microenvironment-based prognostic index for osteosarcoma. **2023**, 30, o
- 35 Hypoxia and the Metastatic Cascade. **2023**, 181-216 o
- 34 Synthesis and biological evaluation of novel pteridin-7(8H)-one derivatives as potent CDK2 inhibitors. **2023**, 129284 o
- 33 Hypoxic Tumor Microenvironment: Driver for Cancer Progression. **2023**, 65-88 o
- 32 Relevant Membrane Transport Proteins as Possible Gatekeepers for Effective Pharmacological Ascorbate Treatment in Cancer. **2023**, 12, 916 o
- 31 Hypoxia and Extracellular Matrix-Major Drivers of Tumor Metastasis. **2023**, 217-244 o
- 30 A novel defined apoptosis-related gene signature as a prognostic tool in lung adenocarcinoma. o
- 29 Understanding HAT1: A Comprehensive Review of Noncanonical Roles and Connection with Disease. **2023**, 14, 915 o
- 28 ALAN is a computational approach that interprets genomic findings in the context of tumor ecosystems. **2023**, 6, o
- 27 Fine-tuning large neural language models for biomedical natural language processing. **2023**, 4, 100729 o
- 26 Chemical Carcinogens. **2023**, 1-23 o
- 25 Epigenetic regulation of stem cells in lung cancer oncogenesis and therapy resistance. 14, o
- 24 Effect of tumor microenvironment and role of Lymphocyte pattern on biological behavior and survival outcomes in oral squamous cell carcinoma. **2023**, 100041 o
- 23 Stratification of ovarian cancer borderline from high-grade serous carcinoma patients by quantitative serum NMR spectroscopy of metabolites, lipoproteins, and inflammatory markers. 10, o
- 22 Role of the tumor microenvironment in malignant melanoma organoids during the development and metastasis of tumors. 11, o
- 21 Novel Approaches in Cancer Treatment: Tumor Targeted Therapy. **2023**, 1-34 o

2 General aspects of cancer therapy. **2023**, 1-35 o

1 Circadian clocks in health and disease: Dissecting the roles of the biological pacemaker in cancer. 12, 116 o